documents incorporated reference portions proxy statement registrants annual meeting stockholders held may incorporated reference part iii annual report part item business general bristolmyers squibb company may referred bristolmyers squibb bms company us incorporated laws state delaware august name bristolmyers company successor new york business started bristolmyers company changed name bristolmyers squibb company result merger engaged discovery development licensing manufacturing marketing distribution sale biopharmaceutical products global basis operate one segmentbiopharmaceuticals additional information business segments see item financial statementsnote business segment information compete worldwide researchbased drug companies smaller research companies generic drug manufacturers products sold worldwide primarily wholesalers retail pharmacies hospitals government entities medical profession manufacture products united states us puerto rico six foreign countries percentage revenues significant region follows year ended december dollars millions united states europe japan china total revenues acquisitions divestitures since transforming bms leadingedge biopharmaceutical company focused exclusively discovering developing delivering innovative medicines address serious unmet medical needs transformation encompassed areas business operations part strategy divested diabetes nonpharmaceutical businesses implemented acquisition licensing strategy executed productivity transformation initiative pti divestitures included diabetes business february mead johnson december convatec august medical imaging january part acquisition licensing strategy acquired amylin pharmaceuticals inc amylin august inhibitex inc inhibitex february amira pharmaceuticals inc amira september zymogenetics inc zymogenetics october medarex inc medarex september entered several license collaboration arrangements transactions allowed continue allow us focus resources behind growth opportunities drive greatest longterm value disease standpoint focused four core therapeutic areas oncology virology immunology specialty cardiovascular disease products pharmaceutical products include chemicallysynthesized drugs small molecules increasing portion products produced biological processes typically involving recombinant dna technology called biologics small molecule drugs typically administered orally eg form pill tablet although drug delivery mechanisms used well biologics typically administered patients injections infusion revenues come products following therapeutic classes virology including human immunodeficiency virus hiv infection oncology neuroscience metabolics immunoscience cardiovascular pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity business focused innovative biopharmaceutical products rely patent rights various forms regulatory protection maintain market exclusivity products us european union eu countries patent rights forms exclusivity expire generic versions medicine approved marketed often substantial rapid declines sales original innovative product discussion patent rights regulatory forms exclusivity see intellectual property product exclusivity discussion impact generic competition business see generic competition following chart shows key products together year earliest basic exclusivity loss patent rights data exclusivity occurred currently estimated occur us eu japan china also sell pharmaceutical products countries however data provided countrybycountry basis individual country revenues significant outside us eu japan china many instances basic exclusivity loss date listed expiration date patent claims active ingredient drug method using drug approved indication one approved indication instances basic exclusivity loss date listed chart expiration date data exclusivity period situations data exclusivity without patent protection competitor could seek regulatory approval submitting clinical trial data obtain marketing approval prior expiration data exclusivity estimate market exclusivity period products purposes business planning length market exclusivity products impossible predict certainty complex interaction patent regulatory forms exclusivity inherent uncertainties regarding patent litigation assurance particular product enjoy market exclusivity full period time appears estimate exclusivity limited estimate following schedule presents revenues key products estimated basic exclusivity loss us eu japan china total revenues product past currently estimated year basic exclusivity loss dollars millions us eua japan china key products virology baraclude b reyataz c sustiva franchise e oncology erbitux f g sprycel yervoy g g neuroscience abilify h metabolicsm bydureon na j j g byetta na k g g forxigaxigduo na onglyzakombiglyze immunoscience nulojix orencia g g cardiovascular avaproavalide eliquis plavix l note currently estimated earliest year basic exclusivity loss includes statutory extensions exclusivity granted instances may able obtain additional six months exclusivity product based pediatric extension certain instances may laterexpiring patents cover particular forms compositions drug well methods manufacturing methods using drug patents may sometimes result favorable market position products product exclusivity predicted assured us healthcare law enacted qualifying biologic products receive years data exclusivity biosimilar enter market described detail intellectual property product exclusivity indicates brand names products trademarks owned wholly owned bms specific trademark ownership information included currently market product country region indicated uncertainty chinas exclusivity laws resulted generic competition china market references eu throughout include member states european union year ended december basic patent applications filed current member states listed products instances date basic exclusivity loss different various eu member states eu countries basic patent obtained may data protection available b february us district court district delaware invalidated composition matter patent covering baraclude entecavir scheduled expire including granted pediatric exclusivity appeal pending decision expected may face generic competition product beginning company prepared take legal action event teva pharmaceutical industries ltd teva chooses launch generic product prior resolution company 's appeal c data exclusivity eu expires market exclusivity expires exclusivity period relates sustiva brand include exclusivity related combination therapy composition matter patent efavirenz us expired method use patent treatment hiv infection expires september pediatric exclusivity granted provides additional six month period exclusivity added term patents listed orange book e exclusivity period relates sustiva efavirenz brand include exclusivity related combination therapy market exclusivity sustiva expired november countries eu data exclusivity sustiva expired eu f biologic product approved biologics license application bla data exclusivity us expires patent specifically claims composition matter cetuximab active ingredient erbitux rights commercialize cetuximab terminate g exclusivity period based regulatory data protection h rights commercialize abilify aripiprazole us terminate rights commercialize abilify eu terminate june j exclusivity period based formulation patents k exclusivity period based method use patent l data exclusivity eu expired july major markets within europe product national patents expired specifically claim bisulfate form clopidogrel generic alternate salt forms clopidogrel bisulfate marketed compete plavix throughout eu february bms sold astrazeneca plc astrazeneca diabetes business bms comprised global alliance including rights ownership onglyzakombiglyze forxigaxigduo bydureon byetta symlin summary indication intellectual property position product partner thirdparty manufacturing arrangements products us applicable eu japan baraclude baraclude entecavir potent selective inhibitor hepatitis b virus approved us food drug administration fda treatment chronic hepatitis b infection baraclude discovered developed internally february us district court district delaware invalidated composition matter patent covering baraclude scheduled expire appeal pending decision expected may face generic competition product beginning december fda granted pediatric exclusivity baraclude event company successful appeal composition matter patent including pediatric extension expire august company prepared take legal action event teva chooses launch generic product prior resolution company 's appeal information patent litigation matter see item financial statementsnote legal proceedings contingencies composition matter patent expires eu japan uncertainty chinas exclusivity laws resulted generic competition china market entecavir manufactured company third party product finished facilities reyataz reyataz atazanavir sulfate protease inhibitor treatment human immunodeficiency virus hiv developed atazanavir worldwide license novartis pharmaceutical corporation novartis royalty paid based percentage net product sales entitled promote reyataz use combination norvir ritonavir non exclusive license agreement abbvie inc abbvie amended royalty paid based percentage net product sales licensing agreement gilead sciences inc gilead develop commercialize fixeddose combination containing atazanavir one gileads compounds development market exclusivity reyataz expected expire us china major eu member countries japan data exclusivity eu expires manufacture bulk requirements atazanavir finish product facilities sustiva franchise sustiva efavirenz nonnucleoside reverse transcriptase inhibitor treatment hiv sustiva franchise includes sustiva antiretroviral drug used treatment hiv well bulk efavirenz included combination therapy atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oncedaily single tablet threedrug regimen combining sustiva gileads truvada emtricitabine tenofovir disoproxil fumarate information arrangement gilead see strategic alliances item financial statementsnote alliances rights market efavirenz us canada uk france germany ireland italy spain licensed merck co inc merck royalty based percentage revenues efavirenz marketed another company japan composition matter patent efavirenz us expired method use patent treatment hiv infection expires september additional six month period pediatric exclusivity added term patents market exclusivity sustiva expired november countries eu data exclusivity sustiva expired eu certain atripla patents subject patent litigation us time us patents covering efavirenz composition matter method use challenged obtain bulk requirements efavirenz third parties produce finished goods facilities supply third parties bulk efavirenz gilead responsible producing finished atripla product erbitux erbitux cetuximab igg monoclonal antibody designed exclusively target block epidermal growth factor receptor egfr expressed surface certain cancer cells multiple tumor types well normal cells erbitux biological product approved combination irinotecan treatment patients egfrexpressing metastatic colorectal cancer mcrc failed irinotecanbased regimen monotherapy patients intolerant irinotecan fda approved erbitux use combination radiation therapy treatment locally regionally advanced squamous cell carcinoma head neck single agent treatment patients recurrent metastatic squamous cell carcinoma head neck prior platinumbased therapy failed fda also approved erbitux firstline recurrent locoregional metastatic head neck cancer combination platinumbased chemotherapy fluorouracil erbitux marketed north america us agreement imclone systems incorporated imclone predecessor company imclone llc whollyowned subsidiary eli lilly company lilly share copromotion rights erbitux merck kgaa japan codevelopment cocommercialization agreement signed october imclone merck kgaa merck serono japan erbitux received marketing approval japan july use treating patients advanced recurrent colorectal cancer december head neck cancer description alliance imclone see strategic alliances item financial statementsnote alliances data exclusivity erbituxin us expires patent specifically claims composition matter cetuximab active molecule erbitux erbitux approved fda health authorities monotherapy use patent use erbitux combination fluorouracil antineoplastic agent approved fda combination use claimed granted us patent expires including granted patent term extension inventorship use patent challenged three researchers yeda research development company ltd yeda pursuant settlement agreement executed announced december imclone sanofi yeda end worldwide litigation related use patent sanofi yeda granted imclone worldwide license use patent data exclusivity japan expires yeda right license use patent others yedas license patent third parties could result product competition erbitux might otherwise occur unable assess whether extent competitive impact occur quantify impact however yeda granted amgen inc amgen license use patent amgen received fda approval market egfrproduct competes erbitux obtain finished goods requirements cetuximab use north america lilly lilly manufactures bulk requirements cetuximab facilities filling finishing performed thirdparty bms oversight responsibility description supply agreement lilly see manufacturing quality assurance sprycel sprycel dasatinib multitargeted tyrosine kinase inhibitor approved firstline treatment adults philadelphia chromosome positive chronic myeloid leukemia chronic phase treatment adults chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy including gleevec imatinib mesylate sprycel internally discovered part strategic alliance otsuka information alliance otsuka see strategic alliances item financial statementsnote alliances patent term extension granted us extending term basic composition matter patent covering dasatinib june company entered settlement agreement apotex regarding patent infringement suit covering monohydrate form dasatinib whereby apotex launch generic dasatinib monohydrate anda product september earlier certain circumstances us orphan drug exclusivity expired protected product generic applications currently approved orphan indications majority eu countries composition matter patent covering dasatinib expires april excluding potential term extensions composition matter patent expires japan china manufacture bulk requirements dasatinib finish product facilities yervoy yervoy ipilimumab biological product monoclonal antibody treatment patients unresectable inoperable metastatic melanoma yervoy approved us march eu july currently also studied indications including lung cancer well adjuvant melanoma hormonerefractory prostate cancer information research development yervoy see research development yervoy discovered medarex codeveloped company medarex subsidiary patent covering ipilimumab composition matter currently expires us eu excluding potential patent term extensions data exclusivity expires us eu obtain bulk ipilimumab thirdparty manufacturer finish product facilities thirdparty facility abilify abilify aripiprazole atypical antipsychotic agent adult patients schizophrenia bipolar mania disorder major depressive disorder abilify also pediatric uses schizophrenia bipolar disorder among others global commercialization agreement otsuka pharmaceutical co ltd otsuka excluding japan china certain asian countries information arrangement otsuka see strategic alliances item financial statementsnote alliances basic us composition matter patent covering aripiprazole term current abilify agreement expire april including granted patent term extension six month pediatric extension composition matter patent force major eu countries original expiration date extended grant supplementary protection certificate eu countries data exclusivity rights commercialize eu expire june obtain bulk requirements aripiprazole otsuka company otsuka finish product respective facilities bydureon bydureon exenatide extendedrelease injectable suspension onceweekly glucagonlike peptide glp receptor agonist treatment type diabetes bydureon acquired amylin acquisition august bydureon internally discovered amylin former whollyowned subsidiary company prior sale diabetes business february worldwide development commercialization agreement astrazeneca bydureon information arrangement sale diabetes business astrazeneca see item financial statementsnote alliances item financial statementsnote assets heldforsale formulation patents expire us europe data exclusivity expires japan prior sale diabetes business obtained bulk requirements exenatide third parties microspheres manufacturing process required extended release formulation performed company following sale diabetes business astrazeneca assumed manufacturing finishing responsibilities byetta byettaexenatide twice daily glp receptor agonist treatment type diabetes byetta acquired amylin acquisition august byetta internally discovered amylin former whollyowned subsidiary company prior sale diabetes business february worldwide development commercialization agreement astrazeneca byetta information arrangement sale diabetes business astrazeneca see item financial statements note alliances item financial statementsnote assets heldforsale method use patent expires us data exclusivity expires europe japan prior sale diabetes business obtained bulk requirements exenatide third parties manufacturing finishing also took place thirdparty facilities following sale diabetes business astrazeneca assumed manufacturing finishing responsibilities forxiga forxiga dapagliflozin oral sodiumglucose cotransporter sglt treatment type diabetes mellitus forxiga marketed farxiga us document unless specifically noted refer forxiga farxiga forxiga approved us january eu november use adults type diabetes mellitus improve glycemic control adjunct diet exercise discussion see item managements discussion analysis financial condition results operations product pipeline developments forxiga internally discovered prior sale diabetes business february worldwide development commercialization agreement astrazeneca forxiga information arrangement sale diabetes business astrazeneca see item financial statementsnote alliances item financial statementsnote assets heldforsale composition matter patent covering dapagliflozin expires october us may eu prior sale diabetes business manufactured bulk requirements dapagliflozin finished product facilities following sale diabetes business bms continue manufacture bulk requirement finish product pursuant supply arrangement agreed upon connection sale diabetes business astrazeneca onglyzakombiglyze onglyza saxagliptin dipeptidyl peptidase inhibitor oral compound indicated treatment type diabetes adjunct diet exercise kombiglyze saxagliptin metformin hydrochloride extendedrelease approved us combination product indicated adjunct diet exercise improve glycemic control adults type diabetes mellitus treatment saxagliptin metformin appropriate komboglyze saxagliptin metformin immediaterelease approved eu combination product indicated adjunct diet exercise improve glycemic control adults type diabetes mellitus inadequately controlled maximally tolerated dose metformin alone already treated combination saxagliptin metformin separate tablets document unless specifically noted refer kombiglyze komboglyze kombiglyze onglyza internally discovered company kombiglyze codeveloped company astrazeneca prior sale diabetes business february worldwide except japan codevelopment cocommercialization agreement astrazeneca saxagliptin information arrangement sale diabetes business astrazeneca arrangement otsuka japan see strategic alliances item financial statementsnote alliances item financial statementsnote assets heldforsale composition matter patent covering saxagliptin expires july including granted patent term extension us expires eu march eu supplementary protection certificates granted onglyza majority european countries expire october supplementary protection certifications kombiglyze applied granted france italy spain application pending number european countries market exclusivity china expires following sale diabetes business bms continue manufacture bulk requirement finish product pursuant supply arrangement agreed upon connection sale diabetes business astrazeneca nulojix nulojix belatacept biological product fusion protein novel immunosuppressive activity prevention kidney transplant rejection approved launched us june approved eu june launched july belatacept internally discovered developed patent covering belatacept composition matter expires april us may eu data exclusivity expires us june eu june manufacture bulk requirements belatacept finish products facilities orencia orencia abatacept biological product fusion protein novel immunosuppressive activity targeted initially adult patients moderately severely active rheumatoid arthritis inadequate response certain currently available treatments abatacept available intravenous formulation beginning subcutaneous formulation us orencia discovered developed internally since approved eu regions series patents covering abatacept method use us patent term extension granted one composition matter patents extending term us patent eu composition matter patent covering abatacept expired majority eu countries applied supplementary protection certificates also pediatric extension supplementary protection certificates protection protection certificates granted data exclusivity expires us eu japan bulk abatacept manufactured company third party finish formulations product facilities see strategic alliances discussion collaborations ono pharmaceutical co ltd ono orencia japan avaproavalide avaproavalide irbesartanirbesartanhydrochlorothiazide angiotensin ii receptor antagonist indicated treatment hypertension diabetic nephropathy irbesartan codeveloped jointly marketed sanofi end october bms sanofi announced restructuring alliance following loss exclusivity plavix avaproavalide many major markets information alliance sanofi restructuring see strategic alliances item financial statementsnote alliances composition matter patent expired us march countries eu data exclusivity eu expired august avapro october avalide company sanofi manufacture bulk requirements irbesartan finishing performed sanofi alliance restructuring bmss manufacturing obligations phase sanofi assuming companys manufacturing supply obligations irbesartan products end eliquis eliquis apixaban oral factor xa inhibitor targeted stroke prevention atrial fibrillation prevention treatment venous thromboembolic vte disorders apixaban discovered internally part alliance pfizer inc pfizer information alliance pfizer see item financial statementsnote alliances composition matter patent covering apixaban us expires february excluding potential patent term extensions eu expires applied supplementary protection certificates supplementary protection certificates granted expire data exclusivity eu expires apixaban manufactured company third party product finished facilities plavix plavix clopidogrel bisulfate platelet aggregation inhibitor approved protection fatal nonfatal heart attack stroke patients history heart attack stroke peripheral arterial disease acute coronary syndrome clopidogrel bisulfate codeveloped jointly marketed sanofi october bms sanofi announced restructuring alliance following loss exclusivity plavix avaproavalide many major markets information alliance sanofi restructuring see strategic alliances item financial statementsnote alliances composition matter patent us expired may eu regulatory data exclusivity protection expired july europe national patents specifically claim bisulfate form clopidogrel expired plavix faces generic competition globally obtain bulk requirements clopidogrel bisulfate sanofi prior january company sanofi finished product respective facilities effective january company longer finishes clopidogrel bisulfate facilities research development invest heavily research development rd believe critical longterm competitiveness major rd facilities new jersey connecticut research development also carried various facilities throughout world including belgium uk india sites us supplement internal drug discovery development programs alliances collaborative agreements help us bring new products pipeline drug development engage services physicians hospitals medical schools research organizations worldwide conduct clinical trials establish safety effectiveness new products management continues emphasize leadership innovation productivity quality strategies success research development activities concentrate research development efforts following disease areas significant unmet medical needs oncology human immunodeficiency virus hivacquired immunodeficiency syndrome aids hepatitis immunologic disorders cardiovascular fibrotic disease also continue analyze may selectively pursue promising leads areas addition discovering developing new molecular entities look ways expand value existing products new indications formulations provide additional benefits patients order new drug reach market industry practice government regulations us eu foreign countries provide determination drugs effectiveness safety preclinical tests controlled clinical evaluation clinical development potential new drug includes phase phase ii phase iii clinical trials designed specifically support new drug application particular indication assuming trials successful phase clinical trials involve small number healthy volunteers patients suffering indicated disease test safety proper dosing phase ii clinical trials involve larger patient population investigate side effects efficacy optimal dosage drug candidate phase iii clinical trials conducted confirm phase ii results significantly larger patient population longer term provide reliable conclusive data regarding safety efficacy drug candidate rd process typically takes fourteen years longer approximately three years often spent phase iii latestage development consider rd programs phase iii significant rd programs programs include investigational compounds phase iii development initial indications marketed products phase iii development additional indications formulations drug development time consuming expensive risky average one chemical compounds discovered pharmaceutical industry researchers proves medically effective safe enough become approved medicine drug candidates fail stage process even latestage product candidates sometimes fail receive regulatory approval according kmr group based industry success rates approximately compounds enter phase development fail achieve regulatory approval failure rate compounds enter phase ii development approximately compounds enter phase iii development approximately total research development expenses include costs discovery research preclinical development early latestage clinical development drug formulation well postcommercialization medical support marketed products proportionate allocations enterprisewide costs appropriate costs research development spending billion billion billion includes payments thirdparty collaborations contracts end employed approximately people rd activities including substantial number physicians scientists holding graduate postgraduate degrees higherskilled technical personnel manage rd programs portfolio basis investing resources stage research development early discovery latestage development continually evaluate portfolio rd assets ensure appropriate balance earlystage latestage programs support future growth company spending latestage development programs represented approximately annual rd expenses last three years individual investigational compound marketed product represented rd expenses last three years listed several latestage investigational compounds phase iii clinical trials regulatory review least one potential indication whether investigational compounds ultimately becomes one marketed products depends results clinical studies competitive landscape potential products market manufacturing processes necessary produce potential product commercial scale among factors however noted assurance seek regulatory approval compounds approval sought obtained also assurance compound approved commercially successful stage development determine intellectual property issues patent protection may may available investigational compounds patent coverage highlighted includes patent terms patent term extensions granted asunaprevir asunaprevir oral small molecule ns protease inhibitor phase iii development commenced treatment hepatitis c virus infection currently registrational process japan patent covering asunaprevir composition matter expires us daclatasvir daclatasvir oral small molecule nsa replication complex inhibitor phase iii development commenced treatment hepatitis c virus infection currently registrational process japan eu patent covering daclatasvir composition matter expires us bms bms oral small molecule nonnucleoside nsb inhibitor phase iii development commenced treatment hepatitis c virus infection patent covering bms composition matter expires us peginterferon lambda peginterferon lambda novel type interferon phase iii development commenced hepatitis c virus infection patent covering peginterferon lambda composition matter expires us elotuzumab elotuzumab humanized monoclonal antibody investigated anticancer treatment discovered pdl biopharma became part facet biotech corporation facet spinoff facet subsequently acquired abbott laboratories abbott became part abbvie inc abbvie following spinoff abbott elotuzumab part alliance abbvie phase iii trials commenced multiple myeloma abbvie owns patent covering elotuzumab composition matter expires us nivolumab nivolumab fully human monoclonal antibody binds programmed death receptor pd nkt cells investigated anticancer treatment phase iii trials commenced nonsmallcell lung cancer renal cell cancer melanoma jointly patent ono covering nivolumab composition matter expires us fda granted fast track designation nivolumab three tumor types nonsmallcell lung cancer renal cell carcinoma advanced melanoma february bms sold astrazeneca diabetes business bms comprised global alliance including rights ownership metreleptin metreleptin protein development treatment lipodystrophy currently registrational process following table lists potential additional indications andor formulations key marketed products phase iii development currently regulatory review key marketed product potential indication andor formulation baraclude pediatric extension eu reyataz pediatric extension fixed dose combination cobicistat additional formulations erbitux additional indication esophageal cancer yervoy additional indications adjuvant melanoma prostate cancer nonsmallcell lung cancer small cell lung cancer additional indication melanoma combination nivolumab orencia additional indications lupus nephritis psoriatic arthritis eliquis additional indication vte treatment vte prevention us following key developments currently expected occur respect significant pipeline programs outcome timing expected developments dependent upon number factors including among things availability data outcome certain clinical trials acceptance presentations certain medical meetings andor actions health authorities undertake obligation publicly update information whether result new information future events otherwise asunaprevir potential approval japan hepatitis c virus infection planned submission us hepatitis c virus infection daclatasvir potential approval eu japan hepatitis c virus infection planned submission us hepatitis c virus infection nivolumab data available clinical trials potential submission based registrational trials sprycel five year data available first line cml yervoy data available phase iii study adjuvant melanoma eliquis potential approval vte treatment vte prevention us strategic alliances enter strategic alliances third parties transfer rights develop manufacture market andor sell pharmaceutical products owned parties alliances include licensing arrangements codevelopment comarketing agreements copromotion arrangements joint ventures alliances involve sharing research development costs risk incurring research development expenses compounds lead revenue generating products reduced however profitability alliance products generally lower profits alliance products shared alliance partners actively pursue arrangements view alliances important complement discovery development commercialization activities strategic alliances third parties rights manufacture market andor sell pharmaceutical products contain customary early termination provisions typically found agreements kind generally based partys material breach bankruptcy voluntary involuntary product safety concerns amount notice required early termination generally ranges immediately upon notice days receipt notice termination immediately upon notice generally available party files voluntary bankruptcy petition material safety issue arises product medical riskbenefit incompatible welfare patients continue develop commercialize product termination upon days notice generally available involuntary bankruptcy petition filed dismissed material breach party occurred cured number alliance agreements also permit alliance partner us terminate without cause typically exercisable substantial advance written notice often exercisable specified period time elapsed alliance agreement signed strategic alliances typically otherwise contain provisions provide party right terminate alliance short notice general retain rights product brought alliance another party partys intellectual property alliance terminates loss rights one products marketed sold us pursuant strategic alliance could material results operations cash flows could material financial condition liquidity customary pharmaceutical industry terms strategic alliances generally co extensive exclusivity period may vary countrybycountry basis significant current alliances currently marketed products investigational compounds described current marketed productsinlicensed otsuka maintain worldwide commercialization agreement otsuka codevelop copromote abilify abilify agreement excluding certain asian countries us portion agreement amended expires upon expected loss product exclusivity april agreement expires european union eu countries june nonus country exclusive right sell abilify agreement expires later april loss exclusivity country otsuka principal thirdparty product sales us united kingdom germany france spain italy certain european countries bms principal thirdparty product sales exclusive distributor exclusive right sell abilify remaining territories alliance revenue recognized bms 's share total net sales third party customers territories us bms 's contractual share beginning january bmss contractual share changed percentages total us net product sales set forth table assessment bms 's expected annual contractual share completed quarterly reporting period adjusted based upon reported us abilify net sales december bms 's annual contractual share alliance revenue recognized interim period quarter exceed amounts due contract annual us net product sales bms share us net product sales billion billion billion billion billion billion billion billion billion excess billion uk germany france spain italy certain european countries otsuka principal bms 's contractual share thirdparty net product sales countries us alliance revenue recognized abilify shipped risks rewards ownership transferred thirdparty customers bms recognizes net product sales certain countries exclusive distributor product exclusive right sell abilify terms abilify agreement amended purchase active pharmaceutical ingredient product otsuka perform finish manufacturing sale us otsuka thirdparty customers terms extension agreement paid otsuka million amortized reduction alliance revenues expected loss us exclusivity april otsuka receives royalty based total us net product sales otsuka responsible us expenses related commercialization abilify us amendment otsuka assumed responsibility providing funding sales force efforts effective january consideration bms paid otsuka million january responsible funding certain operating expenses million million million eu otsuka reimbursed bms sales force effort provided march otsuka assumed responsibility providing funding sales force efforts eu effective april abilify agreement expires april us june eu countries country exclusive right sell abilify agreement expires later april loss exclusivity country us portion abilify agreement oncology agreement described include changeofcontrol provision acquired acquiring company competing product abilify new company assume abilify agreement amended oncology agreement currently exists acquiring company product competes abilify otsuka elect request acquiring company choose whether divest abilify competing product scenario abilify divested otsuka would obligated acquire rights abilify agreement amended price according predetermined schedule agreements also provide event generic competitor abilify option terminating abilify april amendment agreement previously amended remaining force exercise option either would receive payment otsuka according predetermined schedule oncology agreement would terminate time ii oncology agreement would continue truncated period according predetermined schedule early termination abilify agreement immediate upon notice case voluntary bankruptcy ii minimum payments made otsuka iii first commercial sale occurred within three months receipt necessary approvals days material breach occurred cured commencement cure occurred within days notice material breach days case involuntary bankruptcy petition filed dismissed addition termination available otsuka upon days notice event challenge otsukas patent rights marketbymarket basis event market product direct competition abilify upon termination expiration abilify agreement retain rights abilify recognized total revenues abilify billion billion discussion oncology agreement otsuka see current marketed productsinternally discovered discussion strategic alliance otsuka see item financial statementsnote alliances gilead joint ventures gilead develop commercialize atripla us canada europe company gilead share responsibility certain activities related commercialization atripla us canada throughout eu certain european countries gilead recognizes atripla revenues us canada countries europe alliance revenues recognized atripla include bulk efavirenz component atripla calculated differently eu us following loss exclusivity sustiva eu alliance revenues deferred related alliance receivable recognized atripla sold thirdparty customers recognized efavirenz alliance revenues billion billion billion related atripla net product sales joint venture arrangement company gilead us continue terminated mutual agreement parties otherwise described event material breach one party nonbreaching party may terminate joint venture parties agree desirable practicable withdraw combination product markets commercialized time one generic versions partys component products appear market us party right terminate joint venture thereby acquire rights combination product us canada however three years terminated party continue receive percentage net product sales based contribution bulk components atripla otherwise retains rights products entered licensing agreement gilead develop commercialize fixeddose combination containing reyataz gileads cobicistat pharmacoenhancing boosting agent currently phase iii clinical trials increases blood levels certain hiv medicines potentially allow one pill daily dosing cobicistat currently registrational process fda discussion strategic alliance gilead see item financial statementsnote alliances lilly egfr commercialization agreement lilly lillys subsidiary imclone codevelopment copromotion erbitux us canada japan egfr agreement respect erbitux net product sales north america lilly receives distribution fee based flat rate net product north america plus reimbursement certain royalties paid lilly company lilly share one half profits losses evenly japan merck kgaa receiving half profits losses japan parties share royalties payable third parties pursuant formula set forth commercialization agreement purchase north american commercial requirements bulk erbitux lilly agreement expires erbitux north america september early termination available based material breach effective days notice material breach material breach cured commencement cure occurred upon six months notice us exists significant concern regarding regulatory patient safety issue would seriously impact longterm viability product upon termination expiration alliance retain rights erbitux north america share codevelopment copromotion rights erbitux merck kgaa japan agreement signed october expiring lilly merck kgaa merck japan lilly ability terminate agreement determines commercially unreasonable continue erbitux received marketing approval japan july use erbitux treating patients advanced recurrent colorectal cancer head neck cancer december recognized net product sales erbitux million million million discussion strategic alliance lilly see item financial statementsnote alliances sanofi september bms sanofi restructured terms codevelopment cocommercialization agreements discussed effective january sanofi assumed essentially worldwide operations alliance exception plavix us puerto rico alliance plavix two markets continue unchanged december terms original alliance arrangements described exchange rights assumed sanofi bms receive quarterly royalties january december terminal payment sanofi million end pursuant master restructuring agreement company returned sanofi rights clopidogrel irbesartan markets exception clopidogrel us puerto rico company continues act operating partner majority controlling interest existing local arrangements territory territory b exception clopidogrel us puerto rico terminated mutual agreement products continue sold local country entities territories addition sanofi assumed marketing authorizations products extent currently held company affiliates result sanofi assumed control activities relating distribution commercialization medical affairs clopidogrel irbesartan regions pursuant master restructuring agreement related alliance agreements sanofi assume companys manufacturing supply obligations irbesartan products end company manufacture bulk clopidogrel longer finishes clopidogrel products facilities company retain rights intellectual property developed alliance necessary fulfill continuing obligations alliance arrangements agreements sanofi codevelopment cocommercialization avaproavalide plavix avaproavalide copromoted certain countries outside us tradename aprovelcoaprovel comarketed certain countries outside us us tradename karveakarvezide plavix copromoted certain countries outside us tradename plavix comarketed certain countries outside us us tradename iscover prior worldwide alliance operated framework two geographic territories one covering certain european asian countries referred territory one covering us puerto rico canada australia certain latin american countries referred territory b sanofi acted operating partner territory owned financial controlling interest territory ownership interest territory territory b acted operating partner owned majority controlling interest territory consolidated partnership results territory b territory b managed two separate sets agreements one plavix us puerto rico products australia mexico brazil colombia argentina separate set agreements avaproavalide us puerto rico within territory territory partnership existed supply finished product country within territory manage contract certain central expenses marketing research development royalties countries within territories b structured local affiliate sanofis local affiliate either comarket separate brands ie affiliate operated independently competed selling product different trademarks copromoted single brand ie product trademark beginning royalties received sanofi territory b optout markets former development royalties presented total revenues recognized total revenues territory b territory comarketing countries billion billion billion alliance may terminated sanofi us event voluntary involuntary bankruptcy insolvency case involuntary bankruptcy continues days order decree approving continues unstayed effect days ii material breach obligation major alliance agreement remains uncured days following notice breach except commencement diligent prosecution cure occurred within days notice discussion strategic alliance sanofi see item financial statementsnote alliances current marketed productsinternally discovered otsuka simultaneously extension abilify agreement april company otsuka entered oncology agreement sprycel ixempra ixabepilone includes us japan eu markets oncology territory beginning fee paid otsuka annually based following percentages annual net product sales sprycel ixempra net product sales million million million million million million billion excess billion annual periods otsuka contributes first million certain commercial operational expenses relating oncology products oncology territory costs excess million beginning otsuka copromotes sprycel us japan beginning also copromotes top five eu markets oncology agreement expires respect sprycel ixempra includes changeofcontrol provision acquired abilify agreement described discussion abilify agreement otsuka see current marketed productsinlicensed discussion strategic alliance otsuka see item financial statementsnote alliances addition january granted otsuka exclusive rights japan develop commercialize onglyza agreement entitled receive milestone payments based certain regulatory events well salesbased payments following regulatory approval onglyza japan retained rights copromote onglyza otsuka japan otsuka responsible development costs japan june otsuka assigned rights onglyza exception specific transition services kyowa hakko kirin khk part consent assignment bms waived rights copromote onglyza japan bms supply finished saxagliptin khk february sold astrazeneca diabetes business comprised global alliance including rights ownership onglyza seeitem financial statementsnote assets heldforsale discussion astrazeneca january entered worldwide except japan codevelopment cocommercialization agreement astrazeneca onglyza saxagliptin agreement forxiga sglt agreement bms astrazeneca pharmaceuticals lp whollyowned subsidiary astrazeneca entered alliance regarding worldwide development commercialization amylins portfolio products including bydureon byetta symlin kombiglyze codeveloped astrazeneca saxagliptin agreement exclusive rights develop sell onglyza japan licensed otsuka december june assigned otsuka khk described february sold astrazeneca diabetes business comprised global alliance including rights ownership onglyza forxiga bydureon byetta symlin metreleptin seenote assets heldforsale information astrazeneca terminated existing alliance agreements connection sale entered several new agreements including transitional services agreement supply agreement development agreement supply agreement continue manufacture onglyza kombiglyze forxiga discussion strategic alliance astrazeneca see item financial statementsnote alliances investigational compounds development internally discovered pfizer company pfizer parties worldwide codevelopment cocommercialization agreement eliquis anticoagulant discovered us prevention treatment atrial fibrillation venous thromboembolic vte disorders pfizer funds development costs depending study received million upfront milestone licensing payments pfizer date including million received january could receive additional million pfizer development regulatory milestones met companies share commercialization expenses profits losses equally global basis discussion strategic alliance pfizer see item financial statementsnote alliances investigational compounds developmentinlicensed abbvie august granted exclusive rights facet biotech corporation abbvie codevelopment cocommercialization elotuzumab humanized monoclonal antibody investigated treatment multiple myeloma terms agreement fund development costs elotuzumab upon commercialization abbvie share profits losses us paid tiered royalties outside us solely responsible commercialization elotuzumab addition abbvie may receive milestone payments us based certain regulatory events sales thresholds achieved investigational compounds developmentinternally discovered ono september bms ono entered alliance agreement alliance agreement nivolumab antipd human monoclonal antibody investigated anticancer treatment also subject alliance agreement alliance agreement entered ono medarex whollyowned subsidiary company alliance agreement alliance agreement ono granted bms exclusive right develop commercialize manufacture product containing nivolumab countries world except japan korea taiwan ono remains responsible development commercialization ono entitled receive certain salesbased royalties following regulatory approvals territories excluding three countries connection alliance agreement bms also entered alliance ono whereby granted certain commercialization rights ono ono shares expenses profits losses orencia japan alliances february bms reckitt benckiser group plc reckitt entered three year alliance regarding several overthecounterproducts sold primarily mexico brazil reckitt received right sell distribute market products may certain responsibilities related regulatory matters covered territory bms receive royalties net product sales also exclusively supply certain products reckitt pursuant supply agreement cost plus markup certain limited assets including market authorizations certain employees directly attributed business transferred reckitt start alliance period bms retained ownership assets related business including trademarks covering products bms also granted reckitt option acquire trademarks inventory certain assets exclusively related products end alliance price determined based multiple net product sales plus cost remaining inventory held bms time option exercised assets previously transferred reckitt revert back bms option may exercised reckitt may november case closing would expected occur may nonrefundable upfront alliance proceeds million received bms allocated rights transferred reckitt million fair value option purchase remaining assets million please see item financial statementsnote alliances information regarding alliance february bms medicines company entered two year alliance regarding recothrom recombinant thrombin use topical hemostat control nonarterial bleeding surgical procedures previously acquired bms connection acquisition zymogenetics inc medicines company received right sell distribute market recothrom global basis two years certain responsibilities related regulatory matters covered territory bms exclusively supply recothrom medicines company pursuant supply agreement cost plus markup also receive royalties net product sales recothrom certain employees directly attributed business certain assets transferred medicines company start alliance period including recothrom bla related regulatory assets bms retained assets related recothrom including patents trademarks inventory bms also granted medicines company option acquire patents trademarks inventory certain assets exclusively related recothrom price determined based multiple revenues plus cost remaining inventory held bms time option exercised assets previously transferred medicines company revert back bms option may exercised medicines company february august case closing would expected occur february nonrefundable upfront alliance proceeds million received bms allocated rights transferred medicines company million fair value option purchase remaining assets million please see item financial statementsnote alliances information regarding alliance licensing arrangements addition strategic alliances described inlicensing outlicensing arrangements respect inlicenses agreements novartis reyataz merck efavirenz among others also certain compounds outlicensed third parties development commercialization including obtained acquisitions entitled receive milestone payments compounds move regulatory process royalties based net product sales products commercialized intellectual property product exclusivity license number patents us foreign countries primarily covering products also developed many brand names trademarks products consider overall protection patents trademarks licenses intellectual property rights material value act protect rights infringement pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity products market exclusivity generally determined two forms intellectual property patent rights held innovator company regulatory forms exclusivity innovative drug entitled patents key determinant market exclusivity branded pharmaceuticals patents provide innovator right exclude others practicing invention related medicine patents may cover among things active ingredients various uses drug product pharmaceutical formulations drug delivery mechanisms processes intermediates useful manufacture products protection individual products extends varying periods accordance expiration dates patents various countries protection afforded may also vary country country depends upon type patent scope coverage availability meaningful legal remedies country market exclusivity also sometimes influenced regulatory intellectual property rights many developed countries provide certain nonpatent incentives development medicines example us eu japan certain countries regulatory intellectual property rights offered incentives research medicines rare diseases orphan drugs medicines useful treating pediatric patients incentives extend market exclusivity period product beyond patent term us eu japan china also provide minimum period time approval new drug regulatory agency may rely upon innovators data approve competitors generic copy data protection regions china however questionable whether data protection laws enforceable certain markets patent protection forms market exclusivity may expired data protection particular importance however regulatory forms exclusivity prevent competitor gaining regulatory approval prior expiration regulatory data exclusivity basis competitors safety efficacy data drug even drug identical marketed innovator specific aspects law governing market exclusivity data protection pharmaceuticals vary country country following summarizes key exclusivity rules markets representing significant sales united states us key products protected patents varying terms depending type patent filing date significant portion products patent life however lost time takes innovative company develop obtain regulatory approval new drug compensation least part lost patent term innovator may depending number factors extend expiration date one patent maximum term five years provided extension cause patent effect years date drug approval company seeking market innovative pharmaceutical us must submit complete set safety efficacy data fda innovative pharmaceutical chemical company files new drug application nda medicine biological product biologics license application bla filed type application filed affects regulatory exclusivity rights chemical products competitor seeking launch generic substitute chemical innovative drug us must file abbreviated nda anda fda anda generic manufacturer needs demonstrate bioequivalence generic substitute approved nda drug anda relies upon safety efficacy data previously filed innovator nda innovator company required list certain patents covering medicine fda commonly known orange book absent successful patent challenge fda approve anda innovators listed patents expire however innovator marketed product four years generic manufacturer may file anda allege one patents listed orange book innovators nda either invalid infringed allegation commonly known paragraph iv certification innovator must decide whether file patent infringement suit generic manufacturer time time andas including paragraph iv certifications filed respect certain products evaluate andas casebycase basis warranted file suit generic manufacturer protect patent rights addition benefiting patent protection certain innovative pharmaceutical products receive periods regulatory exclusivity nda designated orphan drug receive seven years exclusivity orphan indication time period neither ndas andas drug product approved orphan use company may also earn six months additional exclusivity drug specific clinical trials conducted written request fda study use medicine treat pediatric patients submission fda made prior loss basic exclusivity medicines approved nda also receive several types regulatory data protection innovative chemical pharmaceutical entitled five years regulatory data protection us competitors file fda approval generic substitutes innovators patent challenged described generic manufacturer may file anda fourth year fiveyear data protection period pharmaceutical drug product contains active ingredient previously approved nda approved new formulation drug new indication basis new clinical trials receives three years data protection formulation indication biologic products us healthcare legislation enacted created approval pathway biosimilar versions innovative biological products previously exist prior time innovative biologics essentially unlimited regulatory exclusivity new regulatory mechanism fda approve products similar generic copies innovative biologics basis less extensive data required full bla innovator marketed product four years manufacturer may file application approval biosimilar version innovator product however although application approval biosimilar may filed four years approval innovator product qualified innovative biological products receive years regulatory exclusivity meaning fda may approve biosimilar version years innovative biological product first approved fda law also provides mechanism innovators enforce patents protect innovative biological products biosimilar applicants challenge patents patent litigation may begin early four years innovative biological products first approved fda us increased likelihood generic biosimilar challenges innovators intellectual property increased risk loss innovators market exclusivity first generic companies increasingly sought challenge innovators basic patents covering major pharmaceutical products second statutory regulatory provisions us limit ability innovator company prevent generic biosimilar drugs approved launched patent litigation ongoing result developments possible predict length market exclusivity particular product certainty based solely expiration relevant patents current forms regulatory exclusivity european union patents pharmaceutical products generally enforceable eu us may extended compensate patent term lost regulatory review process extensions granted countrybycountry basis primary route use obtain marketing authorization pharmaceutical products eu centralized procedure procedure compulsory certain pharmaceutical products particular using biotechnological processes also available certain new chemical compounds products company seeking market innovative pharmaceutical product centralized procedure must file complete set safety data efficacy data part marketing authorization application maa european medicines agency ema ema evaluates maa provides recommendation european commission ec ec approves denies maa also possible new chemical products obtain marketing authorization eu mutual recognition procedure application made single member state member state approves pharmaceutical product national procedure applicant may submit approval mutual recognition procedure member states obtaining marketing authorization approval company must obtain pricing reimbursement pharmaceutical product typically subject member state law certain eu countries process take place simultaneously product marketed eu countries process must completed company market new product pricing reimbursement procedure take months sometimes years complete throughout eu products marketing authorizations filed octobernovember subject regime eight years innovator received first community authorization medicinal product generic company may file marketing authorization application product health authorities marketing authorization application approved generic company may commercialize product either years elapsed initial marketing authorization granted innovator possible extension years available innovator first eight years marketing authorization obtains additional indication significant clinical benefit comparison existing treatments products filed prior octobernovember year period data protection centralized procedures period either six years mutual recognition procedure depending member state contrast us patents eu listed regulatory authorities generic versions pharmaceutical products approved data protection expires regardless whether innovator holds patents covering drug thus possible innovator may seeking enforce patents generic competitor already marketing product also european patent system opposition procedure generic manufacturers may challenge validity patents covering innovator products within nine months grant general eu law treats chemicallysynthesized drugs biologicallyderived drugs respect intellectual property data protection addition relevant legislation annexes related biologic medicinal products ema issued guidelines outline additional information provided biosimilar products also known generic biologics order review application marketing approval japan japan medicines new chemical entities generally afforded eight years data exclusivity approved indications dosage patents pharmaceutical products enforceable generic copies receive regulatory approval data exclusivity patent expirations us patents japan may extended compensate patent term lost regulatory review process general japanese law treats chemicallysynthesized biologicallyderived drugs respect intellectual property market exclusivity china china medicines new chemical entities generally afforded six years data exclusivity approved indications dosage uncertainty chinas exclusivity laws resulted generic competition china market generic copies receive regulatory approval data exclusivity patent expirations currently unlike us china patent term restoration compensate patent term lost regulatory process general chinese law treats chemicallysynthesized biologicallyderived drugs respect intellectual property market exclusivity rest world countries outside us eu japan china wide variety legal systems respect intellectual property market exclusivity pharmaceuticals developed countries utilize systems similar either us eu among developing countries adopted patent laws andor regulatory exclusivity laws others developing countries formally adopted laws order comply world trade organization wto commitments taken steps implement laws meaningful way enforcement wto actions long process governments assurance outcome thus assessing likely future market exclusivity innovative drugs developing countries take account formal legal rights political factors well marketing distribution customers promote appropriate use products directly healthcare professionals providers doctors nurse practitioners physician assistants pharmacists technologists hospitals pharmacy benefit managers pbms managed care organizations mcos also provide information appropriate use products consumers us directtoconsumer print radio television digital advertising promotion addition sponsor general advertising educate public innovative medical research corporate mission discussion regulation promotion marketing pharmaceuticals see government regulation price constraints field sales medical organizations explain risks benefits approved uses products medical professionals work gain access products formularies reimbursement plans lists recommended approved medicines products including medicare part plans providing information clinical profiles products marketing sales prescription pharmaceuticals limited approved uses particular product continue develop scientific data information products provide information response unsolicited inquiries doctors medical professionals managed care organizations operations include several marketing sales organizations product marketing organization supported sales force may responsible selling one products also marketing organizations focus certain classes customers managed care entities certain types marketing tools digital consumer communications sales forces focus communicating information new products new uses well established products promotion physicians increasingly targeted physician specialists treat patients need medicines products sold principally wholesalers lesser extent directly distributors retailers hospitals clinics government agencies pharmacies gross revenues three largest pharmaceutical wholesalers us percentage global gross revenues follows mckesson corporation cardinal health inc amerisourcebergen corporation us business inventory management agreements imas substantially direct wholesaler distributor customers allow us monitor us wholesaler inventory levels requires wholesalers distributors maintain inventory levels one month demand imas including three largest wholesalers expire december subject certain termination provisions number defined countries outside us established full scale distributor model make medically necessary drugs available patients continue marketing authorization trademarks products contracted services fullservice distributor provide distribution logistics regulatory pharmacovigilance sales advertising promotion certain products contracts clearly define terms conditions along services provide supply firm order period monitor incountry sales forecasts ensure reasonable inventory levels products sale maintained fully continuously meet demand products within distributors territory responsibility sales distributorbased countries represented less companys total revenues competition markets compete generally broad based highly competitive compete worldwide researchbased drug companies many smaller research companies limited therapeutic focus generic drug manufacturers important competitive factors include product efficacy safety ease use price demonstrated costeffectiveness marketing effectiveness product labeling customer service research development new products processes sales products impacted new studies indicate competitors product safer effective treating disease particular form disease one products revenues also impacted additional labeling requirements relating safety convenience may imposed products fda similar regulatory agencies different countries competitors introduce new products processes therapeutic cost advantages products subject progressive price reductions decreased volume sales generic competition one biggest competitive challenges face generic pharmaceutical manufacturers us eu regulatory approval process exempts generics costly timeconsuming clinical trials demonstrate safety efficacy allowing generic manufacturers rely safety efficacy innovator product result generic pharmaceutical manufacturers typically invest far less research development researchbased pharmaceutical companies therefore price products significantly lower branded products accordingly branded product loses market exclusivity normally faces intense price competition generic forms product upon expiration loss market exclusivity product lose major portion revenues product short period time rate revenues decline product expiration exclusivity varies country general decline us market rapid developed countries though observed rapid declines number eu countries well also declines developed countries tend rapid developing countries rate revenues decline expiration exclusivity also historically influenced product characteristics example drugs used large patient population eg prescribed key primary care physicians tend experience rapid declines drugs specialized areas medicine eg oncology drugs complex manufacture eg sterile injectable products usually experience slower decline simpler manufacture certain countries outside us patent protection weak nonexistent must compete generic versions shortly launch innovative products addition generic pharmaceutical companies may introduce generic product exclusivity expired resolution related patent litigation information market exclusivity see intellectual property product exclusivity believe longterm competitive position depends upon success discovering developing innovative costeffective products serve unmet medical needs together ability manufacture products efficiently market effectively highly competitive environment managed care organizations growth mcos us also major factor healthcare marketplace half us population participates version managed care mcos include medical insurance companies medical plan administrators healthmaintenance organizations medicare part prescription drug plans alliances hospitals physicians physician organizations organizations consolidating fewer larger entities thus enhancing purchasing strength importance us successfully compete business mcos must often demonstrate products offer medical benefits also cost advantages compared forms care new products introduce compete products already market products later developed competitors noted generic drugs exempt costly timeconsuming clinical trials demonstrate safety efficacy often lower costs brandname drugs mcos focus primarily immediate cost drugs often favor generics reason many governments also encourage use generics alternatives brandname drugs healthcare programs laws us generally allow many cases require pharmacists substitute generic drugs rated government procedures essentially equivalent brandname drug substitution must made unless prescribing physician expressly forbids exclusion product formulary lead sharply reduced usage mco patient population consequently pharmaceutical companies compete aggressively products included possible companies compete inclusion based upon unique features products greater efficacy better patient ease use fewer side effects lower overall cost therapy also important factor products demonstrate fewer therapeutic advantages must compete inclusion based primarily price generally although universally successful major products included mco formularies government regulation price constraints pharmaceutical industry subject extensive global regulation regional country state local agencies federal food drug cosmetic act fdc act federal statutes regulations various state statutes regulations laws regulations foreign governments govern varying degrees testing approval production labeling distribution postmarket surveillance advertising dissemination information promotion products lengthy process laboratory clinical testing data analysis manufacturing development regulatory review necessary required governmental approvals extremely costly significantly delay product introductions given market promotion marketing manufacturing distribution pharmaceutical products extensively regulated major world markets addition operations subject complex federal state local foreign environmental occupational safety laws regulations anticipate laws regulations affecting manufacture sale current products introduction new products continue require substantial scientific technical effort time expense well significant capital investments particular importance fda us jurisdiction virtually activities imposes requirements covering testing safety effectiveness manufacturing labeling marketing advertising postmarketing surveillance products many cases fda requirements increased amount time money necessary develop new products bring market us fda mandates drugs manufactured packaged labeled conformity current good manufacturing practices cgmp established fda complying cgmp regulations manufacturers must continue expend time money effort production recordkeeping quality control ensure products meet applicable specifications requirements ensure product safety efficacy fda periodically inspects drug manufacturing facilities ensure compliance applicable cgmp requirements failure comply statutory regulatory requirements subjects us possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experiences use products must reported fda could result imposition market restrictions labeling changes product removal product approvals may withdrawn compliance regulatory requirements maintained problems concerning safety efficacy occur following approval federal government extensive enforcement powers activities pharmaceutical manufacturers including authority withdraw product approvals commence actions seize prohibit sale unapproved noncomplying products halt manufacturing operations compliance cgmps impose seek injunctions voluntary recalls civil monetary criminal penalties restriction prohibition sales withdrawal approval products marketed us could materially adversely affect business financial condition results operations cash flows marketing authorization products subject revocation applicable governmental agencies addition modifications enhancements approved products changes manufacturing locations many circumstances subject additional fda approvals may may received may subject lengthy application process distribution pharmaceutical products subject prescription drug marketing act pdma part fdc act regulates activities federal state level pdma implementing regulations states permitted require registration manufacturers distributors provide pharmaceuticals even manufacturers distributors place business within state states also permitted adopt regulations limiting distribution product samples licensed practitioners pdma also imposes extensive licensing personnel recordkeeping packaging quantity labeling product handling facility storage security requirements intended prevent sale pharmaceutical product samples product diversions fda amendments act imposed additional obligations pharmaceutical companies delegated enforcement authority fda area drug safety key elements legislation give fda authority require companies conduct postmarketing safety studies drugs impose certain drug labeling changes relating safety mandate risk mitigation measures education healthcare providers restricted distribution medicines require companies publicly disclose data clinical trials prereview television advertisements marketing practices us pharmaceutical manufacturers subject federal state healthcare laws used protect integrity government healthcare programs office inspector general us department health human services oig oversees compliance applicable federal laws connection payment products government funded programs primarily medicaid medicare laws include federal antikickback statute criminalizes offering something value induce recommendation order purchase products services reimbursed government healthcare program oig issued series guidances segments healthcare industry including compliance program guidance pharmaceutical manufacturers oig guidance includes recommendation pharmaceutical manufacturers minimum adhere phrma code voluntary industry code marketing practices subscribe phrma code implemented compliance program address requirements set forth oig guidance compliance healthcare laws failure comply healthcare laws could subject us administrative legal proceedings including actions federal state government agencies actions could result imposition civil criminal sanctions may include fines penalties injunctive remedies impact could materially adversely affect business financial condition results operations cash flows also subject jurisdiction various federal state regulatory enforcement departments agencies federal trade commission department justice department health human services us also licensed us drug enforcement agency procure produce controlled substances therefore subject possible administrative legal proceedings actions organizations actions may result imposition civil criminal sanctions may include fines penalties injunctive administrative remedies activities outside us also subject regulatory requirements governing testing approval safety effectiveness manufacturing labeling marketing products regulatory requirements vary country country whether fda approval approval ec obtained product approval product comparable regulatory authorities countries outside us eu case may must obtained prior marketing product countries approval process may less rigorous country country time required approval may longer shorter required us approval one country assure product approved another country many markets outside us operate environment governmentmandated costcontainment programs several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs andor enacted acrosstheboard price cuts methods cost control eu countries example government regulates pricing new product launch often direct price controls international price comparisons controlling profits andor reference pricing markets uk germany government set pricing restrictions launch pricing freedom subsequently limited operation profit price control plan uk operation reference price system germany companies also face significant delays market access new products mainly france spain italy belgium two years elapse new medicines become available national markets additionally member states eu regularly imposed new additional cost containment measures pharmaceuticals recent years italy example imposed mandatory price decreases existence price differentials within eu due different national pricing reimbursement laws leads significant parallel trade flows us healthcare industry subject various governmentimposed regulations authorizing prices price controls continue impact total revenues participate state government medicaid programs well certain qualifying federal state government programs whereby discounts rebates provided participating state local government entities also participate government programs specify discounts certain government entities significant us department defense us department veterans affairs entities receive minimum discounts based defined nonfederal average manufacturer price purchases march us government enacted healthcare reform legislation signing law patient protection affordable care act hr reconciliation bill containing package changes healthcare bill legislation makes extensive changes current system healthcare insurance benefits intended broaden coverage reduce costs bills significantly change americans receive healthcare coverage pay also significant impact companies particular companies pharmaceutical industry healthcare related industries including bms experienced continue experience additional financial costs certain changes business new healthcare law implemented example minimum rebates medicaid drug sales increased percent percent medicaid rebates also extended drugs used riskbased medicaid managed care plans addition extend discounts certain critical access hospitals cancer hospitals covered entities required expansion b drug pricing program public health service act beginning also required provide percent discount brandname drugs patients fall within medicare part coverage gap also referred donut hole also required pay annual nontaxdeductible fee federal government based allocation market share branded prior year sales certain government programs including medicare medicaid department veterans affairs department defense tricare discussion rebates programs see item managements discussion analysis financial condition results operationstotal revenues critical accounting policies sources availability raw materials general purchase raw materials supplies required production products open market products purchase raw materials supplies one source source available us single source approved source among many available us thereby requiring us obtain raw materials supplies particular source attempt possible mitigate raw material supply risks inventory management alternative sourcing strategies discussion sourcing see manufacturing quality assurance discussions particular products manufacturing quality assurance meet expected product demand operate manage manufacturing network including thirdparty contract manufacturers inventory related thereto manner permits us improve efficiency maintaining flexibility reallocate manufacturing capacity pharmaceutical production processes complex highly regulated vary widely product product given shifting adding manufacturing capacity lengthy process requiring significant capital expenditures well regulatory approvals maintain operate flexible manufacturing network consisting internal external resources minimize unnecessary product transfers inefficient uses manufacturing capacity discussion regulatory impact manufacturing see government regulation price constraints pharmaceutical manufacturing facilities located us puerto rico france italy ireland japan mexico china require significant ongoing capital investment maintenance compliance increasing regulatory requirements addition product line changes next several years expect continue modification existing manufacturing network meet complex processing standards may required newly introduced products including biologics biologics manufacturing involves complex processes traditional pharmaceutical operations fda approved large scale multiproduct bulk biologics manufacturing facility devens massachusetts may continue make capital investments facility rely third parties manufacture supply us portion active ingredients necessary us manufacture various products including baraclude sustiva franchise erbitux yervoy reyataz abilify kombiglyze orencia eliquis avalide plavix beginning february following sale diabetes business astrazeneca astrazeneca assumed manufacturing responsibilities bydureon byettato maintain stable supply products take variety actions including inventory management maintenance additional quantities materials possible designed provide reasonable level ingredients held thirdparty supplier us manufacturing operations interrupted additional protection cases take steps maintain approved backup source available example rely capacity devens massachusetts facility capacity available thirdparty contract manufacturers manufacture orencia thirdparty manufacturer rely existing future products unable maintain stable supply products operate sufficient capacity meet order requirements comply government regulations manufacturing pharmaceuticals meet complex processing requirements biologics business performance prospects could negatively impacted additionally thirdparty suppliers experience extended plant shutdowns substantial unplanned increases demand suspension manufacturing regulatory reasons could experience interruption supply certain products product shortages production could resumed expanded connection divestitures licensing arrangements distribution agreements certain products certain circumstances entered agreements agreed supply products third parties addition liabilities could arise failure supply products agreements arrangements could require us invest facilities production nonstrategic products result additional regulatory filings obligations cause interruption manufacturing products success depends great measure upon customer confidence quality products integrity data support safety effectiveness product quality arises total commitment quality parts operations including research development purchasing facilities planning manufacturing distribution maintain qualityassurance procedures relating quality integrity technical information production processes control production processes involves detailed specifications ingredients equipment facilities manufacturing methods processes packaging materials labeling perform tests various stages production processes final product ensure product meets regulatory requirements standards tests may involve chemical physical chemical analyses microbiological testing combination along analyses quality control provided business unitsite quality assurance groups monitor existing manufacturing procedures systems used us subsidiaries thirdparty suppliers environmental regulation facilities operations subject extensive us foreign laws regulations relating environmental protection human health safety including governing discharges pollutants air water use management disposal hazardous radioactive biological materials wastes cleanup contamination pollution controls permits required many operations permits subject modification renewal revocation issuing authorities environment health safety group monitors operations around world providing us overview regulatory requirements overseeing implementation standards compliance also incur operating capital costs matters ongoing basis expended approximately million million million capital projects undertaken specifically meet environmental requirements addition invested projects reduce resource use energy water although believe substantial compliance applicable environmental health safety requirements permits required operations nevertheless could incur additional costs including civil criminal fines penalties cleanup costs thirdparty claims property damage personal injury violations liabilities laws many current former facilities operation many years time operators facilities generated used stored disposed substances wastes considered hazardous federal state andor foreign environmental laws including us comprehensive environmental response compensation liability act cercla result soil groundwater certain facilities may contaminated may required make significant expenditures investigate control remediate contamination cases provide compensation andor restoration damages natural resources currently involved investigation remediation current former facilities also identified potentially responsible party prp applicable laws environmental conditions approximately former waste disposal reprocessing facilities operated third parties investigation andor remediation activities ongoing may face liability cercla federal state foreign laws entire cost investigation remediation contaminated sites natural resource damages regardless fault ownership time disposal release addition certain sites bear remediation responsibility pursuant contractual obligations generally thirdparty operator sites involving multiple prps liability expected apportioned based nature amount hazardous substances disposed party site number financially viable prps additional information matters see item financial statementsnote legal proceedings contingencies employees december employed approximately people includes approximately employees process transferred astrazeneca part sale diabetes business february see item financial statementsnote assets heldforsale discussion foreign operations significant operations outside us conducted subsidiaries distributors geographic breakdown total revenues see table captioned geographic areas item financial statementsnote business segment information discussion total revenues geographic area see item managements discussion analysis financial condition results operationstotal revenues international operations subject certain risks inherent conducting business abroad including limited currency fluctuations possible nationalization expropriation price exchange controls counterfeit products limitations foreign participation local enterprises restrictive governmental actions international businesses also subject governmentimposed constraints including laws pricing reimbursement use products depending direction change relative us dollar foreign currency values increase decrease reported dollar value net assets results operations change foreign exchange rates net unfavorable impact growth rate revenues predict certainty future changes foreign exchange rates effect growth rate revenues attempt mitigate impact operational means using various financial instruments see discussions item quantitative qualitative disclosures market risk item financial statementsnote financial instruments fair value measurements bristolmyers squibb website internet website address wwwbmscom website make available free charge annual quarterly current reports including amendments reports soon reasonably practicable electronically file material furnishes material us securities exchange commission sec information relating corporate governance bristolmyers squibb including standards business conduct ethics code ethics senior financial officers code business conduct ethics directors collectively codes corporate governance guidelines information concerning executive committee board directors including board committees committee charters transactions bristolmyers squibb securities directors executive officers available website investorscorporate governance caption print stockholder upon request waivers codes directors executive officers material amendment code business conduct ethics directors code ethics senior financial officers posted promptly website information relating stockholder services including dividend reinvestment plan direct deposit dividends available website investorsstockholder services caption addition information sustainability programs available website responsibility caption incorporate reference certain information parts proxy statement annual meeting stockholders sec allows us disclose important information referring manner please refer information proxy statement annual meeting stockholders annual report available website investorssec filings caption march item risk factors factors described could significantly negatively affect business prospects financial condition operating results credit ratings could cause trading price common stock decline additional risks uncertainties presently known us risks currently consider immaterial may also impair operations financial condition face intense competition manufacturers including innovative medicines lowerpriced generic products bms dependent uptake market expansion marketed brands new indications product extensions well copromotional activities alliance partners deliver future growth competition including lowerpriced generic versions products major challenge within us internationally face patent expirations increasingly aggressive generic competition competition may include new products developed competitors lower prices real perceived superior efficacy benefit safety risk profiles otherwise competitive products ii technological advances patents attained competitors iii clinical study results products competitors products iv business combinations among competitors major customers v competing interests external partnerships develop bring new products markets could also experience limited market access due real perceived differences value propositions products compared competitors possible may lose market exclusivity product earlier expected pharmaceutical biotechnology industries majority innovative products commercial value realized period market exclusivity us countries market exclusivity expires generic versions product approved marketed usually substantial rapid declines products revenues market exclusivity products based upon patent rights andor certain regulatory forms exclusivity scope patent rights varies country country may also dependent availability meaningful legal remedies country failure obtain patent intellectual property rights limitations use loss rights could material us countries including certain eu member states basic patent protections products may exist certain countries historically offer right obtain specific types patents andor licensors file markets addition patent environment unpredictable validity enforceability patents predicted certainty absent relevant patent protection product data exclusivity period expires generic versions product approved marketed addition prior expiration data exclusivity competitor could seek regulatory approval submitting clinical trial data obtain marketing approval manufacturers generic products also increasingly seeking challenge patents expire could face earlierthanexpected competition generic companies products time patents covering two key products sustiva baraclude currently subject patent litigation cases generic manufacturers may choose launch generic product risk expiration applicable patents andor final resolution related patent litigation example may face generic competition baraclude us time following federal courts decision invalidate composition matter patent february assurance particular product enjoy market exclusivity full period time appears estimates disclosed addition countries india allowing competitors manufacture sell generic versions branded products known compulsory licensing negatively impact protections afforded company increased pricing pressure restrictions us abroad managed care organizations institutional purchasers government agencies program among others could negatively affect revenues profit margins products continue subject increasing pressures across portfolio relating market access pricing rebates restrictions us eu regions around world including limited rules practices managed care organizations institutional governmental purchasers ii judicial decisions governmental laws regulations medicare medicaid us healthcare reform including patient protection affordable care act iii potential impact pharmaceutical reimbursement medicare part formularies product pricing general iv delays gaining reimbursement v government price erosion mechanisms across europe countries resulting deflation pharmaceutical product pricing vi collection delays government funded public hospitals vii impact pricing parallel trade across borders viii developments technology andor industry practices could directly indirectly impact reimbursement policies practices thirdparty payers ix limited market access due real perceived differences value propositions products compared competing products may experience difficulties delays development commercialization new products developing commercializing new products includes inherent risks uncertainties compounds products may appear promising development fail reach market within expected optimal timeframe fail ever reach market approved product extensions additional indications including due efficacy safety concerns delay denial regulatory approvals delays difficulties producing products commercial scale excessive costs manufacture ii failure enter successfully implement optimal alliances development andor commercialization new products iii failure maintain consistent scope variety promising latestage products iv failure one products achieve maintain commercial viability v changes regulatory approval processes may cause delays denials new product approvals observed recent trend us food drug administration fda delay approval decision new product beyond announced action date six months longer regulatory approval delays especially common product expected risk evaluation mitigation strategy required fda address significant riskbenefit issues inability bring product market significant delay expected approval related launch date new product could negatively impact revenues earnings product obtained acquisition could result significant impairment process research development intangible assets certain acquired pipeline programs cancelled believe commercial prospects reduced may recognize material noncash impairment charges programs finally natural manmade disaster sabotage research development labs compound library andor loss key molecules intermediaries could negatively impact product development cycle failure execute business strategy could adversely impact growth profitability biopharmaceutical company focus innovative products significant unmet medical needs oncology virology immunology specialty cardiovascular disease may able consistently maintain rich pipeline internal research development transactions third parties support future revenue growth competition among major pharmaceutical companies acquisition product licensing opportunities intense may able locate suitable acquisition targets licensing partners reasonable prices successfully execute transactions also may able successfully realize expected efficiencies effectiveness changes structure operations specialty care strategy including recent reorganizations research development organization commercial operations well evolution support functions enterprises services organization ongoing continuous improvement initiatives addition realizing synergies expected benefits acquisitions divestitures mergers alliances restructuring strategic initiatives may take longer expected complete may encounter difficulties including need regulatory approvals applicable unable support grow currently marketed products successfully execute launches newly approved products advance latestage pipeline manage change transformational issues manage costs effectively operating results financial condition could negatively impacted addition failure hire retain personnel right expertise experience critical operations could adversely impact execution business strategy public announcement data clinical studies news developments related latestage immunooncology compounds likely cause significant volatility stock price development key immunooncology compounds whether alone part combination therapy delayed discontinued stock price could decline significantly evolving specialty care biopharmaceutical company focusing efforts resources certain disease areas oncology virology immunology specialty cardiovascular disease focused portfolio investors placing heightened scrutiny latestage compounds particular nivolumab important asset immunooncology portfolio expect receive significant amount data clinical trials evaluating nivolumab fully human monoclonal antibody investigated anticancer treatment nonsmalllung cancer renal cell cancer melanoma along tumor types alone combination approved cancer products yervoy announcement data clinical studies news developments related latestage immunooncology compounds nivolumab likely cause significant volatility stock price furthermore announcement negative unexpected data discontinuation development key immunooncology compounds whether alone part combination therapy delay anticipated timelines filing regulatory approval likely cause stock price decline significantly assurance data clinical studies support filing regulatory approval even approved key immunooncology compounds become commercially successful businesses acquire may underperform may able successfully integrate existing business may continue support pipeline compounds products obtained licensing acquisitions future revenues profits cash flows acquired companys products technologies pipeline candidates may materialize due lower product uptake delayed missed pipeline opportunities inability capture expected synergies increased competition safety concerns regulatory issues supply chain problems factors beyond control substantial difficulties costs delays could result integrating acquisitions including research development manufacturing distribution sales marketing promotion information technology activities ii policies procedures processes controls compliance iii company cultures iv compensation structures human resource activities v tax considerations depend certain key products revenues cash flows earnings historically derived majority revenue earnings several key products heavily dependent one two products past years dependence profitability key products likely continue abilify revenues billion represented revenues reyataz sustiva franchise combined revenues billion represented revenues respectively baraclude orencia sprycel revenues totaled billion billion billion respectively reduction revenues one products could significantly negatively impact revenues cash flows earnings changes us foreign laws regulations may negatively affect revenues profit margins could become subject new government laws regulations could negatively affect business operating results financial condition company additional healthcare reform initiatives us countries including additional mandatory discounts ii increasing tax revenues us countries means reduce debt changing tax rates limiting phasingout eliminating deductions tax credits modifying tax collection processes taxing certain tax havens taxing certain excess income intellectual property changing rules earnings repatriations changing tax laws iii new laws regulations judicial governmental decisions affecting pricing drug reimbursement receivable payments access marketing within across jurisdictions iv changes intellectual property law v changes accounting standards vi increasing data privacy regulations enforcement vii emerging new regulatory requirements reporting payments value transfers healthcare professionals including us national physician payment transparency program viii potential impact importation restrictions legislative andor regulatory changes product labeling changes marketed products could result unexpected safety efficacy concerns negative impact products revenues regulatory authorities change labeling pharmaceutical product time including product marketed several years changes often result additional data postmarketing studies headtohead trials adverse events reports studies identify biomarkers objective characteristics indicate particular response product therapy studies produce important additional information product new information added products label affect safety andor efficacy profile product leading potential product recalls withdrawals declining revenue well product liability claims sometimes additional information studies identifies portion patient population may nonresponsive medicine labeling changes based studies may limit patient population studies providing additional information may sponsored us also sponsored competitors insurance companies government institutions managed care organizations influential scientists investigators interested parties additional safety efficacy information studies assist us healthcare providers identifying best patient population products also negatively impact revenues product due product returns limited patient population going forward additionally certain study results especially headtohead trials could affect products formulary listing could also adversely affect revenues could experience difficulties delays manufacturing distribution sale products product supply related patient access could negatively impacted among things seizure recalls products forced closings manufacturing plants ii supply chain continuity including natural manmade disasters one facilities critical supplier well failure failure suppliers comply current good manufacturing practices applicable regulations quality assurance guidelines could lead manufacturing shutdowns product shortages delays product manufacturing iii manufacturing quality assurancequality control supply problems governmental approval delays iv failure sole source single source supplier provide us necessary raw materials supplies finished goods extended period time v failure thirdparty manufacturer supply us finished product time vi construction regulatory approval delays new facilities expansion existing facilities including intended support future demand biologics products vii failure meet new emerging regulations requiring products tracked throughout distribution channels using unique identifiers verify authenticity supply chain viii manufacturing distribution issues including limits manufacturing capacity due regulatory requirements changes types products produced biologics physical limitations business interruptions adverse outcomes legal matters could negatively affect business current future lawsuits claims proceedings government investigations could preclude delay commercialization products could adversely affect operations profitability liquidity financial condition possible insurance recoveries available legal matters include intellectual property disputes ii adverse decisions litigation including product liability commercial cases iii antibribery regulations us foreign corrupt practice act uk antibribery act iv recalls withdrawals pharmaceutical products forced closings manufacturing plants v failure fulfill obligations supply contracts government customers vi product pricing promotional matters vii lawsuits claims asserting investigations violations securities antitrust federal state pricing consumer protection data privacy laws viii environmental health safety matters iv tax liabilities depend third parties meet contractual regulatory obligations rely suppliers vendors outsourcing partners alliance partners third parties research develop manufacture commercialize copromote sell products manage certain marketing selling human resource finance information technology business unit functional services meet contractual regulatory obligations relation arrangements us thirdparty providers located markets subject political social risk corruption infrastructure problems natural disasters addition country specific privacy data security risks given current legal regulatory environments failure critical third party meet obligations including future royalty milestone payments adequately deploy business continuity plans event crisis andor satisfactorily resolve significant disagreements us address factors could material adverse impact companys operations results addition third parties violate alleged violated laws regulations including local pharmaceutical code us foreign corrupt practice act uk bribery act similar laws regulations performance obligations us possible could suffer financial reputational harm negative outcomes including possible legal consequences increasingly dependent information technology systems infrastructure face certain risks including cyber security data leakage significant breakdown invasion corruption destruction interruption critical information technology systems infrastructure workforce others authorized access systems unauthorized persons could negatively impact operations everincreasing use evolution technology including cloudbased computing creates opportunities unintentional dissemination intentional destruction confidential information stored systems nonencrypted portable media storage devices could also experience business interruption information theft confidential information reputational damage industrial espionage attacks malware cyber attacks may compromise system infrastructure lead data leakage either internally thirdparty providers although aggregate impact operations financial condition material date target events nature expect continue invested industry appropriate protections monitoring practices data information technology reduce risks continue monitor systems ongoing basis current potential threats assurance however efforts prevent breakdowns breaches third party providers databases systems could adversely affect business social media platforms present risks challenges inappropriate andor unauthorized use certain media vehicles could cause brand damage information leakage could lead legal implications including improper collection andor dissemination personally identifiable information addition negative inaccurate posts comments us social networking web site could damage reputation brand image goodwill disclosure nonpublic companysensitive information workforce others external media channels could lead information loss might structured processes place secure protect information identifying new points entry social media continues expand presents new challenges adverse changes us global regional local economic conditions could adversely affect profitability global economic risks pose significant challenges companys growth profitability difficult mitigate worlds major economies hold historicallyhigh debt levels experiencing slow growth high unemployment several risks lie ahead including management us debt level european sovereign debt crisis significant operations europe including manufacturing exposure customer credit risks europe including governmentguaranteed hospital receivables markets payments received time addition future pension plan funding requirements continue sensitive global economic conditions related impact equity markets also exposed commercial risks economic factors control could pose significant challenges underlying profitability changes foreign currency exchange rates interest rates could material adverse effect operating results liquidity significant operations outside us revenues operations outside us accounted approximately revenues exposed fluctuations foreign currency exchange rates difficult mitigate also exposed changes interest rates ability access money markets andor capital markets could impeded adverse liquidity market conditions occur illegal distribution sale third parties counterfeit versions products stolen products could negative impact reputation business third parties may illegally distribute sell counterfeit versions products meet rigorous manufacturing testing standards patient receives counterfeit drug may risk number dangerous health consequences reputation business could suffer harm result counterfeit drugs sold brand name addition thefts inventory warehouses plants intransit properly stored later sold unauthorized channels could adversely impact patient safety reputation business item b unresolved staff comments none item properties world headquarters located park avenue new york ny lease approximately square feet floor space lease approximately properties countries manufacture products worldwide locations owned us manufacturing locations aggregate square feet floor space geographic area follows december number locations square feet united states europe rest world total portions manufacturing locations properties owned leased us us elsewhere used research development administration storage distribution information properties see item businessmanufacturing quality assurance item legal proceedings information pertaining legal proceedings found item financial statementsnote legal proceedings contingencies incorporated reference herein item mine safety disclosures applicable part ia executive officers registrant listed information executive officers february executive officers elected board directors initial term continues first board meeting following next annual meeting stockholders thereafter elected oneyear term successors elected executive officers serve pleasure board directors name current position age employment history past years lamberto andreotti executive vice president president worldwide pharmaceuticals chief executive officer director executive vice president chief operating officer worldwide pharmaceuticals member senior management team executive vice president chief operating officer president chief operating officer director company present chief executive officer director company charles bancroft vice president finance worldwide pharmaceuticals executive vice president chief financial officer chief financial officer company member senior management team present executive vice president chief financial officer company giovanni caforio md senior vice president us oncology executive vice president chief commercial senior vice president oncology us global commercialization officer senior vice president oncology immunology global commercialization member senior management team president us pharmaceuticals present executive vice president chief commercial officer joseph c caldarella vice president corporate controller senior vice president corporate controller present senior vice president corporate controller francis cuss mb bchir frcp senior vice president discovery exploratory clinical research executive vice president chief scientific officer senior vice president research member senior management team present executive vice president chief scientific officer brian daniels md senior vice president global clinical development senior vice president global development present senior vice president global development medical affairs medical affairs research development member senior management team john e elicker senior director investor relations senior vice president public affairs investor vice president investor relations relations senior vice president investor relations member senior management team present senior vice president public affairs investor relations frances heller head strategic alliances novartis pharmaceuticals senior vice president business development executive vice president exelixis member senior management team instructor stanford university present senior vice president business development sandra leung vice president corporate secretary acting general counsel general counsel corporate secretary present general counsel corporate secretary member senior management team samuel j moed senior vice president worldwide strategy operations senior vice president strategic planning senior vice president strategy analysis present senior vice president strategic planning analysis member senior management team name current position age employment history past years anne nielsen vice president senior counsel senior vice president chief compliance vice president associate general counsel ethics officer senior vice president deputy general counsel member senior management team present senior vice president chief compliance ethics officer louis schmukler senior vice president pharmaceutical operating unit wyeth pharmaceuticals president global manufacturing supply inc member senior management team senior vice president specialtybiotechnology operating unit pfizer present president global manufacturing supply paul von autenried vice president chief information officer senior vice president enterprise services chief senior vice president chief information officer information officer present senior vice president enterprise services chief information officer member senior management team part ii item market registrants common stock stockholder matters market prices bristolmyers squibb common stock traded new york stock exchange nyse symbol bmy quarterly summary high low market prices presented high low high low common first quarter second quarter third quarter fourth quarter holders common stock number record holders common stock december number record holders based upon actual number holders registered books date include holders shares street names persons partnerships associations corporations entities identified security position listings maintained depository trust companies dividends board directors declared following dividends per share paid quarters indicated common preferred first quarter second quarter third quarter fourth quarter december board directors declared quarterly dividend per share common stock paid february shareholders record january board directors also declared quarterly dividend per share preferred stock payable march shareholders record february issuer purchases equity securities following table summarizes surrenders repurchases equity securities month period ended december total number shares approximate dollar value average price purchased part shares may yet total number paid publicly announced purchased period shares purchaseda per sharea plans programsb plans programsb dollars millions except per share data january february march three months ended march april may june three months ended june july august september three months ended september october november december three months ended december twelve months ended december total number shares purchased total number shares purchased part publicly announced programs different shares common stock withheld us employee restricted stock awards order satisfy applicable tax withholding obligations b may board directors authorized repurchase billion common stock june board directors increased authorization repurchase common stock additional billion repurchase program expiration date may consider future repurchases item selected financial data five year financial summary amounts millions except per share data income statement dataa total revenues continuing operations net earnings net earnings attributable noncontrolling interest bms net earnings per common share attributable bms basic diluted average common shares outstanding basic diluted cash dividends paid bms common preferred stock cash dividends declared per common share financial position data december cash cash equivalents marketable securitiesb total assets longterm debtc equity discussion items affected comparability results years see item managements discussion analysis financial condition results operationsnongaap financial measures b includes current noncurrent marketable securities c also includes current portion longterm debt item managements discussion analysis financial condition results operations executive summary bristolmyers squibb company may referred bristolmyers squibb bms company us global specialty care biopharmaceutical company whose mission discover develop deliver innovative medicines help patients prevail serious diseases license manufacture market distribute sell pharmaceutical products global basis comparability total revenues earnings prior year periods impacted reduction share abilify aripiprazole revenues acquisition amylin expanded diabetes alliance arrangement astrazeneca loss exclusivity plavix billion intangible asset impairment charge transitioned away plavix avaproavalide continued grow key brands also shifted strategic focus earlystage research development advanced immunooncology portfolio hepatitis c portfolio rest latestage pipeline february bms sold astrazeneca diabetes business bms comprised global alliance including rights ownership onglyza saxagliptin forxiga dapagliflozin bydureon exenatide extendedrelease injectable suspension byetta exenatide symlin pramlintide acetate metreleptin astrazeneca paid billion bms closing million milestone february approval farxiga dapagliflozin us make contingent regulatory salesbased milestone payments million royalty payments based net sales see item financial statementsnote assets heldforsale discussion highlights following table summarizes financial information year ended december dollars millions except per share data total revenues total expenses earnings income taxes provision forbenefit income taxes effective taxbenefit rate net earnings attributable bms gaap nongaap diluted earnings per share gaap nongaap cash cash equivalents marketable securities nongaap financial measures including nongaap earnings related eps information adjusted exclude specified items represent certain costs expenses gains losses items impacting comparability financial results detailed listing specified items information reconciliations nongaap financial measures see nongaap financial measures business environment pharmaceuticalbiotechnology industry highly competitive subject numerous government regulations many competitive factors may significantly affect revenues products including product efficacy safety price demand competition costeffectiveness marketing effectiveness market access product labeling quality control quality assurance manufacturing operations research development new products successfully compete healthcare industry must demonstrate products offer medical benefits cost advantages new product introductions often compete products already market therapeutic category addition potential competition new products competitors may introduce future manufacture branded products priced higher generic products generic competition one key challenges pharmaceuticalbiotechnology industry majority innovative products commercial value usually realized market exclusivity period afterwards longer protected patent subject new competing products form generic brands upon exclusivity loss experience significant reduction products sales short period time competitors seeking approval biological products full biologics license application bla must file safety efficacy data address challenges biologics manufacturing involving complex processes costs pharmaceutical operations us healthcare legislation enacted abbreviated path regulatory approval biosimilar versions biological products path approval biosimilar products us healthcare legislation significantly affects regulatory data exclusivity biological products legislation provides regulatory mechanism allowing regulatory approval biologic drugs similar necessarily generic copies innovative drugs basis less extensive data required full bla possible time reasonably assess impact us biosimilar legislation company globally healthcare industry subject various governmentimposed regulations authorizing prices price controls continue impact total revenues march us government enacted healthcare reform legislation signing law patient protection affordable care act hr reconciliation bill containing package changes healthcare bill continue experience additional financial costs certain changes business healthcare law provisions become effective aggregate financial impact us healthcare reform next years depends number factors including limited pending implementation guidance potential changes sales volume eligible new rebates discounts fees expected increase number people healthcare coverage patient protection affordable care act many regions outside us operate environments governmentmandated costcontainment programs regulatory bodies groups exerting downward pressure pricing example pricing freedom limited united kingdom uk operation profit control plan germany operation reference price system many european countries continuing fiscal challenges healthcare payers including government agencies reduced expected continue reduce cost healthcare actions directly indirectly impose additional price restrictions companies also face significant delays market access new products two years elapse drug approval new medicines available countries growth managed care organizations mcos us significantly impacted competition healthcare industry mcos seek reduce healthcare expenditures participants volume purchases longterm contractual discounts various pharmaceutical providers market potential created large pool participants marketing prescription drugs mcos important part strategy companies compete inclusion mco formularies generally successful key products included believe developments managed care industry including going consolidation continue downward pressure prices pharmaceutical biotechnology production processes complex highly regulated vary widely product shifting adding manufacturing capacity usually lengthy process requiring significant capital expenditures regulatory approvals biologics manufacturing involves complex processes traditional pharmaceutical operations biologics become larger percentage product portfolio continue maintain supply arrangements thirdparty manufacturers incur substantial investments increase internal capacity produce biologics commercial scale united states food drug administration fda approved large scale multiproduct bulk biologics manufacturing facility devens massachusetts may continue make capital investments facility maintain competitive position market strive uphold position depending success discovering developing delivering innovative costeffective products help patients prevail serious diseases subject number significant pending lawsuits claims proceedings investigations possible time reasonably assess final outcomes investigations litigations additional discussion legal matters see item financial statementsnote legal proceedings contingencies strategy since transforming bms leadingedge biopharma company focused exclusively discovering developing delivering innovative medicines address serious unmet medical needs continue evolve driven fundamental objective grow marketed products progress pipeline focused four core therapeutic areas oncology virology immunology specialty cardiovascular disease within oncology pioneering innovative medicines area immunooncology unlock bodys immune system battle cancer yervoy ipilimumab first immunooncology agent introduced treatment metastatic melanoma continue invest significantly deep pipeline innovative medicines area covering broad array cancers evolving commercial model growing marketed product portfolio manner consistent overall strategy oncology building success yervoy yielded revenues nearly billion products sprycel dasatinib erbitux cetuximab beyond oncology continue support key brands virology franchise reyataz atazanavir sulfate baraclude entecavir together accounting approximately billion revenues addition investing orencia abatacept key brand immunology portfolio accounted approximately billion revenues additionally strongly committed eliquis apixaban novel oral anticoagulant launched globally february divested diabetes portfolio allows us accelerate evolution business model leading specialty care biopharma company transaction also allows us focus resources behind growth opportunities drive greatest longterm value looking ahead continue implement biopharma strategy driving growth key brands executing new product launches investing pipeline maintaining culture continuous improvement pursuing disciplined capital allocation including business development product pipeline developments manage research development rd programs portfolio basis investing resources stage research development early discovery latestage development continually evaluate portfolio rd assets ensure appropriate balance earlystage latestage programs support future growth consider rd programs entered phase iii development significant programs constitute latestage development pipeline development programs include investigational compounds phase iii development initial indications marketed products phase iii development additional indications formulations spending programs represents approximately annual rd expenses individual investigational compound marketed product represented rd expenses last three years expect latestage development programs make market latestage development programs rd programs could potentially impact revenue earnings within next years following recent significant developments marketed products latestage pipeline hepatitis c portfolio daclatasvir nsa replication complex inhibitor development asunaprevir ns protease inhibitor development bms nsb nonnucleoside polymerase inhibitor development january company announced european medicines agency ema validated marketing authorization application maa use daclatasvir treatment adults chronic hepatitis c compensated liver disease including genotype application seeks approval daclatasvir use combination agents including sofosbuvir treatment chronic hepatitis c ema 's validation marks start accelerated regulatory review process november company announced submission new drug application nda japan 's pharmaceutical medical devices agency submission based results phase iii study demonstrating week alloral regimen daclatasvir asunaprevir achieved overall sustained virologic response weeks end treatment japanese patients chronic hepatitis genotype b either interferon ineligibleintolerant nonresponders null partial interferonbased therapies april european association study liver amsterdam company announced new phase ii data demonstrating week triple directacting antiviral treatment regimens daclatasvir asunaprevir bms showed high rates sustained virologic response treatmentnave genotype chronic hepatitis c patients time points ranging weeks posttreatment fda designated tripledaa regimen breakthrough therapy treatment chronic hepatitis c baraclude entecavir oral antiviral agent treatment chronic hepatitis b december company announced fda granted additional six month period exclusivity market baraclude february us district court district delaware invalidated composition matter patent covering baraclude scheduled expire see item financial statementsnote legal proceedings contingencies discussion company prepared take legal action event teva pharmaceutical industries ltd teva chooses launch generic product prior resolution company 's appeal sustiva efavirenz nonnucleoside reverse transcriptase inhibitor treatment human immunodeficiency virus hiv february company announced fda granted additional sixmonth period exclusivity market sustiva exclusivity sustiva us scheduled expire march nivolumab fully human monoclonal antibody binds programmed death receptor pd nkt cells investigated anti cancer treatment october company announced longterm followup results lung cancer cohort n expanded phase doseranging study nivolumab results showed sustained activity heavily pretreated patients nonsmallcell lung cancer defined one twoyear survival rates respectively across dose cohorts june company announced results study doseranging phase trial evaluating safety antitumor activity nivolumab combined either concurrently sequentially yervoy patients advanced melanoma patients received dose used phase iii trial mgkg nivolumab mgkg yervoy concurrent regimen confirmed objective responses modified world health organization criteria nine responders tumors shrank least time first scheduled clinical treatment assessment weeks including three complete responses sprycel dasatanib oral inhibitor multiple tyrosine kinases indicated firstline treatment adults philadelphia chromosomepositive chronic myeloid leukemia chronic phase treatment adults chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy including gleevec imatinib meslylate sprycel part strategic alliance otsuka december american society hematology company otsuka announced fouryear followup data phase iii dasision study sprycel mg daily vs gleevec mg daily firstline treatment adults philadelphia chromosomepositive chronic phase chronic myeloid leukemia four years sprycel patients vs gleevec patients achieved major molecular response additionally sprycel patients vs gleevec patients achieved bcrabl three months considered optimal molecular response defined treatment guidelines european leukemianet guidelines patients arms achieved response three months improved overall survival progressionfree survival four years versus four years sprycel patients n gleevec patients n remained treatment yervoy ipilimumab monoclonal antibody treatment patients unresectable inoperable metastatic melanoma november ema approved use yervoy first line chemotherapy nave advanced melanoma patients september european cancer congress results presented pooled analysis survival data studies patients metastatic locally advanced unresectable melanoma treated yervoy different doses regimens including investigational dose mgkg patients followed years analysis found plateau survival curve begins three years patients followed ten years three years patients alive september company announced results phase iii randomized doubleblind clinical trial study comparing yervoy placebo following radiation patients advanced metastatic castrationresistant prostate cancer received prior treatment docetaxel study 's primary endpoint overall survival reach statistical significance however antitumor activity observed across efficacy endpoints including progression freesurvival elotuzumab humanized monoclonal antibody investigated anticancer treatment elotuzumab part strategic alliance abbvie inc abbvie june company abbvie announced updated efficacy safety data small randomized phase ii openlabel study patients previouslytreated multiple myeloma evaluated two doses elotuzumab combination lenalidomide lowdose dexamethasone mgkg arm dose used ongoing phase iii trials median progressionfree survival pfs time without disease progression months median followup months objective response rate orr previously reported median pfs months mgkg arm median followup months orr abilify aripiprazole antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder part strategic alliance otsuka january european commission ec approved abilify treatment pediatric bipolar mania metreleptin protein development treatment lipodystrophy part strategic alliance astrazeneca included sale diabetes business june company astrazeneca announced fda accepted filing granted priority review designation bla july fda notified company partner astrazeneca require threemonth extension complete review data supporting bla december company astrazeneca announced fda 's endocrinologic metabolic drugs advisory committee emdac recommended metreleptin treatment pediatric adult patients generalized lipodystrophy ld emdac recommend metreleptin patients partial ld indication currently proposed company astrazeneca remain committed pursuing metreleptin treatment patients metabolic disorders associated partial ld companies acknowledged emdac 's feedback continue work fda identify appropriate patients partial ld may benefit metreleptin prescription drug user free act pdufa date date decision fda expected february farxigaxigduo dapagliflozin metformin hydrochloride oral sodiumglucose cotransporter sglt inhibitor treatment diabetes part strategic alliance astrazeneca included sale diabetes business january company astrazeneca announced xigduo granted marketing authorization european commission treatment type diabetes eu january company astrazeneca announced fda approved farxiga improve glycemic control along diet exercise adults type diabetes september annual meeting european association study diabetes easd company astrazeneca announced results phase iii study evaluating dapagliflozin adult patients type diabetes inadequately controlled combination treatment metformin plus sulfonylurea patients treated dapagliflozin add therapy metformin plus sulfonylurea demonstrated significant improvements glycosylated hemoglobin levels hbac among key secondary endpoints significant reductions fasting plasma glucose body weight compared placebo weeks significant improvements also observed seated systolic blood pressure eight weeks patients treated dapagliflozin compared placebo june company astrazeneca announced results twoweek phase iia pilot study evaluating farxiga added insulin adult patients suboptimally controlled type diabetes showed mean daily blood glucose derived point glucose measurements trended downward treatment groups day seven reductions total daily insulin dosing day seven observed farxiga march japanese ministry health labor welfare also accepted review regulatory submission farxiga treatment type diabetes january chinas state food drug administration accepted review regulatory submission farxiga treatment type diabetes onglyza saxagliptin oncedaily oral tablet treatment type diabetes part strategic alliance astrazeneca included sale diabetes business february fda announced requesting clinical trial data investigate possible association use onglyzakombiglyze heart failure fda stated request part broader evaluation fda conducting type diabetes drug therapies cardiovascular risk september european society cardiology company astrazeneca announced full results savor clinical trial adult patients type diabetes study onglyza met primary safety objective demonstrating increased risk primary composite endpoint cardiovascular death nonfatal myocardial infarction nonfatal ischemic stroke added patient 's current standard care without anti diabetic therapies compared placebo onglyza meet primary efficacy endpoint superiority placebo composite endpoint patients treated onglyza experienced improved glycemic control reduced development progression microalbuminuria two years assessed exploratory analyses subsequent meeting annual meeting easd additional subanalyses savor presented subanalyses found increased rate hypoglycemia among patients treated onglyza compared placebo added metformin monotherapy baseline subanalyses also found higher rates hypoglycemia onglyza group compared placebo group among patients taking sulfonylureas agents known cause hypoglycemia baseline addition subanalyses found rates adjudicationconfirmed pancreatitis balanced onglyza placebo treatment groups observed rates pancreatic cancer also low patients onglyza arm versus patients placebo arm orencia abatacept fusion protein indicated adult patients moderate severe rheumatoid arthritis inadequate response one currently available treatments methotrexate antitumor necrosis factor therapy june company ono pharmaceutical co ltd announced japanese ministry health labour welfare approved subcutaneous formulation orencia treatment rheumatoid arthritis cases existing treatments inadequate june company announced results year two data ample compared subcutaneous formulation orencia versus humira adalimumab background methotrexate biologic nave patients moderate severe rheumatoid arthritis ample met primary endpoint measured noninferiority american college rheumatology improvement year one orencia regimen achieved comparable rates efficacy versus humira regimen vs respectively eliquis oral factor xa inhibitor targeted stroke prevention nonvalvular atrial fibrillation nvaf prevention treatment venous thromboembolic vte disorders eliquis part strategic alliance pfizer december company pfizer announced fda accepted review supplemental new drug application eliquis treatment deep vein thrombosis dvt pulmonary embolism pe reduction risk recurrent dvt pe pdufa date august november european medicines agency accepted review application eliquis treatment dvt pe prevention recurrent dvt pe september european society cardiology esc congress company pfizer announced results posthoc subanalysis phase iii aristotle trial evaluated eliquis compared warfarin patients without types valvular heart disease vhd eligible enrollment aristotle trial including mitral regurgitation mitral stenosis aortic regurgitation aortic stenosis tricuspid regurgitation valve surgery results subanalysis consistent results overall aristotle trial demonstrated eliquis compared warfarin reduced stroke systemic embolism caused fewer major bleeding events reduced allcause mortality nvaf patients without vhd august esc company pfizer announced results posthoc subanalysis phase iii aristotle trial showed comparable rates clinical events versus warfarin treatment arm day period following procedure required temporary discontinuation anticoagulant prior following procedure july company pfizer announced fda accepted review supplemental new drug application eliquis prophylaxis deep vein thrombosis may lead pulmonary embolism adult patients undergone hip knee replacement surgery pdufa date march june company pfizer announced results phase iii amplify trial evaluated eliquis versus current standard care treatment acute venous thromboembolism published online new england journal medicine presented international society thrombosis haemostasis congress amsterdam results showed eliquis demonstrated comparable efficacy significantly lower rates major bleeding patients compared current standard care may company pfizer announced results prespecified subanalysis aristotle trial published circulation peer reviewed journal american heart association trends across subgroup analysis consistent overall study results demonstrated eliquis ' superiority versus warfarin reduction stroke systemic embolism number major bleeding events mortality patients nvaf eliquis received regulatory approval reduction risk stroke systemic embolism patients nvaf south korea january israel russia february mexico colombia april eliquis received regulatory approval prevention venous thromboembolic events adult patients undergone elective hip knee replacement surgery china january mexico april results operations total revenues composition changes revenues follows year ended december vs vs total revenues analysis change analysis change total foreign total foreign dollars millions change volume price exchange change volume price exchange united states europe rest world othera na na na na total total revenues include royalties alliancerelated revenues products sold regional commercial organizations change excess single country outside us contributed total revenues period presented general business seasonal change us revenues periods attributed volume reflects exclusivity loss plavix may avaproavalide march partially offset increased demand key products amylinrelated product revenues following completion acquisition august change us revenues attributed price result reduction share abilify aripiprazole revenues impact partially offset higher average net selling prices abilify key products change us revenues attributed price result higher average net selling prices abilify key products partially offset reduction share abilify revenues see key products discussion total revenues key product revenues europe increased due volume growth key products amylinrelated product revenues following transition nonus operations second quarter favorable foreign exchange partially offset restructured sanofi agreement see item financial statementsnote alliances discussion revenues decreased primarily due unfavorable foreign exchange lower revenues certain mature brands divestitures generic competition well generic competition plavix avaproavalide partially offset volume growth key products revenues periods continued negatively impacted fiscal challenges many european countries healthcare payers including government agencies reduced expected continue reduce healthcare costs actions directly indirectly impose additional price reductions measures include limited mandatory discounts rebates restrictive measures revenues rest world increased due volume growth key products partially offset restructured sanofi agreement unfavorable foreign exchange particularly japan generic competition mature brands revenues rest world decreased due generic competition plavix avaproavalide lower revenues mature brands generic competition divestitures partially offset volume growth key products revenues increased due higher royalties resulting restructured sanofi agreement alliance revenue attributed mature brands overthecounter products alliances revenues increased due enhanced royaltyrelated revenues higher revenues attributed active pharmaceutical ingredient supply agreements resulting divestitures manufacturing facilities restructured alliance agreements revenues expected decline upon expiration certain royalty alliance agreements see item financial statementsnote alliances discussion alliances february bms sold astrazeneca diabetes business bms comprised global alliance including rights ownership onglyza forxiga bydureon byetta symlin metreleptin total revenues products billion see item financial statementsnote assets heldforsale discussion recognize revenue net grosstonet adjustments described critical accounting policies share certain abilify atripla revenues reflected net grosstonet adjustments alliance revenues although presented grosstonet adjustment tables share abilify atripla grosstonet adjustments approximately billion billion billion changes grossto net adjustments impacted additional rebates discounts required us healthcare reform reduction share abilify revenues activities ending reserve balances significant category grosstonet adjustments follows healthcare chargebacks rebates related government cash contract medicaid sales dollars millions programs discounts discounts rebates returns adjustments total balance january provision related sale made current period prior period returns payments amylin acquisition impact foreign currency translation balance december provision related sale made current period prior period returns payments assetsrelated liabilities heldforsale impact foreign currency translation balance december reconciliation gross product sales net product sales significant category grosstonet adjustments follows year ended december change dollars millions vs vs gross product sales grosstonet adjustments chargebacks related government programs cash discounts managed healthcare rebates contract discounts medicaid rebates sales returns adjustments total grosstonet adjustments net product sales change excess grosstonet adjustment rates primarily function changes revenues mix contractual legislative discounts rebates grosstonet adjustments decreased due chargebacks related government programs cash discounts medicaid rebates decreased periods result lower plavix revenues following loss exclusivity managed healthcare rebates contract discounts increased primarily due amylinrelated net product sales managed healthcare rebates contract discounts decreased primarily result lower plavix revenues following loss exclusivity managed healthcare rebates contract discounts also decreased due million reduction estimated amount medicare part coverage gap discounts attributable prior period rebates receiving actual invoices nonrenewal plavix contract discounts medicare part program january estimated medicaid rebates attributable prior period sales reduced million million receiving actual invoices information certain state medicaid administrative offices provision sales returns higher result loss exclusivity plavix avaproavalide us sales return reserves products million million december respectively determined considering several factors including estimated inventory levels distribution channels accordance company policy products eligible returned six months prior twelve months product expiration adjustments reserves might required future revised estimates various assumptions including actual returns mostly expected occur adjustments increased primarily due higher government rebates nonus markets adjustments increased due us copay coupon programs key products revenues key products represented total revenue following table presents us international revenues key product percentage change prior period foreign exchange impact compared prior period commentary detailing reasons significant variances key products provided change attributable year ended december change foreign exchange dollars millions vs vs vs vs key products virology baraclude entecavir us nonus reyataz atazanavir sulfate us nonus sustiva efavirenz franchise us nonus oncology erbitux cetuximab us nonus sprycel dasatinib us nonus yervoy ipilimumab na us nonus na neuroscience abilify aripiprazole us nonus metabolics bydureon exenatide extendedrelease injectable suspension na na na na us na na na nonus na na na na byetta exenatide na na na na us na na na nonus na na na na forxiga dapagliflozin na na na na na us na na na na na na nonus na na na na na onglyzakombiglyze saxagliptinsaxagliptin metformin us nonus change attributable year ended december change foreign exchange dollars millions vs vs vs vs key products continued immunoscience nulojix belatacept na us nonus na na orencia abatacept us nonus cardiovascular avaproavalide irbesartanirbesartanhydrochlorothiazide us nonus eliquis apixaban na na us na na na nonus na na plavix clopidogrel bisulfate us nonus mature products us nonus change excess baraclude oral antiviral agent treatment chronic hepatitis b us revenues periods increased due higher average net selling prices higher demand may experience rapid significant decline us revenues beginning due possible generic competition following federal courts decision february invalidating composition matter patent international revenues increased periods due higher demand partially offset unfavorable foreign exchange reyataz protease inhibitor treatment hiv us revenues decreased due lower demand partially offset higher average net selling prices us revenues increased due higher average net selling prices international revenues increased due higher demand timing government purchases certain countries international revenues decreased due unfavorable foreign exchange timing government purchases certain countries lower demand resulting competing products sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv includes sustiva antiretroviral drug bulk efavirenz also included combination therapy atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg product sold alliance gilead us revenues increased due higher average net selling prices partially offset lower demand us revenues increased primarily due higher demand higher average net selling prices international revenues increased due favorable foreign exchange international revenues decreased due unfavorable foreign exchange erbitux monoclonal antibody designed exclusively target block epidermal growth factor receptor expressed surface certain cancer cells multiple tumor types well normal cells currently indicated use colorectal cancer head neck cancer erbitux part strategic alliance lilly us revenues periods remained relatively flat sprycel oral inhibitor multiple tyrosine kinases indicated firstline treatment adults philadelphia chromosomepositive chronic myeloid leukemia chronic phase treatment adults chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy including gleevec imatinib meslylate sprycel part strategic alliance otsuka us revenues periods increased primarily due higher demand higher average net selling prices international revenues periods increased primarily due higher demand partially offset unfavorable foreign exchange yervoy monoclonal antibody treatment patients unresectable inoperable metastatic melanoma us revenues periods increased due higher demand us revenues also favorably impacted recognition million revenues previously deferred sufficient historical experience estimate sales returns developed international revenues periods increased due higher demand abilify antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder part strategic alliance otsuka us revenues decreased due reduction contractual share revenues partially offset higher average net selling prices us revenues increased due higher average net selling prices million reduction bmss share estimated amount customer rebates discounts attributable based actual invoices received international revenues periods increased primarily due higher demand international revenues impacted unfavorable foreign exchange bydureon onceweekly glp receptor agonist treatment type diabetes part strategic alliance astrazeneca us revenues included results since completion amylin acquisition august transition international operations bydureon majority markets lilly completed second quarter see item financial statementsnote alliances discussion byetta twice daily glucagonlike peptide glp receptor agonist treatment type diabetes part strategic alliance astrazeneca us revenues included results since completion amylin acquisition august transition international operations byetta majority markets lilly completed second quarter see item financial statementsnote alliances discussion forxiga oral sodiumglucose cotransporter sglt inhibitor treatment type diabetes part strategic alliance astrazeneca forxiga launched treatment type diabetes limited number eu markets fourth quarter continues launched various eu markets onglyzakombiglyze known eu onglyzakomboglyze oncedaily oral tablet treatment type diabetes part strategic alliance astrazeneca us revenues increased primarily due higher average net selling prices us revenues increased primarily due higher overall demand higher average net selling prices international revenues increased periods primarily due higher demand partially offset unfavorable foreign exchange nulojix fusion protein novel immunosuppressive activity targeted prevention kidney transplant rejection nulojix approved launched us eu orencia fusion protein indicated adult patients moderate severe rheumatoid arthritis inadequate response one currently available treatments methotrexate antitumor necrosis factor therapy us revenues periods increased primarily due higher demand higher average net selling prices international revenues periods increased primarily due higher demand partially driven launch subcutaneous formulation orencia certain eu markets beginning second quarter partially offset unfavorable foreign exchange avaproavalide known eu aprovelkarvea angiotensin ii receptor blocker treatment hypertension diabetic nephropathy also part sanofi alliance us revenues longer recognized following restructured sanofi agreement effective january negative sales due increase sales return reserve avalide us revenues decreased due loss exclusivity march international revenues impacted changes attributed restructured sanofi agreement see item financial statementsnote alliances discussion international revenues decreased due lower demand including generic competition certain eu markets canada eliquis oral factor xa inhibitor targeted stroke prevention atrial fibrillation prevention treatment vte disorders eliquis part strategic alliance pfizer eliquis launched us europe japan canada first quarter continues launched various markets reduction risk stroke systemic embolism patients nvaf eliquis approved eu vte prevention may launched limited number eu countries beginning may plavix platelet aggregation inhibitor part alliance sanofi us revenues periods decreased due loss exclusivity may international revenues impacted changes attributed restructured sanofi agreement see item financial statementsnote alliances discussion international revenues negatively impacted generic clopidogrel products eu canada australia mature products includes products including lost exclusivity major markets overthecounter brands royalty related revenue us revenues decreased periods generic erosion certain products partially offset sales symlin following completion amylin acquisition august international revenues increased due certain alliances partially offset continued generic erosion products international revenues decreased due continued generic erosion certain brands unfavorable foreign exchange international revenues expected decline upon expiration certain royalty alliance agreements estimated enduser demand pursuant us securities exchange commission sec consent order described sec consent order monitor level inventory hand us wholesaler distribution channel outside us direct customer distribution channel obligated disclose products levels inventory excess one month hand expected demand subject de minimis exception estimated levels inventory distribution channel excess one month hand products material dates indicated us products estimated levels inventory distribution channel excess one month hand december international products estimated levels inventory distribution channel excess one month hand september dafalgan analgesic product sold principally europe months inventory hand direct customers september december level inventory hand primarily due ordering patterns pharmacists france reyataz months inventory hand internationally september compared month inventory hand december level inventory hand due government purchasing patterns brazil us generally determine months hand estimates using inventory levels product hand amount outmovement provided three largest wholesalers account approximately total gross sales us products factors may influence estimates include generic competition seasonality products wholesaler purchases light increases wholesaler list prices new product launches new warehouse openings wholesalers new customer stockings wholesalers addition estimates calculated using thirdparty data may impacted recordkeeping processes businesses outside us significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely direct customer product level inventory ultimate patientconsumer demand outmovement data exist otherwise available developed variety methodologies estimate data including using factors historical sales made direct customers thirdparty market research data related prescription trends enduser demand accordingly rely variety methods estimate direct customer product level inventory calculate months hand factors may affect estimates include generic competition seasonality products direct customer purchases light price increases new product launches new warehouse openings direct customers new customer stockings direct customers expected direct customer purchases governmental bidding situations information required estimate months hand direct customer distribution channel nonus business year ended december available prior filing annual report disclose product levels inventory excess one month hand expected demand subject de minimis exception next quarterly report form q expenses change dollar millions vs vs cost products sold marketing selling administrative advertising product promotion research development impairment charge bms intangible asset na incomeexpense total expenses change excess cost products sold cost products sold include material costs internal labor overhead owned manufacturing sites thirdparty processing costs supply chain costs settlement foreign currency forward contracts used hedge forecasted intercompany inventory purchase transactions essentially costs managed global manufacturing supply organization cost products also includes royalties profit sharing attributed licensed products alliances amortization acquired developed technology costs business combinations milestone payments occur regulatory approval cost products sold vary periods result product mix particularly resulting royalties profit sharing expenses connection alliances price inflation costs attributed rationalization manufacturing sites resulting accelerated depreciation impairment charges stranded costs addition changes foreign currency may also provide volatility certain costs denominated foreign currencies cost products sold percentage total revenues changes primarily attributed less favorable product mix result royalties profit sharing expenses connection alliances cost products sold relatively flat higher profit sharing expenses connection alliances including resulting amylin acquisition august higher net amortization costs attributable amylin acquisition partially offset lower royalties following loss exclusivity plavix avaproavalide higher impairment charges decrease cost products sold primarily attributed lower sales volume following loss exclusivity plavix avaproavalide resulted lower royalties connection sanofi alliance favorable foreign exchange partially offset impairment charges discussed higher amortization costs resulting amylin acquisition net amortization amylin alliance proceeds impairment charges million recognized including million related continued competitive pricing pressures reduction undiscounted projected cash flows amount less carrying value developed technology intangible asset remaining million impairment charge related abandonment manufacturing facility resulting outsourcing manufacturing process marketing selling administrative marketing selling administrative expenses include salary benefit costs thirdparty professional marketing fees outsourcing fees shipping handling costs expenses attributed product manufacturing costs research development expenses expenses managed regional commercialization organizations global corporate organizations finance law information technology human resources marketing selling administrative expenses decreased due accelerated vesting stock options restricted stock units related amylin acquisition million lower pharmaceutical company fee assessed federal government reduction sales related activities certain products coincide respective lifecycles partially offset higher spending support launch new key products additional spending following amylin acquisition marketing selling administrative expenses increased primarily result amylin acquisition million including accelerated vesting stock options restricted stock units partially offset reduction salesrelated activities plavix avaproavalide marketing selling administrative expenses also impacted favorable foreign exchange advertising product promotion advertising product promotion expenses include media sample direct consumer programs advertising product promotion expenses increased primarily due higher spending recently launched key products advertising product promotion expenses decreased primarily due lower spending promotion plavix avaproavalide abilify certain mature brands us coincide product life cycle research development research development expenses include salary benefit costs thirdparty grants fees paid clinical research organizations supplies facility costs total research development expenses include costs discovery research preclinical development early lateclinical development drug formulation well clinical trials medical support marketed products proportionate allocations enterprisewide costs facilities information technology employee stock compensation costs appropriate costs upfront licensing fees related payments upon achievement regulatory contractual milestones also included certain expenses shared alliance partners based upon contractual agreements expenses managed global research development organization approximately billion billion billion total spend respectively attributed development activities remainder attributed preclinical research activities expenses vary periods number reasons including timing upfront milestone licensing payments research development expenses decreased primarily due prior year impairment charges accelerated vesting stock options restricted stock units related amylin acquisition upfront milestone licensing payments partially offset additional costs following amylin acquisition higher clinical grant spending research development expenses increased primarily million expenses related amylin acquisition including accelerated vesting amylin stock options restricted stock units million partially offset favorable foreign exchange net impact upfront milestone licensing payments iprd impairment charges refer specified items included nongaap financial measures amounts attributed period iprd impairment charges relate projects previously acquired medarex inc medarex acquisition inhibitex inc inhibitex acquisition including million related fv nucleoside inhibitor reduction shinglesassociated pain resulting unfavorable clinical trial results decisions cease development impairment charge bms intangible asset billion impairment charge recognized development bms formerly inx compound acquired part acquisition inhibitex treat hepatitis c virus infection discontinued interest patient safety see item financial statements note goodwill intangible assets information intangible assets highly vulnerable impairment charges particularly newly acquired assets recently launched products iprd assets initially measured fair value therefore reduction expectations used valuations could potentially lead impairment see critical accounting policies discussion incomeexpense incomeexpense include year ended december dollars millions interest expense investment income provision restructuring litigation chargesrecoveries equity net income affiliates outlicensed intangible asset impairment gain sale product lines businesses assets income received alliance partners net pension curtailments settlements incomeexpense interest expense increased periods due higher average borrowings provision restructuring primarily attributable employee termination benefits employee termination costs million incurred result workforce reductions several european countries employee reductions primarily attributed sales force reductions resulting restructuring sanofi otsuka agreements streamlining operations due challenging market conditions europe litigation chargesrecoveries included million share apotex damages award concerning plavix equity net income affiliates primarily related international partnership sanofi europe asia decreased periods result restructuring sanofi agreement continues negatively impacted generic competition plavix europe asia equity net income affiliates decreased due continued impact generic competition international plavix net sales conversion certain territories optout markets impact unfavorable foreign exchange outlicensed intangible asset impairment charges related assets acquired medarex zymogenetics inc zymogenetics acquisitions resulted unfavorable clinical trial results andor abandonment programs gain sale product lines businesses assets primarily related sale building mexico sale mature brands income alliance partners includes royalties amortization upfront milestone licensing payments related certain alliances decrease us plavix net product sales resulted lower development royalties owed sanofi royalties received sanofi except europe asia presented revenues beginning result restructured sanofi agreement see item financial statementsnote alliances discussion pension settlement charges recognized determining annual lump sum payments would exceed annual interest service costs certain pension plans including primary us pension plan charges included acceleration portion unrecognized actuarial losses similar charges may occur future see item financial statementsnote pension postretirement postemployment liabilities detail change primarily related higher acquisition costs losses debt repurchases sales tax reimbursements gains debt repurchases higher upfront milestone licensing receipts income taxes dollars millions earnings income taxes provision forbenefit income taxes effective taxbenefit rate change effective tax rates primarily due million tax benefit attributed capital loss deduction resulting tax insolvency inhibitex impact deduction reduced effective tax rate percentage points changes resulted tax benefits attributable higher impairment charges including million impairment charge bms intangible asset us favorable earnings mix high low tax jurisdictions attributable lower plavix revenues lesser extent internal transfer intellectual property fourth quarter legal enactment research development tax credit higher charges contingent tax matters historically effective income tax rate lower us statutory rate due decision indefinitely reinvest earnings certain manufacturing operations ireland puerto rico favorable tax rates ireland puerto rico grants scheduled expire prior noncontrolling interest see item financial statementsnote alliances discussion plavix avaproavalide partnerships sanofi territory covering americas decrease noncontrolling interest periods resulted exclusivity loss us plavix may avaproavalide march summary noncontrolling interest follows year ended december dollars millions sanofi partnerships noncontrolling interestpretax income taxes net earnings attributable noncontrolling interestnet taxes nongaap financial measures nongaap financial measures including nongaap earnings related eps information adjusted exclude certain costs expenses gains losses specified items due significant andor unusual nature evaluated individual basis similar charges gains items recognized prior periods reasonably possible could reoccur future periods nongaap information intended portray results baseline performance include discovery development licensing manufacturing marketing distribution sale pharmaceutical products global basis enhance investors overall understanding past financial performance prospects future example nongaap earnings eps information indication baseline performance items considered us reflective ongoing results addition information among primary indicators use basis evaluating performance allocating resources setting incentive compensation targets planning forecasting future periods information intended considered isolation substitute net earnings diluted eps prepared accordance gaap specified items follows year ended december dollars millions accelerated depreciation asset impairment shutdown costs amortization acquired amylin intangible assets amortization amylin alliance proceeds amortization amylin inventory adjustment cost products sold stock compensation accelerated vesting amylin awards process standardization implementation costs marketing selling administrative stock compensation accelerated vesting amylin awards upfront milestone licensing payments iprd impairment research development impairment charge bms intangible asset provision restructuring gain sale product lines businesses assets pension settlements acquisition alliance related items litigation chargesrecoveries upfront milestone licensing receipts outlicensed intangible asset impairment loss debt repurchases incomeexpense increase pretax income income tax items specified tax benefita income taxes increase net earnings specified tax benefit relates capital loss deduction specified tax benefit relates releases tax reserves specified prior periods reconciliations gaap nongaap follows year ended december dollars millions except per share data net earnings attributable bms gaap earnings attributable unvested restricted shares net earnings attributable bms used diluted eps calculation gaap net earnings attributable bms gaap less specified items net earnings attributable bms nongaap earnings attributable unvested restricted shares net earnings attributable bms used diluted eps calculation nongaap average common shares outstanding diluted diluted eps attributable bms gaap diluted eps attributable specified items diluted eps attributable bms nongaap financial position liquidity capital resources net debt position follows dollars millions cash cash equivalents marketable securities current marketable securities noncurrent total cash cash equivalents marketable securities shortterm borrowings current portion longterm debt longterm debt net debt position cash cash equivalents marketable securities held us approximately billion december remaining billion held primarily lowtax jurisdictions attributable earnings expected indefinitely reinvested offshore cash repatriations subject restrictions certain jurisdictions may subject withholding additional us income taxes started issuing commercial paper meet nearterm domestic liquidity requirements average amount commercial paper outstanding million weightedaverage interest rate maximum monthend amount commercial paper outstanding million outstanding borrowings december continue issue commercial paper asneeded basis february bms sold astrazeneca diabetes business bms comprised global alliance terms agreement astrazeneca made upfront payment billion company bms also received million milestone payment february approval farxiga us seeitem financial statementsnote assets heldforsale discussion january notices provided holders notes due bms exercise call option redeem notes entirety february outstanding principal amount notes million investment portfolio includes noncurrent marketable securities subject changes fair value result interest rate fluctuations market factors may impact results operations investment policy places limits investments amount time maturity investments institution policy also requires investments entered corporate financial institutions meet high credit quality standards see item financial statementsnote financial instruments fair value measurements two separate billion fiveyear revolving credit facilities syndicate lenders facilities provide customary terms conditions financial covenants extendable anniversary date consent lenders borrowings outstanding either revolving credit facility december october bms issued billion senior unsecured notes registered public offering consisting million aggregate principal amount notes due million aggregate principal amount notes due million aggregate principal amount notes due proceeds used general corporate purposes including repayment commercial paper borrowings additional regulations us could passed future could reduce results operations operating cash flow liquidity financial flexibility also continue monitor potential impact economic conditions certain european countries related impact prescription trends pricing discounts creditworthiness customers ability collect outstanding receivables direct customers currently believe economic conditions eu material impact liquidity cash flow financial flexibility mechanism limit overall credit exposures additional source liquidity sell trade receivables third parties principally wholesalers japan certain governmentbacked entities italy portugal spain sales trade receivables italy portugal spain million million million sales receivables japan million million million sales agreements allow recourse event uncollectibility retain interest underlying assets sold continue manage operating cash flows focusing working capital items directly affected changes sales volume receivables inventories accounts payable dollars millions december december net trade receivables inventories accounts payable total credit ratings moodys investors service longterm shortterm credit ratings currently prime respectively longterm credit outlook revised stable negative september standard poors longterm shortterm credit ratings currently respectively longterm credit outlook remains stable fitch lowered longterm credit rating lowered shortterm credit rating f f revised longterm credit outlook negative stable july stable negative december credit ratings considered investment grade longterm ratings reflect agencies ' opinion low default risk somewhat susceptible adverse effects changes circumstances economic conditions shortterm ratings reflect agencies ' opinion good extremely strong capacity timely repayment cash flows following discussion cash flow activities dollars millions cash flow provided byused operating activities investing activities financing activities operating activities cash flow operating activities represents cash receipts cash disbursements activities investing activities financing activities operating cash flow derived adjusting net earnings noncontrolling interest noncash operating items gains losses attributed investing financing activities changes operating assets liabilities resulting timing differences receipts payments cash transactions recognized results operations result changes cash operating activities reflect timing cash collections customers alliance partners payments suppliers alliance partners employees pension contributions tax payments ordinary course business changes cash provided operating activities periods primarily attributable upfront milestone contingent alliance proceeds million billion billion astrazeneca consideration entering amylin alliance million lower operating cash flows million billion attributed plavix avaproavalide revenue reductions following loss exclusivity products changes including working capital requirements period investing activities changes cash used investing activities primarily attributable cash used fund acquisitions amylin billion inhibitex billion amira million cash used sales purchases maturities marketable securities million million primarily attributed timing investments time deposits corporate debt securities maturities greater days cash generated sales purchases maturities marketable securities billion cash used partially fund acquisitions investing activities included litigation recoveries million financing activities changes cash used financing activities primarily attributable cash used repurchase common stock million billion billion may board directors authorized repurchase billion june board directors increased authorization repurchase stock additional billion repurchase program expiration date may consider future repurchases dividend payments billion dividends declared per common share december declared quarterly dividend per common share expect pay dividend full year per share dividend decisions made quarterly basis board directors proceeds issuance senior unsecured notes billion billion million principal amount notes matured repaid repayments debt assumed amylin acquisition billion management periodically evaluates potential opportunities repurchase certain debt securities terminate certain interest rate swap contracts prior maturity cash outflows related repurchase debt million million proceeds termination interest rate swap contracts million proceeds stock option exercises million excluding million cash retained excess tax benefits million excluding million cash retained excess tax benefits million excluding million cash retained excess tax benefits amount proceeds vary period based upon fluctuations market value stock relative exercise price stock options factors contractual obligations payments due period contractual obligations december follows obligations expiring period dollars millions total later years shortterm borrowings longterm debt interest longterm debta operating leases purchase obligations uncertain tax positionsb longterm liabilities totalc includes estimated future interest payments shortterm longterm debt securities also includes accrued interest payable recognized consolidated balance sheets consists primarily accrued interest shortterm longterm debt well accrued periodic cash settlements derivatives b due uncertainty related timing reversal uncertain tax positions shortterm uncertain tax benefits provided table see item financial statementsnote income taxes detail c table excludes future contributions us pensions postretirement postemployment benefit plans required contributions contingent upon numerous factors including minimum regulatory funding requirements funded status plan due uncertainty future obligations excluded table contributions us international plans expected million see item financial statementsnote pension postretirement postemployment liabilities detail addition committed billion aggregate potential future research development milestone payments third parties part inlicensing development programs earlystage milestones defined milestones achieved phase iii clinical trials comprised million total committed amount latestage milestones defined milestones achieved post phase iii clinical trials comprised billion total committed amount payments agreements generally due payable upon achievement certain developmental regulatory milestones specific timing predicted addition certain royalty obligations calculated percentage net product sales agreements also provide salesbased milestones aggregating billion would obligated pay alliance partners upon achievement certain sales levels also certain manufacturing development commercialization obligations connection alliance arrangements practicable estimate amount obligations see item financial statementsnote alliances information regarding alliances discussion contractual obligations see item financial statementsnote pension postretirement postemployment liabilities note financial instruments fair value measurements note leases sec consent order previously disclosed august entered final settlement sec concluding investigation concerning certain wholesaler inventory accounting matters settlement reached consent copy attached exhibit quarterly report form q period ended september terms consent agreed subject certain defined exceptions limit sales products sold direct customers including wholesalers distributors hospitals retail outlets pharmacies government purchasers based expected demand amounts exceed approximately one month inventory hand without making timely public disclosure change practice also agreed consent certain measures implemented including establishing formal review certification process annual quarterly reports filed sec b establishing business risk disclosure group c retaining outside consultant comprehensively study help reengineer accounting financial reporting processes publicly disclosing sales incentives offered direct customers purpose inducing purchase products excess expected demand e ensuring budget process gives appropriate weight inputs come bottom top top bottom adequately documenting process established companywide policy limit sales direct customers purpose complying consent policy includes adoption various procedures monitor limit sales direct customers accordance terms consent procedures include governance process escalate appropriate management levels potential questions concerns regarding compliance policy timely resolution questions concerns addition compliance policy monitored regular basis maintain inventory management agreements imas us pharmaceutical wholesalers account nearly gross us revenues current terms imas wholesaler customers provide us weekly information respect months hand productlevel inventories amount outmovement products three largest wholesalers currently account approximately gross us revenues inventory information received wholesalers together internal information used estimate months hand product level inventories wholesalers estimate months hand product inventory levels us businesss wholesaler customers three largest wholesalers extrapolating months hand calculated three largest wholesalers contrast nonus business significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely accordingly rely variety methods estimate months hand product level inventories business units believe abovedescribed procedures provide reasonable basis ensure compliance consent recently issued accounting standards july financial accounting standards board issued update clarified existing guidance presentation unrecognized tax benefits various qualifying tax benefit carryforwards exist including unrecognized tax benefit presented reduction deferred tax assets liability update required adopted annual periods interim reporting periods beginning december early adoption permitted reduction deferred tax assets expected approximately million critical accounting policies preparation financial statements requires use estimates assumptions affect reported amounts assets liabilities reported amounts revenue expenses critical accounting policies significantly impact financial condition results operations require difficult subjective complex judgments often result need make estimates effect matters inherently uncertain uncertainty actual results may vary estimates accounting policies discussed audit committee board directors revenue recognition accounting policy revenue recognition substantial impact reported results relies certain estimates recognize revenue persuasive evidence arrangement exists sales price fixed determinable collectability reasonably assured title substantially risks rewards ownership transferred generally time shipment revenue also reduced grosstonet sales adjustments discussed involve significant estimates judgment considering legal interpretations applicable laws regulations historical experience payer channel mix eg medicare medicaid current contract prices applicable programs unbilled claims processing time lags inventory levels distribution channel estimates assessed period adjusted required revised information actual experience addition see total revenues discussion analysis significant category grosstonet sales adjustments grosstonet adjustments following categories grosstonet adjustments involve significant estimates judgments information obtained external sources chargebacks related government programs us business participates programs government entities significant us department defense us department veterans affairs parties including covered entities b drug pricing program whereby pricing products extended wholesaler list price participating entities entities purchase products wholesalers lower program price wholesalers charge us difference acquisition cost lower program price accounts receivable reduced estimated amount unprocessed chargeback claims attributable sale typically within two four week time lag cash discounts us certain countries cash discounts offered incentive prompt payment generally approximating sales price accounts receivable reduced estimated amount unprocessed cash discounts typically within one month time lag managed healthcare rebates contract discounts rebates discounts offered managed healthcare organizations us managing prescription drug programs medicare advantage prescription drug plans covering medicare part drug benefit addition commercial plans well contract counterparties hospitals group purchasing organizations globally beginning rebates medicare part program included discount companys brandname drugs patients fall within medicare part coverage gap rebates also required us department defense tricare retail pharmacy refund program estimated amount unpaid unbilled rebates discounts presented liability million reversal estimated amount medicare part coverage gap discounts occurred receipt actual invoices medicaid rebates us businesses participates state government medicaid programs qualifying federal state government programs requiring discounts rebates participating state local government entities discounts rebates provided programs included medicaid rebate accrual retroactive january minimum rebates medicaid drug sales increased medicaid rebates also extended drugs used managed medicaid plans beginning march estimated amount unpaid unbilled rebates presented liability estimated medicaid rebates attributable prior period revenues reduced million million sales returns products typically eligible returned six months prior twelve months product expiration accordance policy estimated returns established products determined considering historical experience factors including levels inventory distribution channel estimated shelf life product recalls product discontinuances price changes competitive products introductions generic products introductions competitive new products instances expected precipitous declines demand following loss exclusivity estimated amount product returns presented liability reserves established plavix avaproavalide million million december respectively considering relevant factors well estimated future retail wholesale inventory work would occur loss exclusivity estimated returns new products determined considering historical sales return experience similar products within product line similar therapeutic category defer recognition revenue right return expires sufficient historical experience estimate sales returns developed limited circumstances typically occurs new product extension existing line product historical experience products similar therapeutic category lacking estimated levels inventory distribution channel projected demand also considered estimating sales returns new products use information external sources information external sources used estimate grosstonet adjustments estimate inventory wholesalers based projected prescription demandbased sales products historical inventory experience well analysis thirdparty information including written oral information obtained certain wholesalers respect inventory levels sellthrough customers thirdparty market research data internal information inventory information received wholesalers product recordkeeping process excludes inventory held intermediaries sell retailers hospitals also continued practice combining retail mail prescription volume retailequivalent basis use methodology internal demand forecasts also use information external sources identify prescription trends patient demand average selling prices estimates subject inherent limitations estimates rely thirdparty information certain thirdparty information form estimates reflect limitations including lags date thirdparty information generated date receive thirdparty information retirement benefits accounting pension postretirement benefit plans requires actuarial valuations based significant assumptions discount rates expected longterm rates return plan assets consultation actuaries significant assumptions others salary growth retirement turnover healthcare trends mortality rates evaluated selected based expectations actual experience remeasurement date pension expense could vary within range outcomes material effect reported earnings projected benefit obligations future cash funding actual results given year may differ estimated economic factors yield high quality corporate bonds coincides cash flows plans estimated payouts used determining discount rate citigroup pension discount curve used us plans us plans pension expense determined using weightedaverage discount rate present value benefit obligations december us pension plans determined using discount rate discount rate used determining us plans pension expense reduced additional expense would increase approximately million assumed discount rate used determining us pension plans projected benefit obligation december reduced additional projected benefit obligation would increase approximately million expected longterm rate return plan assets estimated considering expected returns individual asset classes input external advisors also consider longterm historical returns including actual performance compared benchmarks similar investments us plans pension expense determined using expected longterm rate return plan assets expected longterm rate return plan assets used determining us plans pension expense reduced expense would increase million detailed discussion retirement benefits see item financial statementsnote pension postretirement postemployment liabilities business combinations goodwill intangible assets acquired business combinations licensing transactions billion representing total assets including billion included assets heldforsale december assets acquired liabilities assumed recognized date acquisition respective fair values excess purchase price estimated fair values net assets acquired recognized goodwill fair value intangible assets including iprd typically determined using income method method starts forecast net cash flows risk adjusted estimated probabilities technical regulatory success iprd adjusted present value using appropriate discount rate reflects risk associated cash flow streams assets valued market participant view might different specific bms views valuation process complex requires significant input judgment using internal external sources although valuations required finalized within oneyear period must consider facts evidence available acquisition date complex judgmental matters applicable valuation process summarized unit accounting intangible assets valued single global assets rather multiple assets jurisdiction indication considering development stage expected levels incremental costs obtain additional approvals risks associated development amount timing benefits expected derived future expected patent lives various jurisdictions intention promote asset global brand estimated useful life asset life expected contribute meaningful cash flows determined considering pertinent matters associated asset including expected regulatory approval dates unapproved exclusivity periods legal regulatory contractual provisions well effects obsolescence demand competition economic factors including barriers entry probability technical regulatory success ptrs rate ptrs rates determined based upon industry averages considering respective programs development stage disease indication adjusted specific information data known acquisition date subsequent clinical results internal external data obtained could alter ptrs rate materially impact estimated fair value intangible asset subsequent periods leading impairment charges projections future revenues estimated considering many factors initial market opportunity pricing sales trajectories peak sales levels competitive environment product evolution future costs expenses estimated considering historical market trends market participant synergies timing level additional development costs obtain initial additional regulatory approvals maintain enhance product generally assume initial positive cash flows commence shortly receipt expected regulatory approvals typically may occur number years actual cash flows attributed project likely different assumed since projections subjected multiple factors including trial results regulatory matters could materially change ultimate commercial success asset well significantly alter costs develop respective asset commercially viable products tax rates expected future income tax effected using market participant tax rate recent valuations typically use us tax rate applicable state taxes considering jurisdiction intellectual property held location research manufacturing infrastructure also considered earnings repatriation would likely us tax consequences discount rate discount rates selected considering risks inherent future cash flows assessment assets life cycle competitive trends impacting asset including consideration technical legal regulatory economic barriers entry well expected changes standards practice indications addressed asset see item financial statementsnote acquisitions specific details values assigned assets acquired liabilities assumed acquisitions amylin inhibitex amira significant estimates utilized time valuations support fair values lead compounds within acquisitions include estimated phase year first discount useful life development ptrs rate projected positive dollars millions fair value rate utilized years acquisition date utilized cash flow commercialized products bydureon na na na byetta na na na symlin na na na recothrom na na na iprd bms formerly inx na phase ii metreleptin na phase iii na phase impairment goodwill goodwill billion december goodwill tested least annually impairment enterprise level assessing qualitative factors performing quantitative analysis determining whether likely fair value exceeds carrying value examples qualitative factors assessed current year included share price financial performance compared budgets longterm financial plans macroeconomic industry market conditions well substantial excess fair value carrying value net assets annual impairment test performed prior year positive negative influences relevant factor assessed individually aggregate result concluded additional quantitative testing required discussion goodwill acquired inprocess research development intangible assets see item financial statementsnote accounting policiesgoodwill acquired inprocess research development intangible assets intangible assets including iprd intangible assets billion december including licenses million developed technology rights billion capitalized software million iprd million intangible assets tested impairment whenever current facts circumstances warrant review although iprd required tested least annually intangible assets highly vulnerable impairment charges particularly newly acquired assets recently launched products iprd assets initially measured fair value therefore reduction expectations used valuations could potentially lead impairment common potential risks leading impairment include competition earlier expected loss exclusivity pricing pressures adverse regulatory changes clinical trial results delay failure obtain regulatory approval additional development costs inability achieve expected synergies higher operating costs changes tax laws macroeconomic changes complexity estimating fair value intangible assets connection impairment test similar initial valuation considering high risk nature research development industrys success rate bringing developmental compounds market iprd impairment charges likely occur future periods recognized charges billion including billion charge resulting discontinued development bms projects previously acquired medarex inc inhibitex acquisitions resulting unfavorable clinical trial results additional development costs extended development periods decisions cease development also recognized charges million related three medarex projects development ceased iprd closely monitored assessed period impairment addition iprd commercial assets also subject impairment example impairment charge million recognized related nonkey product prior acquisition continuing competitive pricing pressures operate dynamic market regulatory environment events occur causing expectations change quickly thus leading potential impairment charges specific intangible assets material carrying values december exposed potential impairment include iprd assets peginterferon lambda million phase iii development treatment hepatitis c virus millionin phase ii development treatment fibrosis assets monitored changes expectations used initial valuation property plant equipment property plant equipment tested impairment whenever current facts circumstances warrant review additionally longlived assets periodically reviewed determine change facts circumstances would result change estimated useful life asset possibly resulting acceleration depreciation circumstances exist estimate undiscounted future cash flows generated asset appropriate grouping assets compared carrying value determine whether impairment exists lowest level identifiable cash flows asset determined impaired loss measured based difference assets fair value carrying value expectations future cash flows subject change based upon near longterm production volumes margins generated asset well potential alternative future use contingencies normal course business subject contingencies legal proceedings claims arising business cover wide range matters including among others government investigations shareholder lawsuits product environmental liability contractual claims tax matters recognize accruals contingencies probable liability incurred amount loss reasonably estimated estimates subject uncertainties difficult predict actual results could vary estimates discussions contingencies see item financial statementsnote accounting policiescontingencies note income taxes note legal proceedings contingencies income taxes valuation allowances recognized reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecasts future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made deferred tax assets billion net valuation allowances billion december billion net valuation allowances billion december deferred tax assets related us federal net operating loss carryforward million us federal tax credit carryforward million recognized december net operating loss carryforward expires varying amounts beginning us federal tax credit carryforward expires varying amounts beginning realization carryforwards dependent generating sufficient domesticsourced taxable income prior expiration although realization assured believe likely deferred tax assets realized addition deferred tax asset related us federal state capital loss million recognized december carried back three years carried forward five years realization carryforward dependent upon generating sufficient capital gains prior expiration million valuation allowance established item december taxes provided undistributed earnings foreign subsidiaries expected reinvested indefinitely offshore prior mead johnson nutrition company mead johnson splitoff following transactions occurred internal spinoff mead johnson shares still owned us ii conversion mead johnson class b shares class shares iii conversion mead johnson company limited liability company transactions well splitoff mead johnson exchange offer qualify taxexempt transactions internal revenue code based upon private letter ruling received internal revenue service related conversion mead johnson class b shares class shares outside legal opinions certain assumptions representations covenants mead johnson relied upon regarding future conduct business matters could affect tax treatment exchange example current tax law generally creates presumption exchange would taxable us mead johnson shareholders engage transactions result greater change stock ownership four year period beginning two years exchange offer unless established exchange offer part plan series related transactions effect change ownership internal spinoff exchange offer determined qualify tax exempt transaction transaction could subject tax exchange taxable sale us market value addition negative basis excess loss account ela existed investment stock mead johnson prior transactions received opinion outside legal counsel effect likely eliminated ela part transactions taxable income respect ela tax law area complex possible even internal spinoff exchange offer tax exempt internal revenue code irs could assert additional taxable income period respect ela could exposed additional taxes occur based upon understanding internal revenue code opinion outside legal counsel tax reserve million established reducing gain disposal mead johnson included discontinued operations agreed certain tax related indemnities mead johnson set forth tax sharing agreement example mead johnson agreed indemnify us potential tax effects resulting breach certain representations discussed well certain transactions related acquisition mead johnsons stock assets agreed indemnify mead johnson certain taxes related business prior completion ipo created part restructuring facilitate ipo established liabilities possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known discussions income taxes see item financial statementsnote accounting policiesincome taxes note income taxes special note regarding forwardlooking statements annual report including documents incorporated reference written oral statements make time time contain certain forwardlooking statements within meaning section securities act section e securities exchange act identify forwardlooking statements fact use words expect anticipate estimate target may project guidance intend plan believe words terms similar meaning expression connection discussion future operating financial performance one also identify forwardlooking statements fact relate strictly historical current facts forwardlooking statements based current expectations involve inherent risks uncertainties including factors could delay divert change could cause actual outcomes differ materially current expectations statements likely relate among things goals plans projections regarding financial position results operations cash flows market position product development product approvals sales efforts expenses performance results current anticipated products outcome contingencies legal proceedings financial results based current expectations involve inherent risks uncertainties including internal external factors could delay divert change next several years included important factors cautionary statements included annual report particularly item risk factors believe could cause actual results differ materially forwardlooking statement although believe prudent plans assumptions assurance given goal plan set forth forwardlooking statements achieved readers cautioned place undue reliance statements speak date made undertake obligation release publicly revisions forwardlooking statements result new information future events otherwise item quantitative qualitative disclosures market risk exposed market risk resulting changes currency exchange rates interest rates certain derivative financial instruments used available costeffective basis hedge underlying economic exposure financial instruments including derivatives subject counterparty credit risk considered part overall fair value measurement derivative financial instruments used trading purposes foreign exchange risk significant amounts revenues earnings cash flow exposed changes foreign currency rates primary net foreign currency translation exposures euro japanese yen chinese renminbi canadian dollar south korean foreign currency forward contracts used manage foreign exchange risk primarily arises certain intercompany purchase transactions designated foreign currency cash flow hedges appropriate addition exposed foreign exchange transaction risk arises nonfunctional currency denominated assets liabilities earnings denominated nonus dollar currencies foreign currency forward contracts used offset portion exposures designated hedges changes fair value derivatives recognized earnings incurred estimate appreciation underlying currencies hedged levels us dollar variables held constant would decrease fair value foreign exchange forward contracts million december realized appreciation would negatively affect earnings remaining life contracts also exposed translation risk nonus dollardenominated net assets nonus dollar borrowings used hedge foreign currency exposures net investment certain foreign affiliates designated hedges net investments effective portion foreign exchange gains losses hedges recognized part foreign currency translation component accumulated comprehensive incomeloss net investment fall equivalent value nonus debt borrowings change remeasurement basis debt would subject recognition income changes occur additional information see item financial statementsnote financial instruments fair value measurements interest rate risk fixedtofloating interest rate swap contracts used designated fairvalue hedges part interest rate risk management strategy contracts intended provide us appropriate balance fixed floating rate debt estimate increase basis points shortterm longterm interest rates would decrease fair value interest rate swap contracts million excluding effects counterparty credit risk realized fair value reduction would affect earnings remaining life contracts estimate increase basis points longterm interest rates would decrease fair value longterm debt million marketable securities subject changes fair value result interest rate fluctuations market factors policy invest institutions meet high credit quality standards estimate increase basis points interest rates general would decrease fair value debt security portfolio approximately million credit risk although material certain european governmentbacked entities higher risk default identified monitoring economic factors including credit ratings creditdefault swap rates debttogross domestic product ratios addition entity specific factors historically exposure limited factoring receivables credit exposures europe may increase future due reductions factoring arrangements ongoing sovereign debt crisis credit exposure trade receivables greece portugal italy spain approximately million december approximately governmentbacked entities monitor investments counterparties objective minimizing concentrations credit risk investment policy places limits amount time maturity investments individual counterparty policy also requires investments entered corporate financial institutions meet high credit quality standards use derivative instruments exposes us credit risk fair value derivative instrument contract positive exposed credit risk counterparty fails perform fair value derivative instrument contract negative counterparty exposed credit risk fail perform obligation terms agreements posting collateral required party whether derivatives asset liability position policy diversifying derivatives counterparties mitigate overall risk counterparty defaults additional information see item financial statements note financial instruments fair value measurements bristolmyers squibb company consolidated statements earnings dollars shares millions except per share data item financial statements supplementary data year ended december earnings net product sales alliance revenues total revenues cost products sold marketing selling administrative advertising product promotion research development impairment charge bms intangible asset incomeexpense total expenses earnings income taxes provision forbenefit income taxes net earnings net earnings attributable noncontrolling interest net earnings attributable bms earnings per common share basic diluted cash dividends declared per common share accompanying notes integral part consolidated financial statements bristolmyers squibb company consolidated statements comprehensive income dollars millions year ended december comprehensive income net earnings comprehensive incomeloss net taxes reclassifications earnings derivatives qualifying cash flow hedges pension postretirement benefits available sale securities foreign currency translation total comprehensive incomeloss comprehensive income comprehensive income attributable noncontrolling interest comprehensive income attributable bms accompanying notes integral part consolidated financial statements bristolmyers squibb company consolidated balance sheets dollars millions except share per share data december assets current assets cash cash equivalents marketable securities receivables inventories deferred income taxes prepaid expenses assets heldforsale total current assets property plant equipment goodwill intangible assets deferred income taxes marketable securities assets total assets liabilities current liabilities shortterm borrowings current portion longterm debt accounts payable accrued expenses deferred income accrued rebates returns income taxes payable dividends payable liabilities related assets heldforsale total current liabilities pension postretirement postemployment liabilities deferred income income taxes payable deferred income taxes liabilities longterm debt total liabilities commitments contingencies note equity bristolmyers squibb company shareholders equity preferred stock convertible series par value per share authorized million shares issued outstanding liquidation value per share common stock par value per share authorized billion shares billion issued capital excess par value stock accumulated comprehensive loss retained earnings less cost treasury stock million common shares million total bristolmyers squibb company shareholders ' equity noncontrolling interest total equity total liabilities equity accompanying notes integral part consolidated financial statements bristolmyers squibb company consolidated statements cash flows dollars millions year ended december cash flows operating activities net earnings adjustments reconcile net earnings net cash provided operating activities net earnings attributable noncontrolling interest depreciation amortization net deferred income taxes stockbased compensation impairment charges proceeds amylin diabetes alliance changes operating assets liabilities receivables inventories accounts payable deferred income income taxes payable net cash provided operating activities cash flows investing activities proceeds sale maturities marketable securities purchases marketable securities additions property plant equipment capitalized software proceeds sale businesses investing activities purchase businesses net cash acquired net cash used investing activities cash flows financing activities shortterm debt borrowingsrepayments proceeds issuance longterm debt repayments longterm debt interest rate swap contract terminations issuances common stock repurchases common stock dividends net cash used financing activities effect exchange rates cash cash equivalents increasedecrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year accompanying notes integral part consolidated financial statements note accounting policies basis consolidation consolidated financial statements prepared conformity united states us generally accepted accounting principles gaap including accounts bristolmyers squibb company may referred bristolmyers squibb bms company controlled majorityowned subsidiaries intercompany balances transactions eliminated material subsequent events evaluated disclosed report issuance date alliance license arrangements assessed determine whether terms provide economic control entity requiring consolidation entity entities controlled means majority voting interest referred variable interest entities arrangements material variable interest entities periods presented use estimates preparation financial statements requires use management estimates assumptions significant assumptions estimates determining fair value potential impairment intangible assets sales rebate return accruals legal contingencies income taxes pension postretirement benefits actual results may differ estimated results reclassifications certain prior period amounts reclassified conform current period presentation net product sales alliance revenues previously presented aggregate net sales consolidated statements earnings presented separately revenue recognition revenue recognized persuasive evidence arrangement exists sales price fixed determinable collectability reasonably assured title substantially risks rewards ownership transferred generally time shipment including supply commercial products alliance partners principal end customer sale however certain revenue nonus businesses recognized date receipt customer alliance revenue related abilify atripla recognized products sold end customer alliance partner royalties based third party sales recognized earned accordance contract terms third party sales reliably measurable collectability reasonably assured refer note alliances detail regarding alliances provisions made time revenue recognition expected sales returns discounts rebates estimated sales allowances based historical experience updated changes facts circumstances including impact applicable healthcare legislation provisions recognized reduction revenuewhen new product extension existing line product historical experience products similar therapeutic category revenue deferred right return longer exists sufficient historical experience estimate sales returns developed income taxes provision income taxes includes income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax basis assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recognized reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made tax benefits recognized uncertain tax position likely tax position sustained examination taxing authorities based technical merits position tax benefit recognized financial statements particular tax position based largest benefit likely realized upon settlement cash cash equivalents cash cash equivalents include us treasury securities government agency securities bank deposits time deposits money market funds cash equivalents consist highly liquid investments original maturities three months less time purchase recognized cost approximates fair value marketable securities investments companies marketable securities classified availableforsale date purchase reported fair value fair value determined based observable market quotes valuation models using assessments counterparty credit worthiness credit default risk underlying security overall capital market liquidity investments less owned companies accounted using equity method accounting ability exercise significant influence maintained share net income losses equity investments included equity net income affiliates incomeexpense equity investments reviewed impairment assessing decline market value investment carrying value temporary considers intent ability retain investment length time extent market value less cost financial condition investee inventory valuation inventories stated lower average cost market property plant equipment depreciation expenditures additions renewals improvements capitalized cost depreciation computed straightline method based estimated useful lives related assets ranging years buildings years machinery equipment fixtures impairment longlived assets current facts circumstances periodically evaluated determine carrying value depreciable assets held used may recoverable circumstances exist estimate undiscounted future cash flows generated longlived asset appropriate grouping assets compared carrying value determine whether impairment exists lowest level identifiable cash flows asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques using level fair value inputs including discounted value estimated future cash flows capitalized software eligible costs obtain internal use software significant systems projects capitalized amortized estimated useful life software insignificant costs obtain software projects expensed incurred business combinations businesses acquired consolidated upon obtaining control acquiree fair value assets acquired liabilities assumed recognized date acquisition excess purchase price estimated fair values net assets acquired recognized goodwill legal audit business valuation business acquisition costs expensed incurred goodwill acquired inprocess research development intangible assets fair value intangible assets typically determined using income method utilizes level fair value inputs market participant valuations assume global view considering potential jurisdictions indications based discounted aftertax cash flow projections risk adjusted estimated probability technical regulatory success iprd finitelived intangible assets including licenses developed technology rights iprd projects reach commercialization amortized straightline basis estimated useful life estimated useful lives determined considering period assets expected contribute future cash flows goodwill tested least annually impairment assessing qualitative factors performing quantitative analysis determining whether likely fair value net assets carrying amounts examples qualitative factors assessed include share price financial performance compared budgets longterm financial plans macroeconomic industry market conditions well substantial excess fair value carrying value net assets annual impairment test performed prior year relevant factor assessed individually aggregate iprd tested impairment annual basis frequently events occur circumstances change would indicate potential reduction fair values assets carrying value carrying value iprd determined exceed fair value impairment loss recognized difference finitelived intangible assets tested impairment facts circumstances suggest carrying value asset may recoverable carrying value exceeds projected undiscounted pretax cash flows intangible asset impairment loss equal excess carrying value estimated fair value discounted aftertax cash flows recognized restructuring restructuring charges recognized result actions streamline operations rationalize manufacturing facilities judgment used estimating impact restructuring plans including future termination benefits exit costs incurred actions take place actual results could vary estimates contingencies loss contingencies legal proceedings claims may occur wide range matters including government investigations shareholder lawsuits product environmental liability contractual claims tax matters accruals recognized probable liability incurred amount loss reasonably estimated gain contingencies including contingent proceeds related divestitures recognized realized legal fees expensed incurred derivative financial instruments derivatives used principally management interest rate foreign currency exposures held used trading purposes derivatives recognized fair value changes fair value recognized earnings unless specific hedge criteria met derivative designated fair value hedge changes fair value derivative hedged item attributable hedged risk recognized earnings derivative designated cash flow hedge effective portions changes fair value derivative reported accumulated comprehensive incomeloss oci subsequently recognized earnings hedged item affects earnings cash flows classified consistent underlying hedged item derivatives designated assigned hedges forecasted transactions specific assets specific liabilities hedged assets liabilities sold extinguished forecasted transactions hedged longer probable occur gain loss immediately recognized earnings nonderivative instruments primarily euro denominated longterm debt also designated hedges net investments foreign affiliates effective portion designated nonderivative instrument recognized foreign currency translation section oci ineffective portion recognized earnings shipping handling costs shipping handling costs included marketing selling administrative expenses million million million advertising product promotion costs advertising product promotion costs expensed incurred foreign currency translation foreign subsidiary earnings translated us dollars using average exchange rates net assets foreign subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recognized oci research development research development costs expensed incurred clinical study costs accrued service periods specified contracts adjusted necessary based upon ongoing review level effort costs actually incurred strategic alliances third parties provide rights develop manufacture market andor sell pharmaceutical products rights owned party research development recognized net reimbursements connection alliance agreements recently issued accounting standards july financial accounting standards board issued update clarified existing guidance presentation unrecognized tax benefits various qualifying tax benefit carryforwards exist including unrecognized tax benefit presented reduction deferred tax assets liability update required adopted annual periods interim reporting periods beginning december early adoption permitted reduction deferred tax assets expected approximately million note business segment information bms operates single segment engaged discovery development licensing manufacturing marketing distribution sale innovative medicines help patients prevail serious diseases global research development organization supply chain organization responsible development delivery products market regional commercial organizations used distribute sell product business also supported global corporate staff functions segment information consistent financial information regularly reviewed chief executive officer purposes evaluating performance allocating resources setting incentive compensation targets planning forecasting future periods products sold principally wholesalers lesser extent directly distributors retailers hospitals clinics government agencies pharmacies gross revenues three largest pharmaceutical wholesalers us percentage global gross revenues follows mckesson corporation cardinal health inc amerisourcebergen corporation selected geographic area information follows total revenues property plant equipment dollars millions united states europe rest world othera total total revenues include royalties alliancerelated revenues products sold regional commercial organizations total revenues key products follows year ended december dollars millions virology baraclude entecavir reyataz atazanavir sulfate sustiva efavirenz franchisea oncology erbitux cetuximab sprycel dasatinib yervoy ipilimumab neuroscience abilify aripiprazoleb metabolics bydureon exenatide extendedrelease injectable suspension na byetta exenatide na forxiga dapagliflozin na onglyzakombiglyze saxagliptinsaxagliptin metformin immunoscience nulojix belatacept orencia abatacept cardiovascular avaproavalide irbesartanirbesartanhydrochlorothiazide eliquis apixaban plavix clopidogrel bisulfate mature products total revenues includes million million million presented alliance revenue b includes million million million presented alliance revenue note alliances bms enters collaboration arrangements third parties development commercialization certain products although arrangements unique nature parties active participants operating activities collaboration exposed significant risks rewards depending commercial success activities bms may either inlicense intellectual property owned party outlicense intellectual property party arrangements also typically include research development manufacturing andor commercial activities cover single investigational compound commercial product multiple compounds andor products various life cycle stages refer collaborations alliances partners alliance partners payments alliance partners accounted presented results operations considering specific nature payment underlying activities payments relate multiple alliance activities including transfer rights separated individual units accounting standalone value activities occur life arrangements situations arrangement consideration allocated activities rights relative selling price basis multiple alliance activities rights standalone value combined single unit accounting common activities bms alliance partners presented results operations follows bms principal end customer sale thirdparty product sales included net product sales bms 's alliance partner principal end customer sale bms 's contractual share thirdparty sales andor royalty income included alliance revenue sale commercial products considered part bms 's ongoing major central operations refer revenue recognition included note accounting policies information regarding recognition criteria amounts payable bms alliance partners principal end customer sale supply commercial products included alliance revenue sale commercial products considered part bms 's ongoing major central operations amounts payable bms alliance partners profit sharing royalties salesbased fees included cost products sold incurred cost reimbursements parties recognized incurred included cost products sold marketing selling administrative expenses advertising product promotion expenses research development expenses based underlying nature related activities subject reimbursement upfront contingent development approval milestones payable bms alliance partners investigational compounds commercial products deferred amortized shorter contractual term periods related compounds products expected contribute future cash flows amortization presented consistent nature payment arrangement example amounts received investigational compounds presented incomeexpense activities performed time related sale commercial products part bmss ongoing major central operations amounts received commercial products presented alliance revenue sale commercial products considered part bmss ongoing major central operations except astrazeneca plc astrazeneca alliance pertaining amylin products see discussion specific astrazeneca alliance disclosure herein upfront contingent approval milestones payable bms alliance partners commercial products capitalized amortized shorter contractual term periods related products expected contribute future cash flows amortization included cost products sold upfront contingent milestones payable bms alliance partners prior regulatory approval expensed incurred included research development expenses equity net income affiliates included incomeexpense payments bms alliance partners presented cash flows operating activities selected financial information pertaining alliances follows including net product sales bms principal thirdparty customer sale products subject alliance expenses summarized include amounts attributed activities products alliance payments alliance partners related amortization payments deferred capitalized year ended december dollars millions revenues alliances net product sales alliance revenues total revenues payments tofrom alliance partners cost products sold marketing selling administrative advertising product promotion research development incomeexpense net earnings attributable noncontrolling interest pretax selected alliance balance sheet information december dollars millions receivables alliance partners accounts payable alliance partners deferred income alliancesa includes deferred income classified liabilities related assets heldforsale million december specific information pertaining significant alliances discussed including nature purpose significant rights obligations parties specific accounting policy elections income statement classification amounts attributable payments parties otsuka bms worldwide commercialization agreement otsuka pharmaceutical co ltd otsuka codevelop copromote abilify excluding certain asian countries us portion agreement amended expires upon expected loss product exclusivity april agreement expires european union eu countries june nonus country exclusive right sell abilify agreement expires later april loss exclusivity country parties actively participate joint executive governance operating committees although otsuka assumed responsibility providing funding sales force efforts effective january us amendment bms responsible funding certain operating expenses various annual limits bms purchases active pharmaceutical ingredient api otsuka completes manufacture product subsequent sale third party customers us certain countries otsuka assumed responsibility providing funding sales force efforts eu effective april bms also provides certain services including distribution customer management pharmacovigilence otsuka principal thirdparty product sales us united kingdom uk germany france spain italy beginning march bms principal thirdparty product sales exclusive distributor exclusive right sell abilify remaining territories alliance revenue recognized bmss share total net sales thirdparty customers territories us bmss contractual share beginning january bmss contractual share changed percentages total us net sales set forth table assessment bms 's expected annual contractual share completed quarterly reporting period adjusted based upon reported us abilify net sales december bms 's annual contractual share alliance revenue recognized interim period quarter exceed amounts due contract annual us net sales bms share us net sales billion billion billion billion billion billion billion billion billion excess billion united kingdom germany france spain italy beginning march bmss contractual share thirdparty net sales countries us alliance revenue recognized abilify shipped risks rewards ownership transferred thirdparty customers terms us amendment bms paid otsuka million amortized reduction alliance revenue expected loss us exclusivity april unamortized balance included assets otsuka receives royalty based total us net sales included cost products sold otsuka responsible us expenses related commercialization abilify bms otsuka also alliance sprycel ixempra ixabepilone us japan eu parties actively participate various governance committees bms control decision making parties copromote product bms responsible development manufacture product bms also principal endcustomer product sales fee paid otsuka based following percentages annual net sales sprycel ixempra net sales million million million million million million billion excess billion annual periods otsuka contributes first million certain commercial operational expenses relating oncology products oncology territory costs excess million us extension oncology alliance include changeofcontrol provision case acquisition bms acquiring company competing product abilify new company assume abilify agreement amended oncology alliance exists today acquiring company product competes abilify otsuka elect request acquiring company choose whether divest abilify competing product scenario abilify divested otsuka would obligated acquire rights bms abilify agreement amended agreements also provide event generic competitor abilify january bms option terminating abilify april amendment agreement previously amended remaining force bms exercise option either bms would receive payment otsuka according predetermined schedule oncology alliance would terminate time ii oncology alliance would continue truncated period according predetermined schedule summarized financial information related alliance follows year ended december dollars millions revenues otsuka alliances net product sales alliance revenuesa total revenues payments tofrom otsuka cost products sold oncology fee royalties amortization intangible assets cost product supply cost reimbursements tofrom otsuka selected alliance balance sheet information december dollars millions assets extension payment includes amortization extension payment reduction alliance revenue million astrazeneca bms astrazeneca diabetes alliance consisting three worldwide codevelopment commercialization agreements first agreement covered onglyza related combination products sold various names second agreement covered forxiga commercialized farxiga us related combination products third agreement covered amylin 's portfolio products bydureon byetta symlin pramlintide acetate metreleptin currently development well certain assets owned amylin included manufacturing facility onglyza agreement excluded japan upon entering separate agreements coexclusive license rights product products underlying agreement granted astrazeneca exchange upfront payment potential milestone payments parties assumed certain obligations actively participate alliance parties actively participated joint executive committee various operating committees joint responsibilities research development distribution sales marketing activities alliance using resources infrastructures bms manufactured products three alliances principal endcustomer product sales substantially countries alliance agreement determined rights transferred astrazeneca standalone value rights sold separately bms party could astrazeneca received benefit delivered rights without fulfillment ongoing obligations bms alliance agreements including exclusive supply arrangement global alliance treated single unit accounting result upfront proceeds subsequent contingent milestone proceeds amortized life related products bms received billion nonrefundable upfront payment astrazeneca consideration entering amylin alliance astrazeneca exercised option equal governance rights certain key strategic financial decisions regarding amylin alliance paid bms million consideration payments accounted deferred income amortized based relative fair value predominant elements included alliance estimated useful lives intangible assets related bydureon estimated useful life years byetta estimated useful life years symlin estimated life years metreleptin estimated useful life years amylin manufacturing plant estimated useful life years amortization presented reduction cost products sold alliance assets acquired shortly commencement alliance astrazeneca entitled share proceeds sale assets amortization acquired amylin intangible assets manufacturing plant also presented cost products sold bms entitled reimbursements capital expenditures related acquired amylin manufacturing facility bms astrazeneca also shared certain tax attributes related amylin alliance bms received million nonrefundable upfront milestone licensing payments related onglyza date bms also received million non refundable upfront milestone licensing payments related forxiga date amortization onglyza forxiga deferred income included income onglyza forxiga commercial products commencement alliance parties equally shared commercialization development expenses well profits losses summarized financial information related astrazeneca alliances follows year ended december dollars millions revenues astrazeneca alliances net product sales alliance revenues total revenues payments tofrom astrazeneca cost products sold profit sharing amortization deferred income cost reimbursements tofrom astrazeneca recognized cost products sold marketing selling administrative advertising product promotion research development incomeexpense amortization deferred income provision restructuring selected alliance cash flow information nonrefundable upfront milestone licensing payments received amylinrelated products forxiga selected alliance balance sheet information december dollars millions deferred income nonrefundable upfront milestone licensing receiptsa amylinrelated products onglyza forxiga included liabilities related assets heldforsale december february bms sold astrazeneca diabetes business bms comprised global alliance including rights ownership onglyza forxiga bydureon byetta symlin pramlintide acetate metreleptin transaction included shares amylin resulting transfer manufacturing plant intellectual property related onglyza forxiga future purchase bmss manufacturing facility located mount vernon indiana earlier months following closing transaction parties terminated existing alliance agreements connection sale entered several new agreements including transitional services agreement supply agreement development agreement see note assets heldfor sale information gilead bms gilead sciences inc gilead joint ventures us us canada europe develop commercialize atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg combining sustiva product bms truvada emtricitabine tenofovir disoproxil fumarate product gilead joint ventures consolidated gilead parties actively participate joint executive committee various operating committees direct oversight activities joint ventures joint ventures purchase sustiva truvada api bulk form parties complete finishing atripla us canada joint venture sells distributes atripla principal thirdparty customer sales europe gilead affiliates sell distribute atripla principal thirdparty customer sales parties longer coordinate joint promotional activities alliance revenue recognized atripla include bulk efavirenz component atripla based relative ratio average respective net selling prices truvada sustiva alliance revenue deferred related alliance receivable recognized combined product sold thirdparty customers europe following loss exclusivity sustiva effective january percentage atripla net sales bms recognize based ratio difference average net selling prices atripla truvada atripla average net selling price alliance continue either party terminates arrangement last patent expiration occurs atripla truvada sustiva us agreement may terminated gilead upon launch generic version sustiva bms upon launch generic version truvada event gilead terminates agreement upon loss exclusivity sustiva bms receive quarterly royalty payment months following termination payment first months following termination equal atripla net sales multiplied ratio difference average net selling prices atripla truvada atripla average net selling price second third years following termination payment bms reduced respectively atripla net sales multiplied price ratio described bms continue supply sustiva cost plus markup joint ventures threeyear period unless either party elects terminate supply arrangement summarized financial information related alliance follows year ended december dollars millions revenues gilead alliances net product sales alliance revenues total revenues equity net loss affiliates selected alliance balance sheet information december dollars millions deferred revenue lilly bms commercialization agreement eli lilly company lilly lillys november acquisition imclone systems incorporated imclone codevelopment promotion erbitux us expires september parties actively participate joint executive committee various operating committees shared responsibilities research development alliance using resources infrastructures lilly responsible supplying product bms distribution sale bms responsible promotional efforts product north america although lilly right copromote expense bms also codevelopment copromotion rights canada japan bms principal thirdparty customer sales north america commercialization agreement bms pays lilly distribution fee based flat rate net sales erbitux north america plus share certain royalties paid lilly japan bms shares rights erbitux agreement lilly merck kgaa receives pretax profit merck kgaas net sales erbitux japan shared equally lilly march bms lilly terminated arrangement necitumumab imcf rights returning lilly discovered imclone necitumumab fully human monoclonal antibody part alliance bms lilly bms amortizing million license acquisition costs associated erbitux alliance agreement summarized financial information related alliance follows year ended december dollars millions revenues lilly alliance net product sales payments tofrom lilly cost products sold distribution fees royalties amortization intangible asset cost product supply cost reimbursements tofrom lilly incomeexpense japan commercialization fee selected alliance balance sheet information december dollars millions intangible assets nonrefundable upfront milestone licensing payments bms acquired amylin pharmaceuticals inc amylin august see note acquisitions information amylin previously entered settlement termination agreement lilly regarding alliance global development commercialization byetta bydureon exenatide products parties agreed transition full responsibility products amylin transition us operations completed time acquisition transition nonus operations exenatide products majority markets completed april terminating lilly 's exclusive right nonus commercialization exenatide products promissory notes assumed acquisition amylin aggregating billion repaid lilly sanofi september bms sanofi restructured terms codevelopment cocommercialization agreements plavix avaproavalide effective january sanofi assumed essentially worldwide operations alliance exception plavix us puerto rico alliance plavix markets continue unchanged december terms original alliance arrangements described exchange rights assumed sanofi bms receive quarterly royalties january december terminal payment sanofi million end ongoing disputes companies resolved including million payment bms sanofi related avalide supply disruption us accrued beginning royalties received sanofi territory covering americas australia optout markets former development royalties presented alliance revenues million development optout royalty income million million included incomeexpense development royalty expense million million included incomeexpense royalties attributed territory covering europe asia continue earned territory partnership included equity net income affiliates additionally equity net income affiliates included million profit deferred prior restructuring agreement alliance revenues attributed supply irbesartan api sanofi million million million supply arrangement irbesartan expires prior restructuring bmss worldwide alliance sanofi codevelopment cocommercialization avaproavalide plavix operated framework two geographic territories one americas principally us canada puerto rico latin american countries australia europe asia two territory partnerships managed central expenses marketing research development royalties supply finished product individual countries bms acted operating partner owned majority controlling interest territory covering americas australia consolidates country partnership results territory sanofis share results reflected noncontrolling interest bms also recognized net product sales comarketing countries outside territory eg italy irbesartan germany greece spain sanofi acted operating partner owned majority controlling interest territory covering europe asia bms ownership interest territory summarized financial information related alliance follows year ended december dollars millions revenues sanofi alliances net product sales alliance revenues total revenues payments tofrom sanofi cost product supply cost products sold royalties equity net income affiliates incomeexpense noncontrolling interest pretax selected alliance cash flow information distributions tofrom sanofi noncontrolling interest distributions sanofi investment affiliates selected alliance balance sheet information december dollars millions investment affiliates territory covering europe asiaa noncontrolling interest included alliance receivables following summarized financial information interests partnerships sanofi territory covering europe asia consolidated accounted using equity method year ended december dollars millions net sales gross profit net income cost products sold territory covering europe asia includes discovery royalties million million million paid directly sanofi expenses shared based applicable ownership percentages current assets current liabilities include approximately million million million related receivablespayables attributed cash distributions bms sanofi well intercompany balances partnerships within territory remaining current assets current liabilities consist thirdparty trade receivables inventories amounts due bms sanofi purchase inventories royalties expense reimbursements pfizer bms pfizer inc pfizer maintain worldwide codevelopment cocommercialization agreement eliquis anticoagulant discovered bms pfizer funds development costs depending study companies share commercialization expenses profits losses equally global basis certain countries bms global commercialization network pfizer commercialize eliquis alone pay bms compensation based percentage net sales upon entering agreement coexclusive license rights product granted pfizer exchange upfront payment potential milestone payments parties assumed certain obligations actively participate alliance parties actively participate joint executive committee various operating committees joint responsibilities research development distribution sales marketing activities alliance using resources infrastructures bms manufactures product alliance principal endcustomer product sales substantially countries determined rights transferred pfizer standalone value rights sold separately bms party could pfizer received benefit delivered rights without fulfillment ongoing obligations bms alliance agreement including exclusive supply arrangement global alliance treated single unit accounting result upfront proceeds subsequent contingent milestone proceeds amortized life related product bms received million nonrefundable upfront milestone licensing payments related eliquis date including million received january could receive additional million development regulatory milestones amortization eliquis deferred income included income eliquis commercial product commencement alliance summarized financial information related alliance follows year ended december dollars millions revenues pfizer alliance net product sales alliance revenues total revenues payments tofrom pfizer cost products sold profit sharing cost reimbursements tofrom pfizer incomeexpense amortization deferred income selected alliance cash flow information nonrefundable upfront milestone licensing payments receipts selected alliance balance sheet information december dollars millions deferred income reckitt benckiser group may bms reckitt benckiser group plc reckitt entered threeyear alliance several overthecounterproducts sold primarily mexico brazil net sales products approximately million reckitt received right sell distribute market products may certain responsibilities related regulatory matters covered territory bms receive royalties net sales products also exclusively supply certain products reckitt pursuant supply agreement cost plus markup certain limited assets including market authorizations certain employees directly attributed business transferred reckitt start alliance period bms retained ownership assets related business including trademarks covering products bms also granted reckitt option acquire trademarks inventory certain assets exclusively related products end alliance period price determined based multiple sales plus cost remaining inventory held bms time option exercised assets previously transferred reckitt revert back bms option may exercised reckitt may november case closing would expected occur may nonrefundable upfront proceeds million received bms allocated two units accounting including rights transferred reckitt million fair value option purchase remaining assets million using best estimate selling price elements considering various market factors market factors included analysis estimated excess fair value business potential purchase price option exercised fair value option determined using level inputs included liabilities changes estimated fair value option liability significant amount allocated rights transferred reckitt amortized alliance revenue contractual term alliance revenue million including product supply royalties medicines company february bms medicines company entered twoyear alliance recothrom recombinant thrombin use topical hemostat control nonarterial bleeding surgical procedures previously acquired bms connection acquisition zymogenetics inc net product sales recothrom million medicines company received right sell distribute market recothrom global basis two years certain responsibilities related regulatory matters covered territory bms exclusively supply recothrom medicines company pursuant supply agreement cost plus markup also receive royalties net sales recothrom certain employees directly attributed business certain assets transferred medicines company start alliance period including recothrom biologics license application related regulatory assets bms retained assets related recothrom including patents trademarks inventory bms also granted medicines company option acquire patents trademarks inventory certain assets exclusively related recothrom price determined based multiple sales plus cost remaining inventory held bms time option exercised assets previously transferred medicines company revert back bms option may exercised medicines company february august case closing would expected occur february nonrefundable upfront proceeds million received bms allocated two units accounting including rights transferred medicines company million fair value option purchase remaining assets million using best estimate selling price elements considering various market factors market factors included analysis estimated excess fair value business potential purchase price option exercised fair value option determined using level inputs included liabilities changes estimated fair value option liability significant amount allocated rights transferred medicines company amortized alliance revenue contractual term alliance revenue million including product supply royalties valeant october bms pharmaswiss sa whollyowned subsidiary valeant pharmaceuticals international inc valeant entered alliance certain mature brand products europe valeant received right sell distribute market products europe december certain responsibilities related regulatory matters covered territory alliance term bms also exclusively supply products valeant pursuant supply agreement cost plus markup bms also granted valeant option acquire trademarks intellectual property exclusively related products price determined based multiple sales option exercised rights transferred valeant revert back bms option may exercised valeant january june case closing would expected occur december nonrefundable upfront proceeds million received bms allocated two units accounting including rights transferred valeant million fair value option purchase remaining assets million using best estimate selling price elements considering various market factors market factors included analysis estimated excess fair value business potential purchase price option exercised fair value option determined using level inputs included accrued expenses changes estimated fair value option liability significant amount allocated rights transferred valeant amortized alliance revenue contractual term alliance revenue million million including product supply net product sales recognized transitional period million million note acquisitions amylin pharmaceuticals inc acquisition august bms completed acquisition outstanding shares amylin biopharmaceutical company focused discovery development commercialization innovative medicines treat diabetes metabolic diseases acquisition costs million included expenses bms obtained full us commercialization rights amylins two primary commercialized assets bydureon onceweekly diabetes treatment byetta daily diabetes treatment glucagonlike peptide glp receptor agonists approved certain countries improve glycemic control adults type diabetes bms also obtained full commercialization rights symlin amylinomimetic approved us adjunctive therapy mealtime insulin treat diabetes goodwill generated acquisition primarily attributed expansion diabetes franchise iprd attributed metreleptin analog human hormone leptin studied developed treatment diabetes andor hypertriglyceridemia pediatric adult patients inherited acquired lipodystrophy estimated useful life cash flows utilized value metreleptin assumed initial positive cash flows commence shortly expected receipt regulatory approvals subject trial results see note assets heldforsale discussion sale company 's diabetes business including amylin astrazeneca comprised global diabetes alliance inhibitex inc acquisition february bms completed acquisition outstanding shares inhibitex inc inhibitex clinicalstage biopharmaceutical company focused developing products prevent treat serious infectious diseases acquisition costs million included expense bms obtained inhibitexs lead asset inx oral nucleotide polymerase nsb inhibitor phase ii development treatment chronic hepatitis c virus infections goodwill generated acquisition primarily attributed potential offer full portfolio therapy choices hepatitis virus infections well provide additional levels sustainability bmss virology pipeline iprd primarily attributed inx inx expected effective used combination therapy assumed market participants would inherently maintain franchise synergies attributed maximizing cash flows existing virology pipeline assets cash flows utilized value inx included synergies also assumed initial positive cash flows commence shortly expected receipt regulatory approvals subject trial results august company discontinued development inx interest patient safety result company recognized noncash pretax impairment charge billion related iprd intangible asset third quarter information discussion impairment charge see note goodwill intangible assets amira pharmaceuticals inc acquisition september bms completed acquisition outstanding shares amira pharmaceuticals inc amira million cash plus three separate contingent million payments due upon achievement certain development salesbased milestones first contingent payment made fourth quarter purchase price amira includes estimated fair value total contingent consideration million recorded liabilities acquisition costs million included expense amira privatelyheld biotechnology company primarily focused discovery development therapeutic products treatment cardiovascular fibrotic inflammatory diseases acquisition provides bms full rights develop commercialize completed phase clinical studies remainder amira lysophosphatidic acid receptor antagonist program researchers fibrotic expertise preclinical autotaxin program goodwill generated acquisition primarily attributed acquired scientific expertise fibrotic diseases allowing expansion new therapeutic class total consideration transferred allocation acquisition date fair values assets acquired liabilities assumed amylin inhibitex amira acquisitions follows dollars millions identifiable net assets amylin inhibitex amira cash marketable securities inventory property plant equipment developed technology rights iprd assets debt obligations liabilities deferred income taxes total identifiable net assets goodwill total consideration transferred cash paid acquisition amylin included payments million outstanding common stockholders million holders stock options restricted stock units including million attributed accelerated vesting accounted stock compensation expense third quarter results operations cash flows acquired companies included consolidated financial statements acquisition date pro forma supplemental financial information provided impacts acquisitions material operating results year acquisition goodwill iprd intangible assets valued acquisitions nondeductible tax purposes note assets heldforsale february bms sold astrazeneca diabetes business bms comprised global alliance including rights ownership onglyza forxiga bydureon byetta symlin metreleptin transaction included shares amylin previously acquired bms august resulting transfer manufacturing facility west chester ohio intellectual property related onglyza forxiga future purchase bmss manufacturing facility located mount vernon indiana earlier months following closing transaction substantially employees dedicated diabetes business transferred astrazeneca upon closing transaction consideration transaction astrazeneca paid billion bms closing million milestone february approval farxiga us make contingent regulatory salesbased milestone payments million royalty payments based net sales addition astrazeneca make payments million certain assets transferred including mount vernon manufacturing site diabetes business china business treated single disposal group held sale december writedown required fair value business less costs sell exceeded related carrying value following assets liabilities diabetes business heldforsale presented separately bmss accounts december dollars millions december assets receivables inventories deferred income taxes current prepaid expenses property plant equipment goodwilla intangible assets assets total assets heldforsale liabilities shortterm borrowings current portion longterm debt accounts payable accrued expenses deferred income current accrued rebates returns deferred income noncurrent deferred income taxes noncurrent liabilities total liabilities related assets heldforsale allocation goodwill based relative fair value diabetes business december divested company 's reporting unit stock asset purchase agreement contains multiple elements delivered subsequent closing transaction element transaction determined standalone value result portion consideration received closing allocated undelivered elements using relative selling price method including china diabetes business mount vernon manufacturing facility development agreement incremental discount attributed supply agreement remaining amount consideration received closing included calculation estimated net gain disposal contingent consideration including royalties milestone payments received also allocated underlying elements transaction relative selling price basis amounts allocated sale business immediately recognized amounts allocated elements either recognized immediately deferred whole part extent element delivered note incomeexpense incomeexpense includes year ended december dollars millions interest expense investment income provision restructuring see note litigation chargesrecoveries equity net income affiliates outlicensed intangible asset impairment gain sale product lines businesses assets income received alliance partners net pension curtailments settlements incomeexpense note restructuring following provision restructuring year ended december dollars millions employee termination benefits exit costs provision restructuring restructuring charges included termination benefits workforce reductions manufacturing selling administrative research development personnel across geographic regions approximately following table represents activity employee termination exit cost liabilities year ended december dollars millions liability january charges change estimates provision restructuring foreign currency translation amylin acquisition liabilities related assets heldforsale spending liability december note income taxes provisionbenefit income taxes consisted year ended december dollars millions current us nonus total current deferred us nonus total deferred total provisionbenefit effective tax rate reconciliation effective taxbenefit rate us statutory federal income tax rate earnings income taxes dollars millions earningsloss income taxes us nonus total us statutory rate nontax deductible annual pharmaceutical company fee foreign tax effect certain operations ireland puerto rico switzerland state local taxes net valuation allowance us federal state foreign contingent tax matters us federal research development tax credit us tax effect capital losses foreign change effective tax rate due tax benefit million attributable capital loss deduction resulting tax insolvency inhibitex tax benefits attributable higher impairment charges including million impairment charge bms intangible asset us higher charges contingent tax matters million million partially offset favorable earnings mix high low tax jurisdictions primarily attributable lower plavix revenues lesser extent impact internal transfer intellectual property fourth quarter favorable impact current year rate legal enactment research development tax credit retroactive reinstatement research development tax credit recognized million change effective tax rate due tax benefit million attributable capital loss deduction resulting tax insolvency inhibitex favorable earnings mix high low tax jurisdictions primarily attributed lower plavix revenues million impairment charge bms intangible asset us lesser extent internal transfer intellectual property partially offset contingent tax matters resulted million charge million benefit unfavorable impact current year rate delay legal enactment research development tax credit extended december changes prior period estimates upon finalizing us tax returns resulting million benefit deferred taxes valuation allowance components current noncurrent deferred income tax assetsliabilities follows december dollars millions deferred tax assets foreign net operating loss carryforwards milestone payments license fees deferred income us capital losses us federal net operating loss carryforwards pension postretirement benefits state net operating loss credit carryforwards intercompany profit inventory items us federal tax credit carryforwards foreign deferred tax assets sharebased compensation legal settlements repatriation foreign earnings internal transfer intellectual property total deferred tax assets valuation allowance net deferred tax assets deferred tax liabilities depreciation acquired intangible assets total deferred tax liabilities deferred tax assets net recognized assets heldforsale deferred income taxes current deferred income taxes noncurrent us foreign income taxes payable current liabilities related assets heldforsale deferred income taxes noncurrent total us federal net operating loss carryforwards million december carryforwards acquired result certain acquisitions subject limitations section internal revenue code net operating loss carryforwards expire varying amounts beginning us federal tax credit carryforwards expire varying amounts beginning realization us federal tax credit carryforwards dependent generating sufficient domesticsourced taxable income prior expiration capital loss available million carried back carried forward foreign state net operating loss carryforwards expire varying amounts beginning certain amounts unlimited lives management established valuation allowance deferred tax asset likely realized december valuation allowance million established following items million primarily foreign net operating loss tax credit carryforwards million state deferred tax assets including net operating loss tax credit carryforwards million us federal net operating loss carryforwards million us federal capital losses changes valuation allowance follows year ended december dollars millions balance beginning year provision utilization foreign currency translation acquisitions balance end year income tax payments million million million current tax benefit realized result stock related compensation credited capital excess par value stock million million million us taxes provided approximately billion undistributed earnings foreign subsidiaries undistributed earnings indefinitely invested offshore december additional tax provisions required earnings repatriated future us earnings determined remitted foreseeable future due complexities tax laws assumptions would made practicable estimate amounts income taxes provided result bms favorable tax rates ireland puerto rico grants scheduled expire prior business conducted various countries throughout world subject tax numerous jurisdictions significant number tax returns filed subject examination various federal state local tax authorities tax examinations often complex tax authorities may disagree treatment items reported requiring several years resolve liabilities established possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known effect changes estimates related contingent tax liabilities included effective tax rate reconciliation reconciliation beginning ending amount gross unrecognized tax benefits follows year ended december dollars millions balance beginning year gross additions tax positions related current year gross additions tax positions related prior years gross additions tax positions assumed acquisitions gross reductions tax positions related prior years settlements reductions tax positions related lapse statute cumulative translation adjustment balance end year additional information regarding unrecognized tax benefits follows year ended december dollars millions unrecognized tax benefits recognized would impact effective tax rate accrued interest accrued penalties interest expense penalty expense uncertain tax benefits reduce deferred tax assets extent uncertainty directly related asset otherwise recognized either current non current us foreign income taxes payable accrued interest penalties payable unrecognized tax benefits included either current noncurrent us foreign income taxes payable interest penalties related unrecognized tax benefits included income tax expense bms currently examination number tax authorities including limited major tax jurisdictions listed table proposed adjustments tax issues transfer pricing certain tax credits deductibility certain expenses bms estimates reasonably possible total amount unrecognized tax benefits december decrease range approximately million million next twelve months result settlement certain tax audits events expected change unrecognized tax benefits primarily settlement related involve payment additional taxes adjustment certain deferred taxes andor recognition tax benefits bms also anticipates reasonably possible new issues raised tax authorities may require increases balance unrecognized tax benefits however estimate increases reasonably made time bms believes adequately provided open tax years tax jurisdiction following summary major tax jurisdictions tax authorities may assert additional taxes based upon tax years currently audit subsequent years likely audited us canada france germany italy mexico note earnings per share year ended december amounts millions except per share data net earnings attributable bms earnings attributable unvested restricted shares net earnings attributable bms common shareholders earnings per share basic weightedaverage common shares outstanding basic contingently convertible debt common stock equivalents incremental shares attributable sharebased compensation plans weightedaverage common shares outstanding diluted earnings per share diluted antidilutive weightedaverage equivalent shares stock incentive plans note financial instruments fair value measurements financial instruments include cash cash equivalents marketable securities accounts receivable payable debt instruments derivatives changes exchange rates interest rates create exposure market risk certain derivative financial instruments used available costeffective basis hedge underlying economic exposure instruments qualify cash flow net investment fair value hedges upon meeting certain criteria including effectiveness offsetting hedged exposures changes fair value derivatives qualify hedge accounting recognized earnings occur derivative financial instruments used trading purposes financial instruments subject counterparty credit risk considered part overall fair value measurement counterparty credit risk monitored ongoing basis mitigated limiting amounts outstanding individual counterparty utilizing conventional derivative financial instruments entering agreements counterparties meet high credit quality standards consolidated financial statements would materially impacted counterparty failed perform according terms agreement collateral required party whether derivatives asset liability position terms agreements fair value measurements fair values financial instruments classified one following categories level inputs utilize nonbinding quoted prices unadjusted active markets accessible measurement date identical assets liabilities fair value hierarchy gives highest priority level inputs instruments include us treasury securities level inputs utilize observable prices similar instruments nonbinding quoted prices identical similar instruments markets active observable inputs corroborated market data substantially full term assets liabilities instruments include corporate debt securities certificates deposit money market funds foreign currency forward contracts interest rate swap contracts equity funds fixed income funds longterm debt additionally certain corporate debt securities utilize thirdparty matrix pricing model uses significant inputs corroborated market data substantially full term assets equity fixed income funds primarily invested publicly traded securities valued respective net asset value underlying investments significant unfunded commitments restrictions redemptions related equity fixed income funds december level derivative instruments valued using london interbank offered rate libor yield curves less credit valuation adjustments observable forward foreign exchange rates reporting date valuations derivative contracts may fluctuate considerably periodtoperiod due volatility underlying foreign currencies underlying interest rates driven market conditions duration contract credit adjustment volatility may significant impact valuation interest rate swaps due changes counterparty credit ratings credit default swap spreads level unobservable inputs used little market data available fair value written options sell assets certain businesses connection alliance agreements see note alliances discussion based option pricing methodology considers revenue profitability projections volatility discount rates potential exercise price assumptionsthe fair value contingent consideration related acquisition see note acquisitions estimated utilizing model considered probability achieving milestone discount rates valuation models auction rate security ars floating rate security frs portfolio based expected cash flow streams collateral values including assessments counterparty credit quality default risk underlying security discount rates overall capital market liquidity fair value ars frs material december financial assets liabilities measured fair value recurring basis summarized december december dollars millions level level level total level level level total cash cash equivalents money market securities marketable securities certificates deposit corporate debt securities us treasury securities equity funds fixed income funds ars frs derivative assets interest rate swap contracts foreign currency forward contracts derivative liabilities interest rate swap contracts foreign currency forward contracts written option liabilitiesa contingent consideration liabilityb written option liabilities million million included accrued expenses liabilities respectively see note alliances information b contingent consideration liability included liabilities see note acquisitions information following table summarizes activity financial assets utilizing level fair value measurements written contingent written contingent option consideration ars option consideration ars dollars millions liabilities liability frs liabilities liability frs fair value january additions new alliances unrealized gains sales fair value december availableforsale securities following table summarizes availableforsale securities gross gross unrealized unrealized gain loss amortized accumulated accumulated dollars millions cost oci oci fair value december certificates deposit corporate debt securities ars total december certificates deposit corporate debt securities us treasury securities ars frs total availableforsale securities included current marketable securities million december noncurrent availableforsale corporate debt securities maturing within five years million december auction rate securities maturing beyond years million december fair value option financial assets company invests equity fixed income funds designed offset changes fair value certain employee retirement benefits investments equity fixed income funds included current marketable securities million million respectively december million million respectively december investment income resulting change fair value investments equity fixed income funds million million qualifying hedges following summarizes fair value outstanding derivatives december december dollars millions balance sheet location notional fair value notional fair value derivatives designated hedging instruments interest rate swap contracts assets interest rate swap contracts liabilities foreign currency forward contracts prepaid expenses foreign currency forward contracts assets foreign currency forward contracts accrued expenses foreign currency forward contracts liabilities cash flow hedges foreign currency forward contracts primarily utilized hedge forecasted intercompany inventory purchase transactions certain foreign currencies forward contracts designated cash flow hedges effective portion changes fair value temporarily reported accumulated oci recognized earnings hedged item affects earnings net gains foreign currency forward contracts expected reclassified cost products sold within next two years including million pretax gains reclassified within next months notional amount outstanding foreign currency forward contracts primarily attributed euro million japanese yen million december cash flow hedge accounting discontinued forecasted transaction longer probable occurring originally forecasted date days thereafter hedge longer effective assessments determine whether derivatives designated qualifying hedges highly effective offsetting changes cash flows hedged items performed inception quarterly basis ineffective portion change fair value included current period earnings earnings impact related discontinued cash flow hedges hedge ineffectiveness significant periods presented net investment hedges nonus dollar borrowings million million designated hedge foreign currency exposures net investment certain foreign affiliates borrowings designated net investment hedges recognized long term debt effective portion foreign exchange gains losses remeasurement debt recognized foreign currency translation component accumulated oci related offset long term debt fair value hedges fixedtofloating interest rate swap contracts designated fair value hedges used part interest rate risk management strategy create appropriate balance fixed floating rate debt swaps underlying debt benchmark risk hedged recorded fair value effective interest rate paid fixedtofloating interest rate swaps onemonth libor december plus interest rate spread ranging underlying swap terminated prior maturity fair value basis adjustment underlying debt instrument amortized earnings reduction interest expense remaining life debt fixedtofloating interest rate swap contracts executed convert million notional amount fixed rate variable rate debt fixedtofloating interest rate swap contracts billion notional amount billion notional amount terminated generating total proceeds million including accrued interest million debt obligations shortterm borrowings current portion longterm debt includes december dollars millions bank drafts shortterm borrowings current portion longterm debt total longterm debt current portion longterm debt includes december dollars millions principal value notes due euro notes due notes due notes due notes due euro notes due notes due debentures due notes due debentures due notes due notes due notes due notes due debentures due maturing subtotal adjustments principal value fair value interest rate swap contracts unamortized basis adjustment swap terminations unamortized bond discounts total current portion longterm debta longterm debt included liabilities related assets heldforsale december included debt million floating rate convertible senior debentures due redeemed holders par september fundamental change ownership occurs debentures callable par time company debentures current conversion price equal conversion rate shares principal amount subject certain antidilutive adjustments average amount commercial paper outstanding million weightedaverage interest rate maximum month end amount commercial paper outstanding million outstanding borrowings december fourth quarter billion senior unsecured notes issued million aggregate principal amount notes due million aggregate principal amount notes due million aggregate principal amount notes due registered public offering interest notes paid semiannually notes rank equally right payment bmss existing future senior unsecured indebtedness bms may redeem notes whole part time predetermined redemption price net proceeds note issuances million net discount million deferred loan issuance costs million third quarter billion senior unsecured notes issued million aggregate principal amount notes due million aggregate principal amount notes due million aggregate principal amount notes due registered public offering interest notes paid semiannually notes rank equally right payment bmss existing future senior unsecured indebtedness bms may redeem notes whole part time predetermined redemption price net proceeds note issuances million net discount million deferred loan issuance costs million million principal amount notes due matured repaid third quarter substantially billion debt obligations assumed acquisition amylin repaid third quarter including promissory note lilly respect revenue sharing obligation amylin senior notes due january notices provided holders notes due bms exercise call option redeem notes entirety february outstanding principal amount notes million principal value longterm debt obligations million december million due million due million due million due remaining million due thereafter fair value longterm debt million million december respectively estimated based upon quoted market prices similar debt instruments fair value shortterm borrowings approximates carrying value due short maturities debt instruments debt repurchases debt repurchase activity including repayment amylin debt obligations follows dollars millions principal amount carrying value repurchase price notional amount interest rate swap contracts terminated swap termination proceeds total lossgain interest payments million million million net amounts related interest rate swap contracts bms two separate billion fiveyear revolving credit facilities syndicate lenders facilities provide customary terms conditions financial covenants extendable anniversary date consent lenders borrowings outstanding either revolving credit facility december december million financial guarantees provided form standby letters credit performance bonds standby letters credit issued financial institutions support guarantees made bms affiliates various obligations performance bonds issued support range ongoing operating activities including sale products hospitals foreign ministries health bonds customs duties value added tax guarantees related miscellaneous legal actions significant majority outstanding financial guarantees expire within year expected funded note receivables receivables include december dollars millions trade receivables less allowances net trade receivables alliance partners receivables prepaid refundable income taxes miscellaneous receivables receivables nonus receivables sold nonrecourse basis million million million aggregate receivables three pharmaceutical wholesalers us represented total trade receivables december respectively changes allowances bad debt chargebacks cash discounts follows year ended december dollars millions balance beginning year provision utilization assets heldforsale balance end year note inventories inventories include december dollars millions finished goods work process raw packaging materials inventories inventories expected remain onhand beyond one year included assets million december million december note property plant equipment property plant equipment includes december dollars millions land buildings machinery equipment fixtures construction progress gross property plant equipment less accumulated depreciation property plant equipment property plant equipment related mount vernon indiana manufacturing facility approximately million december facility expected sold earlier months following closing diabetes business transaction included assets heldforsale assets available immediate sale present condition expected sold within year see note alliances discussion sale diabetes business depreciation expense million million million note goodwill intangible assets changes carrying amount goodwill follows december dollars millions carrying amount goodwill january acquisitions inhibitex amylin assets heldforsale carrying amount goodwill december first quarter purchase price allocation finalized amylin acquisition resulting million adjustment goodwill deferred income taxes goodwill million allocated sale diabetes business included assets heldforsale seenote assets heldforsale discussion intangible assets include december december gross net gross net estimated carrying accumulated carrying carrying accumulated carrying dollars millions useful lives amount amortization amount amount amortization amount licenses years developed technology rights years capitalized software years total finitelived intangible assets iprd total intangible assets changes intangible assets follows dollars millions intangible assets carrying amount january capitalized software additions acquisitions amortization expense impairment charges assets heldforsale intangible assets net carrying amount december developed technology rights million iprd million related sale diabetes business reclassified assets heldforsale december see note assets heldforsale discussion annual amortization expense intangible assets expected approximately million million million million million million thereafter bms announced discontinued development bms formerly known inx nucleotide polymerase nsb inhibitor phase ii development treatment hepatitis c virus infection august decision made interest patient safety based rapid thorough ongoing assessment patients phase ii study voluntarily suspended august bms acquired bms acquisition inhibitex february result termination development program million pretax impairment charge recognized iprd intangible asset impairment charge million recognized related continued competitive pricing pressures partial writedown fair value developed technology rights related previously acquired nonkey product note accrued expenses accrued expenses include december dollars millions employee compensation benefits royalties accrued research development restructuring current pension postretirement benefits accrued litigation total accrued expenses note sales rebates return accruals reductions trade receivables accrued rebates returns liabilities follows december dollars millions chargebacks related government programs cash discounts reductions trade receivables managed healthcare rebates contract discounts medicaid rebates sales returns adjustments accrued rebates returns note deferred income deferred income includes december dollars millions upfront milestone licensing receipts atripla deferred revenue gain saleleaseback transactions total deferred income current portion noncurrent portion upfront milestone licensing receipts amortized expected life product information pertaining upfront milestone licensing receipts deferred revenue related atripla seenote alliances deferred gains several saleleaseback transactions amortized remaining lease terms related facilities amortization deferred income million million million deferred income million included liabilities related assets heldforsale december seenote assets heldforsale discussion note equity common stock capital treasury stock excess par value retained noncontrolling dollars shares millions shares par value stock earnings shares cost interest balance january net earnings cash dividends declared stock repurchase program employee stock compensation plans comprehensive income attributable noncontrolling interest distributions balance december net earnings cash dividends declared stock repurchase program employee stock compensation plans comprehensive income attributable noncontrolling interest distributions balance december net earnings cash dividends declared stock repurchase program employee stock compensation plans distributions balance december treasury stock recognized cost reacquire shares shares issued treasury recognized utilizing firstin firstout method may board directors authorized repurchase billion common stock june board directors increased authorization repurchase stock additional billion repurchase program expiration date may consider future repurchases noncontrolling interest primarily related plavix avaproavalide partnerships sanofi territory covering americas net earnings attributable noncontrolling interest presented net taxes million million million corresponding increase provision income taxes distribution partnership profits sanofi sanofis funding ongoing partnership operations occur routine basis activity includes pretax income distributions related partnerships components comprehensive incomeloss follows dollars millions pretax tax tax derivatives qualifying cash flow hedgesa unrealized gains reclassified net earnings derivatives qualifying cash flow hedges pension postretirement benefits actuarial losses amortizationb settlements curtailmentsc pension postretirement benefits available sale securities unrealized gains foreign currency translation derivatives qualifying cash flow hedgesa unrealized gains reclassified net earnings derivatives qualifying cash flow hedges pension postretirement benefits actuarial losses amortizationb settlements curtailmentsc pension postretirement benefits available sale securities unrealized gains realized gainsd available sale securities foreign currency translation derivatives qualifying cash flow hedgesa unrealized gains reclassified net earnings derivatives qualifying cash flow hedges pension postretirement benefits actuarial gains amortizationb settlementsc pension postretirement benefits available sale securities unrealized losses realized gainsd available sale securities foreign currency translation reclassifications net earnings derivatives qualifying effective hedges recognized costs products sold b actuarial losses prior service costcredits amortized cost products sold research development marketing selling administrative expenses c pension settlements curtailments recognized incomeexpense realized gainslosses available sale securities recognized incomeexpense accumulated balances related component comprehensive incomeloss net taxes follows december dollars millions derivatives qualifying cash flow hedges pension postretirement benefits available sale securities foreign currency translation accumulated comprehensive incomeloss note pension postretirement postemployment liabilities company certain subsidiaries sponsor defined benefit pension plans defined contribution plans termination indemnity plans regular fulltime employees principal defined benefit pension plan bristolmyers squibb retirement income plan covers us employees represents approximately consolidated pension plan assets obligations respectively funding policy contribute least minimum amount required employee retirement income security act erisa plan benefits based primarily participants years credited service final average compensation plan assets consist principally equity fixedincome securities comprehensive medical group life benefits provided substantially us retirees elect participate comprehensive medical group life plans medical plan contributory contributions adjusted periodically vary date retirement life insurance plan noncontributory plan assets consist principally equity fixedincome securities similar plans exist employees certain countries outside us net periodic benefit creditcost defined benefit pension postretirement benefit plans includes pension benefits benefits dollars millions service cost benefits earned year interest cost projected benefit obligation expected return plan assets amortization prior service credits amortization net actuarial loss curtailments settlements total net periodic benefit creditcost pension settlement charges recognized determining annual lump sum payments exceed annual interest service costs certain pension plans including primary us pension plan changes defined benefit postretirement benefit plan obligations assets funded status amounts recognized consolidated balance sheets follows pension benefits benefits dollars millions benefit obligations beginning year service costbenefits earned year interest cost plan participants contributions curtailments settlements plan amendments actuarial lossesgains retiree drug subsidy benefits paid exchange rate losses benefit obligations end year fair value plan assets beginning year actual return plan assets employer contributions plan participants contributions settlements retiree drug subsidy benefits paid exchange rate gains fair value plan assets end year funded status assetsliabilities recognized assets accrued expenses pension postretirement liabilities funded status recognized accumulated comprehensive loss net actuarial lossesgains net obligation adoption prior service credit total accumulated benefit obligation defined benefit pension plans million million december respectively additional information related pension plans follows dollars millions pension plans projected benefit obligations excess plan assets projected benefit obligation fair value plan assets pension plans accumulated benefit obligations excess plan assets accumulated benefit obligation fair value plan assets actuarial assumptions weightedaverage assumptions used determine benefit obligations december follows pension benefits benefits discount rate rate compensation increase weightedaverage actuarial assumptions used determine net periodic benefit creditcost years ended december follows pension benefits benefits discount rate expected longterm return plan assets rate compensation increase yield high quality corporate bonds matches duration benefit obligations used determining discount rate citigroup pension discount curve used developing discount rate us plans several factors considered developing expected return plan assets including longterm historical returns input external advisors individual asset class return forecasts developed based upon market conditions example priceearnings levels yields longterm growth expectations expected longterm rate return weightedaverage target asset allocation individual asset class historical longterm actual annualized returns us pension plans follows years years years accumulated comprehensive loss reduced million result actuarial gains attributed benefit obligation million higher expected return plan assets million actuarial gains resulted prevailing equity fixed income market conditions increase interest rates expected return plan assets determined using expected rate return calculated value assets referred marketrelated value fair value plan assets exceeded marketrelated value million december differences assumed actual returns amortized marketrelated value straightline basis threeyear period gains losses resulted changes actuarial assumptions changes discount rate differences assumed actual experience differences actual expected return plan assets gains losses except differences amortized market related value amortized extent exceed higher marketrelated value projected benefit obligation respective plan majority remaining actuarial losses amortized life expectancy plans participants us plans years expected remaining service periods plans cost products sold research development marketing selling administrative expenses amortization net actuarial loss prior service credit expected approximately million assumed healthcare cost trend rates december follows healthcare cost trend rate assumed next year rate cost trend rate assumed decline ultimate trend rate year rate reaches ultimate trend rate assumed healthcare cost trend rates effect amounts reported healthcare plans onepercentagepoint change assumed healthcare cost trend rates would material impact service interest cost post retirement benefit obligation plan assets fair value pension postretirement plan assets asset category december follows december december dollars millions level level level total level level level total equity securities equity funds fixed income funds corporate debt securities venture capital limited partnerships government mortgage backed securities us treasury agency securities shortterm investment funds insurance contracts event driven hedge funds collateralized mortgage obligation bonds state municipal bonds asset backed securities real estate cash cash equivalents total plan assets fair value investment valuation policies per investment class follows level inputs utilize quoted prices unadjusted active markets accessible measurement date identical assets liabilities fair value hierarchy gives highest priority level inputs instruments include equity securities equity funds real estate funds fixed income funds publicly traded national securities exchange cash cash equivalents cash cash equivalents highly liquid investments original maturities three months less time purchase recognized cost approximates fair value pending trade sales purchases included cash cash equivalents final settlement level inputs include observable prices similar instruments quoted prices identical similar instruments markets active observable inputs corroborated market data substantially full term assets liabilities equity funds fixed income funds event driven hedge funds shortterm investment funds classified level within fair value hierarchy valued net asset value shares held year end significant unfunded commitments restrictions redemptions related investments valued nav december corporate debt securities government mortgage backed securities collateralized mortgage obligation bonds asset backed securities us treasury agency securities state municipal bonds classified level within fair value hierarchy valued utilizing observable prices similar instruments quoted prices identical similar instruments markets active level unobservable inputs used little market data available venture capital limited partnerships classified level within fair value hierarchy invest underlying securities whose market values determined using pricing models discounted cash flow methodologies similar techniques significant unobservable inputs used valuation methodologies include discount rates earning interest taxes depreciation amortization ebitda multiples revenue multiples significant changes inputs could result significantly lower higher fair value measurements insurance contract interests carried contract value approximates estimated fair value based fair value underlying investment insurance company insurance contracts held certain foreign pension plans valuation models corporate debt securities government mortgage backed securities collateralized mortgage obligation bonds asset backed securities classified level within fair value hierarchy based estimated bids brokers thirdparty vendor sources utilize expected cash flow streams collateral values including assessments counterparty credit quality default risk discount rates overall capital market liquidity following summarizes activity financial assets utilizing level fair value measurements venture capital limited insurance dollars millions partnerships contracts total fair value january purchases sales settlements realized lossesgains unrealized gainslosses fair value december purchases sales settlements realized gains unrealized gains fair value december investment strategy emphasizes equities order achieve higher expected returns lower expenses required cash contributions longterm target asset allocation public equity us international global private equity longduration fixed income maintained us pension plans investments diversified within three major asset categories approximately us pension plans equity investments actively managed venture capital limited partnerships typically valued three month lag using latest available information bms common stock represents less plan assets december contributions contributions us pension plans million million million contributions international pension plans million million million aggregate contributions us international plans expected approximately million estimated future benefit payments pension dollars millions benefits benefits years savings plans principal defined contribution plan bristolmyers squibb savings investment program contribution based employee contributions level company match expense attributed defined contribution plans us million million post employment benefit plans postemployment liabilities longterm disability benefits million million december respectively related credit million expense million million termination indemnity plans international statutory termination obligations recognized undiscounted basis assuming employee termination measurement date liability recognized obligations million million december respectively note employee stock benefit plans may shareholders approved stock award incentive plan plan replaced stock incentive plan shares common stock reserved issuance pursuant stock plans options conversions preferred stock million december shares available granted active plans adjusted combination plans million december shares stock option exercise share unit vesting issued treasury stock shares actually delivered participants connection award restrictions lapsed reduce number shares reserved shares tendered prior year pay purchase price options shares previously utilized satisfy withholding tax obligations upon exercise continue available reserved executive officers key employees may granted options purchase common stock less market price date option granted options generally become exercisable ratably four years maximum term ten years additionally plan provides granting stock appreciation rights whereby grantee may surrender exercisable rights receive common stock andor cash measured excess market price common stock option exercise price common stock stock units may granted key employees subject restrictions continuous employment restrictions expire four year period date grant compensation expense recognized vesting period stock unit right receive stock end specified vesting period voting rights market share units granted certain executives beginning vesting conditioned upon continuous employment vesting date payout factor equals least share price award date payout factor share price vesting date divided share price award date maximum share price used payout factor calculated using average closing prices grant vest date nine trading days immediately preceding grant vest date vesting occurs ratably four years longterm performance awards three year cycle delivered form target number performance share units number shares ultimately issued calculated based actual performance compared earnings targets performance criteria established beginning year three year performance cycle awards annual goals maximum payout threshold targets met performance period payment made plan annual period vesting occurs end three year period stockbased compensation expense based awards ultimately expected vest recognized vesting period acceleration unvested stock options restricted stock units connection acquisition amylin resulted stockbased compensation expense forfeitures estimated based historical experience time grant revised subsequent periods actual forfeitures differ estimates stockbased compensation expense follows years ended december dollars millions stock options restricted stock market share units longterm performance awards amylin stock options restricted stock units see note total stockbased compensation expense income tax benefit sharebased compensation activities follows longterm performance stock options restricted stock units market share units awards weighted number weighted number weighted number weighted number average average average average options exercise price nonvested grantdate nonvested grantdate nonvested grantdate shares thousands outstanding shares awards fair value awards fair value awards fair value balance january granted releasedexercised adjustments actual payout forfeitedcanceled balance december vested expected vest total compensation costs related sharebased payment awards yet recognized weightedaverage period awards expected recognized december follows longterm restricted market performance dollars millions stock units share units awards unrecognized compensation cost expected weightedaverage period years compensation cost recognized additional information related sharebased compensation awards summarized follows amounts millions except per share data weightedaverage grant date fair value per share restricted stock units market share units longterm performance awards fair value options awards vested year stock options restricted stock units market share units longterm performance awards total intrinsic value stock options exercised year fair value restricted stock units longterm performance awards determined based closing trading price companys common stock grant date fair value market share units approximated closing trading price company 's common stock grant date estimated date grant considering payout formula probability satisfying market conditions following table summarizes significant ranges outstanding exercisable options december amounts millions except per share data options outstanding exercisable number weightedaverage weightedaverage outstanding exercisable remaining contractual exercise price aggregate range exercise prices thousands life years per share intrinsic value aggregate intrinsic value preceding table represents total pretax intrinsic value based closing stock price december note leases minimum rental commitments noncancelable operating leases primarily real estate motor vehicles effect december follows years ending december dollars millions later years total minimum rental commitments operating lease expense million million million sublease income material periods presented note legal proceedings contingencies company certain subsidiaries involved various lawsuits claims government investigations legal proceedings arise ordinary course business company recognizes accruals contingencies probable liability incurred amount loss reasonably estimated matters involve patent infringement antitrust securities pricing sales marketing practices environmental commercial health safety matters consumer fraud employment matters product liability insurance coverage legal proceedings material company believes could become material described although company believes substantial defenses matters assurance increase scope pending matters future lawsuits claims government investigations legal proceedings material unless otherwise noted company unable assess outcome respective litigation able provide estimated range potential loss furthermore failure enforce patent rights would likely result substantial decreases respective product revenues generic competition intellectual property atripla april teva pharmaceutical industries ltd teva filed abbreviated new drug application anda manufacture market generic version atripla atripla single tablet threedrug regimen combining companys sustiva efavirenz gileads truvada time companys us patent rights covering sustivas composition matter method use challenged teva sent gilead paragraph iv certification letter challenging two fifteen orange booklisted patents atripla may gilead filed patent infringement action teva us district court southern district new york sdny january company received notice teva amended anda challenging eight additional orange booklisted patents atripla march company merck sharp dohme corp merck filed patent infringement action teva also sdny relating two us patents claim crystalline polymorph forms efavirenz august company merck teva reached settlement relating two efavirenz polymorph patents case dismissed march gilead filed two patent infringement actions teva sdny relating six orange booklisted patents atripla april gilead teva reached agreement principle settle lawsuit patents covering tenofovir disoproxil fumarate contained atripla truvada products baraclude august teva filed anda manufacture market generic versions baraclude company received paragraph iv certification letter teva challenging one orange booklisted patent baraclude us patent patent covering entecavir molecule september company filed patent infringement lawsuit us district court district delaware delaware district court teva infringement february delaware district court ruled company invalidated patent company appealed delaware district courts decision decision expected firsthalf october teva 's anda generic version entecavir tentatively approved fda company prepared take legal action event teva chooses launch generic product prior resolution company 's appeal could rapid significant negative impact us net product sales baraclude beginning early net product sales baraclude us million baraclude south korea daewoong pharmaceutical co ltd hanmi pharmaceuticals co ltd initiated separate invalidity actions korean intellectual property office kipo korean patent patent patent expires october korean equivalent patent us composition matter patent invalidity actions pending decision expected first half although outcome actions unclear time risk decision invalidating patent encourage generic companies launch generic versions baraclude prior october net product sales baraclude south korea million plavixaustralia previously disclosed sanofi notified august genrx proprietary limited genrx obtained regulatory approval application clopidogrel bisulfate mg tablets australia genrx formerly subsidiary apotex inc apotex since changed name apotex august apotex filed application federal court australia federal court seeking revocation sanofis australian patent case nsd sanofi filed counterclaims infringement sought injunction september federal court granted sanofis injunction subsidiary company subsequently added party proceedings february second company spirit pharmaceuticals pty ltd also filed revocation suit patent case consolidated apotex case trial occurred april august federal court australia held claims patent covering clopidogrel bisulfate hydrochloride hydrobromide taurocholate salts valid federal court also held process claims pharmaceutical composition claims claim directed clopidogrel pharmaceutically acceptable salts invalid company sanofi filed notices appeal full court federal court australia full court appealing holding invalidity claim covering clopidogrel pharmaceutically acceptable salts process claims pharmaceutical composition claims stayed federal courts ruling apotex filed notice appeal appealing holding validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claims hearing appeals occurred february september full court held claims patent invalid november company sanofi applied high court australia high court special leave appeal judgment full court march high court denied company sanofis request hear appeal full court decision case remanded federal court proceedings related damages sought apotex australian government intervened matter also seeking damages alleged losses experienced period injunction place possible time predict outcome australian governments claim impact company plavixcanada apotex inc april apotex filed impeachment action sanofi federal court canada alleging sanofis canadian patent patent invalid june sanofi filed defense impeachment action filed suit apotex infringement patent trial completed june december federal court canada issued decision patent invalid july federal court appeal reversed federal court canada 's decision upheld validity ' patent case remanded federal court canada consider damages owed company apotex infringement patent september apotex sought leave appeal decision federal court appeal supreme court canada february supreme court canada decided hear case general commercial litigation remaining apotex matters related plavix previously disclosed november apotex filed lawsuit new jersey superior court company sanofi seeking payment million plus interest calculated rate per month paid related breakup march proposed settlement agreement relating thethen pending plavix patent litigation apotex april new jersey superior court granted companys crossmotion summary judgment motion denied apotexs motion summary judgment apotex appealed decisions new jersey appellate division reversed grant summary judgments remanding case back superior court additional proceedings parties agreed resolve matter binding arbitration currently scheduled march resolution matter expected material impact company january apotex filed lawsuit florida state court broward county alleging breach contract relating may proposed settlement agreement apotex relating pending plavix patent litigation trial held march jury verdict delivered favor company apotex appealed decision pricing sales promotional practices litigation investigations abilify federal subpoena january company received subpoena united states attorneys office sdny requesting information related among things sales marketing abilify possible time assess outcome matter potential impact company abilify state attorneys general investigation march company received letter delaware attorney generals office advising multistate coalition investigating whether certain abilify marketing practices violated respective states consumer protection statutes company entered tolling agreement states possible time reasonably assess outcome investigation potential impact company abilify copay assistance litigation march company partner otsuka named codefendants putative class action lawsuit filed union health welfare funds sdny plaintiffs challenging legality abilify copay assistance program federal antitrust racketeer influenced corrupt organizations rico laws seeking damages company otsuka filed motion dismiss complaint june court granted company 's motion dismissing claims allowing plaintiffs replead rico claim august plaintiffs moved leave file amended complaint motion court granted part one claim alleging tortious interference contract remains outstanding company possible time reasonably assess outcome litigation potential impact company although time resolution matter expected material impact company awp litigation previously disclosed company together number pharmaceutical manufacturers defendant number private class actions well suits brought attorneys general various states actions plaintiffs allege defendants caused average wholesale prices awps products inflated thereby injuring government programs entities persons reimbursed prescription drugs based awps company remains defendant two state attorneys general suits pending state courts pennsylvania wisconsin beginning august company defendant trial commonwealth court pennsylvania commonwealth court brought commonwealth pennsylvania september jury issued verdict company finding company liable fraudulent negligent misrepresentation however commonwealth court judge issued decision pennsylvania consumer protection claim go jury finding company liable million enjoining company contributing provision inflated awps company appealed decision pennsylvania supreme court oral argument took place may qui tam litigation march company served unsealed qui tam complaint filed three former sales representatives california superior court county los angeles california department insurance elected intervene lawsuit complaint alleges company paid kickbacks california providers pharmacies violation california insurance frauds prevention act cal ins code possible time reasonably assess outcome lawsuit impact company product liability litigation company party various product liability lawsuits previously disclosed addition lawsuits company also faces unfiled claims involving products plavix previously disclosed company certain affiliates sanofi defendants number individual lawsuits various state federal courts claiming personal injury damage allegedly sustained using plavix currently claims involving injury plaintiffs well claims spouses andor beneficiaries filed state federal courts various states including california illinois new jersey delaware new york february judicial panel multidistrict litigation granted company sanofis motion establish multidistrict litigation coordinate federal pretrial proceedings plavix product liability related cases new jersey federal court possible time reasonably assess outcome lawsuits potential impact company reglan company one number defendants numerous lawsuits behalf approximately plaintiffs including injury plaintiffs claiming personal injury allegedly sustained using reglan another brand generic drug metoclopramide product indicated gastroesophageal reflux certain gastrointestinal disorders well claims spouses andor beneficiaries company generic subsidiary apothecon inc distributed metoclopramide tablets manufactured another party possible time reasonably assess outcome lawsuits resolution pending lawsuits however expected material impact company hormone replacement therapy company one number defendants masstort litigation plaintiffs allege among things various hormone therapy products including hormone therapy products formerly manufactured company estrace estradiol delestrogen ovcon cause breast cancer stroke blood clots cardiac injuries women defendants aware risks failed warn consumers company agreed resolve claims approximately plaintiffs also reached settlement principle resolve additional claims company remains defendant approximately three actively pending lawsuits federal state courts throughout us companys hormone therapy products sold companies january august resolution remaining lawsuits expected material impact company byetta amylin former subsidiary company lilly codefendants product liability litigation related byetta date separate lawsuits pending behalf approximately plaintiffs include injury plaintiffs well claims spouses andor beneficiaries various courts us company agreed principle resolve claims majority cases brought individuals allege personal injury sustained using byetta primarily pancreatic cancer pancreatitis cases claiming alleged wrongful death majority cases pending federal court san diego recently established multidistrict litigation next largest contingent cases pending coordinated proceeding california superior court los angeles amylin lilly currently scheduled trial singleplaintiff case february california superior court los angeles amylin product liability insurance covering substantial number claims involving byetta additional liability amylin respect byetta expected shared company astrazeneca possible reasonably predict outcome lawsuit claim proceeding potential impact company bms august company announced discontinued development bms investigational compound tested clinical trials treat hepatitis c virus infection due emergence serious safety issue date company aware ten lawsuits filed company plaintiffs texas oklahoma virginia removed federal court alleging participated clinical trials bms suffered injuries result thereof company settled vast majority known claims including eight filed claims one claim filed state court remains outstanding resolution remaining lawsuits potential future lawsuits expected material impact company environmental proceedings previously reported company party several environmental proceedings matters responsible various state federal foreign laws including comprehensive environmental response compensation liability act cercla certain costs investigating andor remediating contamination resulting past industrial activity companys current former sites waste disposal reprocessing facilities operated thirdparties cercla matters respect cercla matters company responsible various state federal foreign laws company typically estimates potential costs based information obtained us environmental protection agency counterpart state foreign agency andor studies prepared independent consultants including total estimated costs site expected costsharing potentially responsible parties company accrues liabilities probable reasonably estimable company estimated share future costs sites million december represents sum best estimates best estimate reasonably made estimates minimal probable amount among range costs without taking account potential recoveries parties new brunswick facilityenvironmental personal injury lawsuits since may lawsuits filed company new jersey superior court behalf current former residents new brunswick new jersey live lived adjacent companys new brunswick facility complaints allege various personal injuries resulting environmental contamination new brunswick facility historical operations site claims medical monitoring portion complaints also assert claims alleged property damage october new jersey supreme court granted mass tort status cases transferred new jersey superior court atlantic county centralized case management purposes since october additional cases filed new jersey superior court removed company united states district court district new jersey accordingly excess cases state federal court actions discovery ongoing first trial currently scheduled commence state court august company intends defend vigorously litigation possible time reasonably assess outcome lawsuits potential impact company north brunswick township board education previously disclosed october company contacted counsel representing north brunswick nj board education boe regarding site waste materials er squibb sons may disposed fill material containing industrial waste heavy metals excess residential standards discovered expansion project north brunswick township high school well number neighboring residential properties adjacent public park areas january new jersey department environmental protection njdep sent company others information request letter possible waste disposal site company responded march boe township current owners school property park conducting jointly financing soil remediation work ground water investigation work work plan approved njdep asked company contribute cost company actively monitoring cleanup project including costs date neither school board township asserted claim company instead company local entities negotiated agreement attempt resolve matter informal means avoid litigation central component agreement provision company interim funding help defray cleanup costs assure work interrupted company transmitted interim funding payments december november parties commenced mediation late however efforts successful parties moved binding allocation process parties expected conduct fact expert discovery followed formal evidentiary hearings written argument hearings scheduled commence march addition september township boe filed suits several parties alleged contributed waste materials site company currently believe responsible additional amounts beyond two interim payments totaling million already transmitted additional possible loss expected material proceedings sec germany investigation october sec informed company begun formal inquiry activities certain companys german pharmaceutical subsidiaries employees andor agents secs inquiry encompasses matters formerly investigation german prosecutor munich germany since resolved company understands inquiry concerns potential violations foreign corrupt practices act fcpa company cooperating sec fcpa investigation march company received subpoena sec subpoena issued connection investigation fcpa primarily relates sales marketing practices various countries company cooperating government investigation matters note selected quarterly financial data unaudited dollars millions except per share data first quarter second quarter third quarter fourth quarter year total revenues gross margin net earnings net earningsloss attributable noncontrolling interest bms earnings per share basic earnings per share diluted cash dividends declared per common share cash cash equivalents marketable securities total assets longterm debt equity dollars millions except per share data first quarter second quarter third quarter fourth quarter year total revenues gross margin net earningsloss net earningsloss attributable noncontrolling interest bms earningsloss per share basic earningsloss per share diluted cash dividends declared per common share cash cash equivalents marketable securities total assets longterm debt equity earnings per share quarters may add amounts year period computed discrete basis marketable securities includes current noncurrent assets also includes current portion longterm debt following specified items affected comparability results first second third fourth dollars millions quarter quarter quarter quarter year accelerated depreciation asset impairment shutdown costs amortization acquired amylin intangible assets amortization amylin alliance proceeds amortization amylin inventory adjustment cost products sold marketing selling administrativea research developmentb provision restructuring pension settlements acquisition alliance related items litigation chargesrecoveries upfront milestone licensing receipts incomeexpense increase pretax income income tax items increase net earnings specified items marketing selling administrative process standardization implementation costs b specified items research development upfront milestone licensing payments first second third fourth dollars millions quarter quarter quarter quarter year accelerated depreciation asset impairment shutdown costs amortization acquired amylin intangible assets amortization amylin alliance proceeds amortization amylin inventory adjustment cost products sold stock compensation accelerated vesting amylin awards process standardization implementation costs marketing selling administrative stock compensation accelerated vesting amylin awards upfront milestone licensing payments iprd impairment research development impairment charge bms intangible asset provision restructuring gain sale product lines businesses assets pension settlements acquisition alliance related items litigation chargesrecoveries upfront milestone licensing receipts outlicensed intangible asset impairment loss debt repurchases incomeexpense increase pretax income income tax items specified tax benefita income taxes increasedecrease net earnings specified tax benefit relates capital loss deduction report independent registered public accounting firm board directors shareholders bristolmyers squibb company audited accompanying consolidated balance sheets bristolmyers squibb company subsidiaries company december related consolidated statements earnings comprehensive income cash flows three years period ended december financial statements responsibility companys management responsibility express opinion financial statements based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidated financial statements present fairly material respects financial position bristolmyers squibb company subsidiaries december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also audited accordance standards public company accounting oversight board united states companys internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion companys internal control financial reporting deloitte touche llp parsippany new jersey february item changes disagreements accountants accounting financial disclosure none item controls procedures evaluation disclosure controls procedures december management carried evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure controls procedures term defined exchange act rule ae based evaluation management concluded december disclosure controls procedures effective managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting supervision participation management including chief executive officer chief financial officer management assessed effectiveness internal control financial reporting december based framework internal controlintegrated framework issued committee sponsoring organizations treadway commission based assessment management concluded companys internal control financial reporting effective december provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance united states generally accepted accounting principles due inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp independent registered public accounting firm audited companys financial statements included report issued report effectiveness companys internal control financial reporting december included herein changes internal control financial reporting december included amylin pharmaceuticals inc acquired assessment effectiveness internal control financial reporting changes internal control financial reporting fourth quarter reasonably likely materially affect companys internal control financial reporting item b information compensation management development committee board directors approved new equity award guidelines executives company beginning equity awards granted march award guidelines expressed percentage salary rather fixed dollar amount grade level committee approved new guidelines respect named executive officers committees regularly scheduled meeting february specific amounts determined awards granted march report independent registered public accounting firm board directors shareholders bristolmyers squibb company audited internal control financial reporting bristolmyers squibb company subsidiaries company december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion companys internal control financial reporting process designed supervision companys principal executive principal financial officers persons performing similar functions effected companys board directors management personnel provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting including possibility collusion improper management override controls material misstatements due error fraud may prevented detected timely basis also projections evaluation effectiveness internal control financial reporting future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion company maintained material respects effective internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission also audited accordance standards public company accounting oversight board united states consolidated financial statements year ended december company report dated february expressed unqualified opinion consolidated financial statements deloitte touche llp parsippany new jersey february part iii item directors executive officers registrant reference made proxy statement filed march respect directors registrant incorporated herein reference made part hereof response information required item b information required item respect executive officers registrant included part ia reliance general instruction g instruction item b regulation sk item executive compensation reference made proxy statement filed march respect executive compensation incorporated herein reference made part hereof response information required item item security ownership certain beneficial owners management related stockholder matters reference made proxy statement filed march respect security ownership certain beneficial owners management incorporated herein reference made part hereof response information required item item certain relationships related transactions reference made proxy statement filed march respect certain relationships related transactions incorporated herein reference made part hereof response information required item item auditor fees reference made proxy statement filed march respect auditor fees incorporated herein reference made part hereof response information required item part iv item